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ABSTRACT 
 
Approximately one-third of the global population is infected with tuberculosis causing 
approximately 1.7 million deaths. Currently, the BCG vaccine is used to protect 
against TB, but it cannot prevent primary infection or reactivation of latent infection. 
Ideally a vaccine should protect against a diverse array of Mycobacterium 
tuberculosis strains and promote a strong, long-lasting TH1 cell-mediated immune 
response. Whilst evaluating the efficiency of novel vaccines using laboratory control 
strains (M. tuberculosis H37Rv, H37Ra and M. bovis-BCG), it is important to test 
efficacy against a representative panel of wild-type circulating strains. In England 
42.2% of TB cases are reported in London and the diversity of nationalities generates 
a diverse pool of strains consisting of globally representative TB strains. The aim of 
the study was to construct a representative panel of strains for vaccine evaluation 
studies and general TB research. 
 
Common M. tuberculosis strains were identified by performing molecular MIRU-
VNTR and spoligotyping on 2363 isolates from TB cases reported in London during a 
one-year period. Epidemiological analysis demonstrated there were representatives 
from 13 global regions, including high TB burden countries. An algorithm was 
designed to select strains for a preliminary panel based on associations between 
MTBC families in clusters of more common strains, the country of birth and VNTR 
sub-clusters. The preliminary panel contained 42 MTBC strains belonging to 10 
MTBC families from patients born in 17 countries. 
 
Results of phylogenetic analysis of all 2363 isolates was used to select a smaller panel 
of strains from the preliminary panel to represent MTBC lineages to investigate if 
wild-type strains were phenotypically similar.  The final panel included five strains 
from each of the Baker et al., 2004 M. tuberculosis lineages (M. tuberculosis Beijing, 
LAM10, two CAS, EAI5 strains representing lineage I, II, III, IV, respectively) and 
an M. africanum strain. 
 
In vitro tissue culture experiments demonstrated significantly higher growth of the 
Beijing strain compared to the other wild-type and laboratory strains. Higher growth 
rates of this strain were also observed in a cell-free culture system. Aerosol challenge 
of guinea pigs with wild-type strains showed a quicker dissemination of the EAI5 
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strain from the lung to the spleen 16 days post-challenge, but significantly higher 
c.f.u. count of the Beijing strain in the spleen 56 days post-challenge. Collectively, the 
data demonstrated that there are phenotypic differences between wild-type circulating 
MTBC strains. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 TUBERCULOSIS – THE DISEASE 
 
1.1.1 Epidemiology 
Globally, tuberculosis (TB) remains one of the major infectious causes of mortality 
resulting annually in 2 million deaths (WHO 2009). According to WHO reports, 
approximately one-third of the global population (nearly 2 billion people) is infected 
with the bacterium causing TB, with 9 million new cases reported annually leading to 
approximately 1.6 million to 1.7 million deaths (WHO 2007). Global rates of active 
TB are increasing at nearly 1 percent (%) per year (Dye 2006). The high TB burden 
areas include Asia (the South-East Asia and Western Pacific regions) and the African 
Region, which account for 55% and 31% of global cases (WHO 2009). The Americas, 
European and Eastern Mediterranean regions accounted for smaller proportions of the 
global cases. 
 
In the United Kingdom (UK), the Health Protection Agency (HPA) reported 8417 TB 
cases in 2007, which is a large increase from the 6726 cases reported in 2000 (HPA 
2008). The TB incidence varies significantly between regions, the lowest incidence 
being in Northern Ireland and the highest in England, which accounted for 7742 of the 
8417 cases; even more astoundingly, 42.2% of the cases reported in England were 
from patients living in London (HPA 2007). In 2007, 3265 cases were notified in the 
city giving an incidence of 43.2/100,000 in the population. 
 
A comparison of TB notifications in London showed that the highest proportions 
(20.6, 24.4, and 20.5%) of patients were from the North East, North West and South 
East areas of London, respectively (HPA 2007). Approximately 75% of people with 
TB in London were born abroad, mainly from high TB incidence countries within the 
Indian subcontinent and African regions (Anderson et al., 2007). With patients from 
so many different countries, it has previously been demonstrated that there are a 
plethora of M. tuberculosis strains circulating in London originating within migrant 
patients from different countries (Dale et al., 2005). 
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The most common causative bacterium of TB in humans is Mycobacterium 
tuberculosis, which belongs to the M. tuberculosis complex (MTBC) group. Other 
species within the group include M. bovis, M. caprae, M. africanum, M. microti, and 
M. canettii. The number of MTBC isolates reported by reference laboratories in the 
UK increased by over 50% between 1994 and 2003 (3264 isolates in 1994, to 4944 
isolates in 2003) (HPA 2008). 
 
1.1.2 Infection and immune response 
Tuberculosis is spread via aerosols, which contain TB bacilli, when infected 
individuals with pulmonary TB cough or sneeze and other individuals inhale the 
droplets containing bacteria. In order to cause infection only a small number of bacilli 
need to be inhaled. An individual with untreated active TB can infect 10 to 15 other 
people on average per year if untreated (WHO 2007). Transmission is more likely 
between members of a family, in schools, prisons and hospitals due to the prolonged 
exposure to the same infectious individuals. The disease is associated with poverty 
and it has been observed that the ideal conditions for rapid spread of TB are crowded 
working and living conditions, as are seen in institutions such as prisons, hospitals, 
crowded refugee shelters and camps (Drobniewski et al., 2000; Drobniewski et al., 
2002; Ruddy et al., 2005; Huang et al., 2007; Schmid et al., 2008). Improved social 
conditions, good institutional cross infection measures and successful treatment 
programmes aid in the reduction of TB incidence. Global migration from high 
incidence countries is a significant influential factor in the rapid spread of TB 
worldwide as approximately 50% of TB cases in industrialised countries are found in 
migrants or those born abroad (HPA 2006).  
 
Individuals who are latently infected with TB bacteria are asymptomatic; infection 
can be detected using tuberculin skin test (TST) or by ex-vivo interferon gamma 
release assays (IGRA). Approximately 10% of infected patients will go on to develop 
active disease, but up to half will develop active TB if severely immunocompromised 
such as co-infection with human immunodeficiency virus (HIV). 
 
M. tuberculosis infection is controlled by the cellular immune system; where this fails 
the patient develops the classic symptoms of fever, weight loss and persistent 
coughing with phlegm. In some cases, the immune system is able to destroy all TB 
bacilli, but in the majority of cases some of the TB bacilli will lay dormant for many 
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years whilst the immune system is able to keep them under control (Crofton et al., 
1992). Figure 1.1 illustrates the process of infection and the progression to disease. 
 
Wallgren, 1948, defined four stages in the infection with TB, the timescales involved 
and the outcomes (Wallgren 1948). Three to eight weeks after bacilli have been 
inhaled and enter the alveoli, the mycobacteria circulate via the lymphatic system to 
lymph nodes in the lung. This first stage marks the point at which tuberculin reactivity 
occurs. The second stage involves haematogenous dissemination of bacteria to other 
parts of the lung and to other organs. This can last for three months and may lead to 
TB meningitis or miliary TB that can be acute or fatal. The next stage, which can be 
delayed for up to two years, lasts for approximately three to seven months involving 
dissemination of bacteria into the pleural space and inflammation of the pleural 
surfaces causing severe chest pain. In the majority of people that are infected with TB, 
the disease does not progress to the final stage. 
 
The process of infection is now known to be much more complex involving 
components of the mycobacterial cell and the host immune system. The bacteria alone 
do not cause disease as the overall immunopathology is a combination of host and 
pathogen interactions. Evolution has not only allowed M. tuberculosis to survive the 
host immune system but to also persist for decades in many infected individuals with 
latent infection (Cole et al., 1998; Lillebaek et al., 2002; Hsu et al., 2003). 
  
Recent reviews by Smith, 2003 and Doherty and Andersen, 2005 describe current 
concepts of the process of infection (Smith 2003; Doherty et al., 2005). Figure 1.2 
illustrates the disease process described by Doherty and Andersen, 2005. The detailed 
events, including which cells and when they are involved, according to Smith, 2003, 
will be described in reference to points 1 to 4. When the TB bacilli in droplets enter 
the alveoli (point 1; Figure 1.2), macrophages are the first cells that the bacilli come 
into contact with, but it is also possible that bacilli are ingested by alveolar epithelial 
type II pneumocytes, which are more abundant than macrophages (Bermudez et al., 
1996; Mehta et al., 1996). Dendritic cells (DC) are of great importance as well 
because they have improved antigen presenting and migratory properties ideal for T 
cell activation with M. tuberculosis antigens and for bacterial dissemination, 
respectively, than macrophages. 
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Figure 1.1 The progression to disease after infection with TB bacilli. Taken from 
Crofton et al., 1992 (Crofton et al., 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, more is understood about the role of macrophages. The primary contact of 
TB bacilli with the host immune system is via the alveolar macrophages and 
surfactants. When bacterial cells come into contact with mannose and possibly 
complement receptors on macrophages, phagocytosis of bacteria takes place and key 
surfactant proteins affect this process in different ways. Phospholipids are a major 
component of surfactants, but there is also 5% to 10% protein present and the primary 
role of surfactants is to decrease the alveolar lining surface tension (Hawgood et al., 
1990). 
 
Surfactant proteins A (SP-A) and D (SP-D) are two surfactants that have been 
identified as being involved in host immunity (Tenner et al., 1989; Persson et al., 
1990; Voorhout et al., 1992; Haagsman 1994; Gaynor et al., 1995; Ferguson et al., 
1999). Both SP-A and SP-D are produced and secreted by alveolar type II epithelial 
cells (Hawgood et al., 1990; Voorhout et al., 1992). The major constituent of 
surfactant is the nonserum protein, SP-A, which is involved in surfactant lipid 
homeostasis, and oligosaccharides of SP-A come together to produce a binding site 
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with increased valency for various molecules including bacterial cell surface 
molecules and receptors on the surface of alveolar type II cells and macrophages 
(Hawgood et al., 1990; Haagsman 1994). Whilst SP-A can upregulate mannose 
receptor activity to enhance binding and phagocytosis of bacilli, SP-D blocks 
mannosyl oligosaccharide residues on the bacilli cell surface to attempt to stop any 
interactions with the macrophage mannose receptor, consequently inhibiting 
phagocytosis (Tenner et al., 1989; Persson et al., 1990; Gaynor et al., 1995; Ferguson 
et al., 1999). 
 
Once intracellular pathogens such as M. tuberculosis enter the macrophage, they exist 
in an endocytic vacuole known as a phagosome. However, whilst the phagosome 
usually fuses with lysosomes in an endocytic pathway to create unfavourable 
surroundings for the pathogen (for example by creating an acidic pH or producing 
toxic peptides, reactive oxygen intermediates and lysosomal enzymes), pathogenic M. 
tuberculosis prevent fusion of phagosomes with lysosomes that prevent the 
development of endosomes (Armstrong et al., 1975; Frehel et al., 1986). 
 
Normally after macrophages are infected and activated, proteases in the vesicles, 
which contain the bacteria, degrade proteins belonging to pathogens to produce 
fragments of peptides, which are transported to the cell surface via major 
histocompatibility complex class II (MHC-II) proteins so the peptides are presented to 
CD4+ T cells, which in their naïve state can differentiate into two types of T cells, TH1 
and TH2 cells, affecting the type of adaptive immune response elicited against the 
bacterial infection (Janeway et al., 2005). However, in the case of M. tuberculosis 
infection of macrophages, to support the studies which have demonstrated that the 
development of endosomes is inhibited, decreased MHC-II protein expression and 
decreased antigen presentation has been observed, meaning CD4+ T cells would not 
recognise infected macrophages (Noss et al., 2001).      
 
In the lungs, infected macrophages produce chemokines to attract cells such as 
neutrophils, lymphocytes and monocytes in their inactive forms (point 2; Figure 1.2), 
and in this form these cells are not sufficiently effective for eradication of bacteria 
(Fenton et al., 1996; van Crevel et al., 2002). Macrophage-derived giant cells and 
lymphocytes are components of granulomatous focal lesions that start to form, 
possibly aiding in the containment of the mycobacterial cells. A caseous centre of the 
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granuloma forms as cellular immunity develops and infected macrophages are killed. 
Around the caseous centre is a zone containing cells that were attracted to the infected 
macrophages (Fenton et al., 1996). There is decreased oxygen, an acidic pH and toxic 
fatty acids in the caseous tissue so bacteria are probably unable to multiply, but some 
bacilli may survive and remain dormant. At this point the infection is latent but can 
persist for the rest of the host’s life, with the host not displaying any symptoms or 
transmitting to other individuals. If the individual has efficient host immunity, 
infection may be permanently detained (point 3; Figure 1.2), leading to the eventual 
evolution of granulomas as small fibrous/calcified lesions (Fenton et al., 1996). 
 
On the other end of the scale, if an infected individual is not able to control the initial 
lung infection or the immune system of latently infected individuals becomes weaker 
(point 4; Figure 1.2) for various reasons, including HIV co-infection, treatment with 
immunosuppressive drugs, aging or malnutrition, the centre of the granuloma may 
liquefy providing revived mycobacterial bacilli with the rich medium required for 
replication (Converse et al., 1996). Active pulmonary or extrapulmonary TB can 
develop as bacteria escape the granuloma and spread to other regions of the lung or 
other tissues through the blood and lymphatic system, respectively. 
 
The exact mechanisms by which M. tuberculosis evade the host immune system are 
still not completely understood. Previous research has elucidated some of the key 
immunological defence mechanisms involved. Figure 1.3 shows some of the possible 
ways in which M. tuberculosis influences the immune system favouring its survival 
(Doherty et al., 2005). Macrophages serve as a habitat for TB bacilli over a long 
period of time and in order to make the environment within the cell more favourable, 
the bacteria influences gene expression within the macrophage. There is upregulation 
of genes encoding molecules that are essential for chemotaxis to attract other cells to 
the infection site, for example, interleukin (IL)-8, which aids in the recruitment of 
neutrophils, and IL-1β that plays a role in granulomatous inflammation (Volpe et al., 
2006). In their study, Volpe et al., 2006, also noted upregulation of macrophage-
derived chemokine (MDC), another chemoattractant that is important for many 
reasons including its influence on T helper type 2 cell activation, and functions of 
DCs and natural killer cells. 
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Figure 1.2 A diagram showing the events that take place within the lungs after an individual 
is infected with TB bacilli. The events occurring at each of the numbered points in the 
diagram are referred to in Section 1.1.2. Diagram adapted from Doherty and Andersen, 2005 
(Doherty et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infection successfully 
contained 
Granuloma shrinks & calcified 
Immune response unsuccessful 
to control bacterial replication 
Granuloma increases in size & cellularity 
Cell death in hypoxic centre of granuloma 
IMMUNOPATHOLOGY 
Necrosis 
(if granuloma is close to surface of lung, tissue 
destruction can spread to mucosal surface) 
Persistent cough with blood in sputum (patient highly 
infectious & spread bacteria by aerosol) 
Infected individual 
Infectious droplets inhaled by host 
& enter via lung mucosal surface 
Droplets deposited in alveolar space 
Phagocytic cells take up bacteria 
Rapid inflammatory response 
Various immune cells accumulate 
Form granulomas 
(made up of small number of infected phagocytes, 
surrounded by activated monocytes/macrophages and 
in outer most layer of activated lymphocytes) 
Point 
4
Point 
3
Point 2
Point 1
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Figure 1.3 A diagram showing how the immune system may kill M. tuberculosis via phagocytosis, and features that may interfere with the response. 
Taken from Doherty and Andersen, 2005 (Doherty et al., 2005). 
   
 
 
 
 
 
 
 
 
 
 
 
 
Whilst chemotaxis helps in the recruitment of cells to the site of infection, which 
would eventually lead to the formation of granulomas, a good inflammatory response 
is also essential. This was demonstrated by Sugawara et al., 2002, who showed that 
the inflammatory host response was strongly stimulated by long chain fatty acids 
expressed on the mycobacterium cell wall, such as mycolic acid (Sugawara et al., 
2002). These long chain fatty acids have multiple roles as they can encourage 
cytokine production, including those that regulate production of interferon-gamma 
(IFN)-γ, and can regulate apoptosis or survival of infected macrophages (Ryll et al., 
2001; Nuzzo et al., 2002). 
 
Increased production of IFN-γ is insufficient for eradicating mycobacterial cells as the 
downstream effects of IFN-γ are inhibited, by the bacteria or components on the 
bacterial cell wall, which modulate the effects of cytokine so it is advantageous for 
the bacteria (Ting et al., 1999). It seems that the necessary immune response to induce 
IFN-γ production is inhibited (Lienhardt et al., 2002). In the study by Lienhardt et al., 
2002, IFN-γ, which is produced by TH1 cells, and IL-4, produced by TH2 cells, were 
measured in vivo; there was a low Th1 and high Th2 response in TB patients 
demonstrating a Th1/ Th2 response imbalance that allows progression of TB to the 
disease state with a consequential poor clinical outcome. A Th1 immune response is 
vital for protection against TB infection and studies have shown that the cytokine IL-
12, which is secreted by infected DCs and macrophages, promote a Th1 response 
which leads to the secretion of other pro-inflammatory cytokines (Flynn et al., 1995). 
There is an increased production of pro-inflammatory cytokines, tumour necrosis 
factor-alpha (TNF-α) and IL-6, by macrophages after infection with virulent M. 
tuberculosis and these cytokines work to reduce mycobacterial burden (Ragno et al., 
2001; Volpe et al., 2006; Bhatt et al., 2007). The role of these two cytokines has been 
further discussed in Chapter 6 of the present study as cytokine production was 
investigated after infecting a tissue culture cell line with different MTBC strains. 
 
Other studies have shown that although a strong Th1 response may be elicited by M. 
tuberculosis this does not always lead to protection against the bacteria (Hovav et al., 
2003). Species within the MTBC specifically have a 27 kiloDalton (27-kDa) 
mycobacterial antigen and immune response to this lipoprotein induces secretion of 
IFN-γ, inducing a strong Th1 response. That there is no evident protective response 
seems to indicate that this lipoprotein is in fact a decoy that can be used to ultimately 
protect the pathogen. However there are lipoproteins that, whilst stimulating an 
immune response to protect the host, in fact have adverse effects. It has been 
suggested that the MTBC species specific 19-kDa antigen is expressed particularly to 
act as a competitive inhibitor; therefore, it would have a higher affinity for antigen 
presenting molecules than other antigens that would truly elicit an effective immune 
response (Yeremeev et al., 2000). Neyrolles et al., 2001 also found that trafficking of 
the 19-kDa lipoprotein within infected macrophages was completely isolated from 
live mycobacterial cells (Neyrolles et al., 2001). 
 
Mycobacterial cells need to be able to survive within the macrophage and obtain 
nutrients required for its survival. One mechanism by which mycobacterial cells 
survive is by disrupting maturation of the phagosome in which it resides, but fusion 
with other vesicles like lysosomes, membrane remodelling and trafficking can still 
take place (Russell et al., 1996). Therefore, M. tuberculosis bacteria can acquire 
essential nutrients, whilst exporting their own proteins. As well as disrupting 
maturation of phagosomes, DCs are specifically targeted by M. tuberculosis as 
interactions between dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) and mycobacterial cell wall component, 
mannosylated lipoarabinomannan (ManLAM), means that the bacteria are internalised 
(Geijtenbeek et al., 2003). M. tuberculosis negatively influences DC maturation and 
positively influences production of IL-10, which is an anti-inflammatory cytokine that 
promotes immunosuppression, ultimately aiding in bacterial cell survival. 
 
Research so far has provided great insight into the process of infection by 
Mycobacterium species and its clinical progression. There is also increased 
understanding of how the mycobacteria are able to survive within the host and 
overcome the most challenging issues of the host immune system, even during its 
latent phase. It is highly possible that there are many other mechanisms and cytokines 
waiting to be discovered by which this pathogen is able to not only survive but to 
infect other individuals contributing to the potential virulence of MTBC strains. There 
are additional factors that play a role in the virulence of mycobacteria. 
 
1.1.3 Mycobacterial virulence factors  
As mentioned in Section 1.1.2, mycobacteria can direct an immune response to 
increase chances of survival (Russell et al., 1996; Geijtenbeek et al., 2003). The 
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degree to which particular strains are able to direct the immune response to self-
protect, therefore reflecting the virulence of strains, can potentially be measured by 
quantifying the amount of cytokines, such as IFN-γ, TNF-α, IL-2, -12 and -6, or 
monitoring the growth of mycobacteria in in vitro models such as monocytic THP-1 
cell line, therefore providing potential markers for virulence of mycobacterial strains 
(Fremond et al., 2004; Theus et al., 2004; Theus et al., 2005; Park et al., 2006; Lee et 
al., 2007; Sow et al., 2007). Identifying any differences in the virulence of M. 
tuberculosis strains, by monitoring the growth of strains in a THP-1 cell line model 
and in a cell-free culture system, and also measuring the production of TNF-α, IL-10, 
-1β and -6 have been demonstrated in the present study and is discussed in greater 
detail in Chapter 6. 
 
In vivo models have provided a good base for comparing virulence of mycobacterial 
strains and a common in vivo marker for virulence is extrapulmonary dissemination of 
TB bacilli as there are histological similarities between primary pulmonary lesions 
observed in guinea pigs and humans (Bhatia et al., 1961; Prabhakar et al., 1987). 
Many studies have used guinea pigs as models for comparing virulence of laboratory 
and wild-type, clinical strains and more importantly for evaluating the performance of 
novel vaccines after aerosol challenge of guinea pigs with TB culture (Bhatia et al., 
1961; Prabhakar et al., 1987; Williams et al., 2000; Williams et al., 2005; Williams et 
al., 2005; Vipond et al., 2006). One particular study by Williams et al., 2005 
demonstrated that the number of mycobacterial bacilli in the spleen at the early time 
point of 16 days post-challenge of guinea pigs with the TB culture provided a good 
marker of how virulent the strain is because an increased mycobacterial load in the 
spleen would indicate the faster dissemination of bacilli from the lungs (Williams et 
al., 2005). Virulence in this study was compared using the percentage weight gain 
data, lung and spleen mycobacterial load 16 and 56 days post-challenge and by 
observing the histopathology of lung and spleen tissue. The same protocol was 
adopted for the present study and is discussed in greater detail in Chapter 8.     
 
Other factors of virulence that have also been successfully identified, but not included 
in the present study, include differences in single-nucleotide polymorphisms (SNPs) 
between virulent M. bovis strains and all Bacillus Calmette–Guérin (BCG) strains 
(Garcia Pelayo et al., 2009). Garcia Pelayo et al., 2009 identified 115 nonsynonymous 
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SNPs (nsSNPs) which play a role in various functions affecting the virulence of 
strains, including central metabolism and transcriptional factors. 
 
M. tuberculosis bind selectively to fibronectin and this binding can be blocked by 
antibodies against members of the antigen 85 (Ag85) complex of fibronectin-binding 
proteins, which include Ag85A, Ag85B, and Ag85C, that are secreted and stored in 
the cell wall of M. tuberculosis (Abou-Zeid et al., 1988; Ratliff et al., 1988; Ratliff et 
al., 1993). Patti et al., 1994 demonstrated that the degree to which pathogens bind to 
fibronectin enhances the virulence of the pathogens as the specific binding could aid 
in the adherence and dissemination of the mycobacteria from the lungs to other organs 
and tissues (Patti et al., 1994). For this reason, proteins from the Ag85 complex 
family have been identified as potential virulence factors and mutating genes, fbpA, 
and fbpB, which express the proteins Ag85A and Ag85B, respectively, has helped to 
identify that fbpA has a function towards the pathogenesis of M. tuberculosis H37Rv 
as loss of expression led to decreased growth in human or mouse macrophage-like 
cell lines (Armitige et al., 2000). 
 
Further investigation of the mycobacterial cell wall chemistry has led to the 
identification of cell wall components that pose as factors of virulence. Microbial 
glycolipids, such as phenolic glycolipid-I from M. leprae, have a role in the virulence 
and pathogenicity by searching for toxic oxygen radicals (Neill et al., 1988; Chan et 
al., 1989). Lipoarabinomannan (LAM) is a complex cell wall-associated glycolipid 
produced abundantly by M. tuberculosis and M. leprae and is made up of mannose 
and arabinose saccharide units linked to a phosphatidylinositol moiety, which helps to 
attach LAM to the mycobacterial cell cytoplasmic membrane (Hunter et al., 1986). 
The LAM component is a suggested mycobacterial virulence factor as LAM provides 
protection against the antimicrobial activities of mononuclear phagocytes (Chan et al., 
1989). 
 
1.1.4 Current immunisation to TB and future novel vaccines  
The current vaccine against TB is the BCG vaccine, which has existed for over 80 
years, and which comes from the original M. bovis isolate at the Institut Pasteur in 
Lille after passaging numerous times from 1909 to 1921 to produce an attenuated 
vaccine strain (WHO 2004). Although reconstituted vaccines contain dead and viable 
M. bovis bacilli leading to variations between administered doses, the BCG vaccine is 
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currently the most widely used TB vaccine and in countries that are included in the 
national childhood immunization programme, the vaccine is administered to over 
80% of neonates and children. 
 
In the UK the BCG immunisation programme commenced in 1953 with the aim of 
protecting young people that just started working; the initial target of the vaccine was 
14 year old children that were just about to leave school (DofH 2006). By the 1960s, 
TB was commonly identified in immigrants from the countries of high TB prevalence 
so the BCG vaccine was administered to children of the new immigrants, even if they 
were born in the UK. The universal school immunisation programme continued until 
2005, when it was decided to suspend it as the TB rates in the British population had 
declined. Currently, the vaccination programme focuses on infants between the ages 
of 0 to 12 months that are born in a high incidence area or that have parents and 
grandparents that were born in a high incidence country (DofH 2006). 
 
Whilst the BCG vaccine provides protection in children against disseminated TB and 
meningitis, it has limited impact on TB transmission as the vaccine is not able to 
prevent primary infection with mycobacterial bacilli and more importantly, it cannot 
stop reactivation of latent pulmonary infection, which is the main source of 
transmission in communities (Rodrigues et al., 1993; WHO 2004). In vivo 
experiments in guinea pigs have demonstrated that the BCG vaccination may be more 
protective against M. bovis infection than infection with M. tuberculosis H37Rv 
(Williams et al., 2000). 
 
The global efficacy of BCG has varied from 0% to 80% in different studies with 
higher efficacy in industrialised countries compared to non-industrialised countries 
closer to the equator (Fine 1995; Fine et al., 1998; Brewer 2000). One reason 
proposed for the variation seen in vaccine efficiency was the difference in the 
exposure of individuals to environmental mycobacteria in the different countries 
because the bacilli in the environment might stimulate the immune system and 
thereby prevent an appropriate response to the BCG vaccine (Fine 1995; Fine et al., 
1998). There have also been variations in the effectiveness of the BCG vaccine 
amongst schoolchildren in the UK with protective levels ranging from 0% to between 
70 and 80% (Sutherland et al., 1987; Rodrigues et al., 1991). 
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The BCG vaccine provides protection for approximately 10 to 15 years after which 
protection may wane, although there is limited data on this (Sterne et al., 1998). As 
part of the BCG vaccination programme, it is not recommended to administer the 
vaccine to individuals over 16 years of age unless the person belongs to a high risk 
group, which includes laboratory and healthcare staff, or for the purposes of traveling 
abroad (DofH 2006). There is no evidence that repeat BCG vaccination increases or 
prolongs protection. 
 
Whilst the use of BCG vaccine is still recommended, there are advancements in 
research leading to a greater understanding of the complex interactions involved in the 
immunological response of the host and the bacteria, and subsequently increased 
research into novel vaccines against TB. Since the sequencing of M. tuberculosis 
H37Rv genome and its annotation by Cole et al., 1998, there has been a rapid 
expansion in the knowledge of the genetics involved in the survival and evolution of 
mycobacteria (Cole et al., 1998).  Ideally an effective vaccine should be able to 
protect individuals against all of the circulating M. tuberculosis strains and promote a 
strong and long-lasting TH1 cell-mediated immune response (refer to Section 1.1.2). 
 
Currently, there are major projects in operation to develop more effective TB 
vaccines. European collaborative projects, like the European Union (EU) TB Vaccine 
Cluster project, aim to develop new TB vaccines that are more effective than BCG. 
Such projects involve a step-wise evaluation of these novel vaccines starting by using 
mice, followed by evaluation in guinea pigs, and finally lead candidates may be tested 
in non-human primates, and/or humans. After observing the protection against 
virulent challenges and immunogenicity following the vaccination of mice with the 
novel vaccines, vaccine candidates that hold potential have been selected for 
evaluation in guinea pigs (Williams et al., 2005). Some of the vaccine candidates 
include recombinant protein (designed to over-express antigenic targets of M. 
tuberculosis that would elicit a protective immune response against TB infection), 
improved BCG strains expressing additional antigens, or the development of 
attenuated strains of M. tuberculosis and M. microti strains (Collins et al., 2001; 
Williams et al., 2005). Prime-boost vaccine strategies were also evaluated and 
involved immunising guinea pigs with BCG followed by a booster, which may be a 
sub-unit antigen expressed as a protein or delivered by a viral vector such as modified 
vaccinia virus Ankara (MVA) (McShane et al., 2004; McShane et al., 2005). 
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The prime-boost strategy, DNA prime MVA/Ag85A boost, which involved firstly 
immunising guinea pigs with DNA expressing Ag85A followed by MVA, provided 
significantly better protection in guinea pigs infected with M. tuberculosis H37Rv 
than in guinea pigs belonging to the saline control group (Williams et al., 2005). In 
this study, protection against TB infection had been determined in terms of prolonged 
survival of guinea pigs infected with TB after administering the DNA prime 
MVA/Ag85A boost, by the reduced number of mycobacterial bacilli in the spleen 
demonstrating slower dissemination of bacilli, and in terms of percentage lung 
consolidation demonstrating reduced lung pathology upon infection after being 
vaccinated using the prime-boost strategy.     
 
Other studies have investigated the potential of new vaccines, including attenuated, 
live vaccines, vaccines designed to increase the efficacy of the present BCG vaccine, 
subunit vaccines designed to supplement or boost the BCG vaccine, and 
deoxyribonucleic acid (DNA) vaccines (Hubbard et al., 1992; Olsen et al., 2003; Pym 
et al., 2003; Gupta et al., 2007). A summary of the different vaccines and their 
strategies have been summarised in Table 1.1, some of which have already been 
described previously in this section. 
 
Whilst live, attenuated vaccines offer great potential for protection against TB, it is a 
challenge to obtain a suitable balance between the level of attenuation and 
maintenance of immunogenicity (Gupta et al., 2007). Attenuated M. tuberculosis 
mutants present species-specific antigens, meaning these strains could potentially 
promote a more improved protection against TB infection than BCG 
(Sambandamurthy et al., 2002; Sambandamurthy et al., 2005). Protection against 
mycobacterial infection has been elicited by M. vaccae in mice as there are common 
antigens between M. tuberculosis and M. vaccae and a live, attenuated form of M. 
microti administered orally to mice provided better protection against infection with 
virulent M. tuberculosis than BCG (Hernandez-Pando et al., 1997; Manabe et al., 
2002).
Table 1.1 A table summarising the novel vaccine candidates that have been discussed in Section 1.1.4 
and additional vaccines that have been studied. Vaccines have been categorised as live, attenuated 
vaccines, recombinant BCG vaccines, subunit vaccines or DNA vaccines. Also included is a reference 
to the source and the study of the vaccines. The antigens described in the table are targets of M. 
tuberculosis that would elicit a protective immune response against TB infection. 
 
Type of 
vaccine Name of vaccine (brief description) Reference 
M. microti ATCC 19422  (Manabe et al., 2002) 
Heat inactivated M. vaccae  (Hernandez-Pando et al., 1997) 
MVA expressing Ag85A (used as a booster after BCG vaccination) (McShane et al., 2004) 
MVA & fowlpox virus, FP9, 
both expressing Ag85A 
(used as a booster after BCG 
vaccination) (Williams et al., 2005) 
M. tuberculosis ΔRD1   (Hsu et al., 2003) 
M. tuberculosis ΔpurC  purine biosynthesis gene (Jackson et al., 1999) 
M. tuberculosis ΔmetB  methionine biosynthesis gene 
M. tuberculosis ΔproC  proline biosynthesis gene 
M. tuberculosis ΔtrpD  tryptophan biosynthesis gene 
(Smith et al., 2001) 
Live, 
attenuated 
M. tuberculosis ΔpanCpanD pantothenate biosynthesis gene (Sambandamurthy et al., 2002) 
BCG :: RD1-2F9 expresses ESAT-6/CFP-10 (Pym et al., 2003) 
rBCG30 expressing Ag85A  (Horwitz et al., 2000) 
ΔureC hly+ rBCG (urease deficient mutant expressing listeriolysin O) (Grode et al., 2005) 
rBCG38 Tice (expresses the 38 kDa antigen of Ag85 complex)  
(Castanon-Arreola et al., 
2005) 
rBCG 19T (expresses the 19 kDa antigen of Ag85 complex)  
rBCG 38T (expresses the 38 kDa antigen of Ag85 complex)  
Recombinant 
BCG 
rBCG E6T (expresses ESAT-6)  
(Rao et al., 2003) 
pJI23 (DNA-64) (gene expressing MPT64 antigen) 
pJI30 (DNA-85B) (gene expressing Ag85B) 
pJIE6 (DNA-E6) (gene expressing ESAT-6) 
(Kamath et al., 1999) 
Ag85B/ESAT-6 fusion 
protein  
(Olsen et al., 2004; 
Langermans et al., 2005) 
Ag85B/TB 10.4 fusion 
protein  (Dietrich et al., 2005) 
Subunit 
single recombinant 
polyprotein Mtb72F 
(polyprotein made up of Mtb 
32 and Mtb 39 proteins) (Skeiky et al., 2004) 
Mtb72F DNA delivered as naked DNA (Skeiky et al., 2004) 
plasmid DNA Mtb 8.4 (expresses an immunoreactive T cell antigen) (Coler et al., 2001) 
MTB41-DNA (antigen eliciting a Th1 response) (Skeiky et al., 2000) 
Ag85A DNA  (Tanghe et al., 2000) 
pE6/85 (expressing ESAT-6/Ag85B) (Derrick et al., 2004) 
MTB Ag ESat-6 
MTB Ag mpt64 
MTB Ag MPT63 
MTB Ag mpt8e 
MTB Ag Ag85b 
MTB Ag katG 
MTB Ag mtb12 
MTB Ag mtb8.4 
MTB Ag MTB39 
DNA 
MTB Ag 1818C 
all genes express M. 
tuberculosis antigens and were 
fused with tissue plasminogen 
activator (TPA) signal 
sequence & ubiquitin (Ub)  
(Delogu et al., 2002) 
 
Attempts to improve the efficacy of the BCG vaccine have been made by adding M. 
tuberculosis genes, which encode proteins known to mediate protection when used as 
subunit vaccines (Dietrich et al., 2006). The recombinant BCG vaccine, rBCG30, 
expresses and secretes the protein Ag85B and has improved protection against TB in 
guinea pig models (Horwitz et al., 2000). Increased protection was also observed in 
animal models administered with a recombinant vaccine expressing region of 
deletion-1 (RD1), but the disadvantage was that the vaccine strain became more 
virulent (Pym et al., 2003). The locus RD1 was selected because this locus contains 
the genes for Early Secreting Antigen Target-6 (ESAT-6) and Culture-filtrate 
proteins-10 (CFP-10), which are both immune targets. 
 
The subunit vaccines are based on the availability of proteins that are secreted by 
mycobacterial bacilli, for recognition of infected macrophages at an early stage in the 
immune response, thereby controlling growth and multiplication of mycobacterial 
cells (Dietrich et al., 2006). Similar targets to those used for preparing the 
recombinant BCG vaccines have also been adopted for some of the subunit vaccines 
being investigated. A significantly higher degree of protection is provided by ESAT-6 
as there is strong recognition of this protein by T cells and also by Ag85A and 
Ag85B, which are also secreted by M. tuberculosis and are crucial targets for a 
protective human T-cell response against the pathogen (Boesen et al., 1995; Kamath 
et al., 1999). In addition to subunit vaccines with single proteins, fusion protein 
subunit vaccines have also been evaluated, including a vaccine containing ESAT-6 
and Ag85B (Olsen et al., 2004; Dietrich et al., 2005; Langermans et al., 2005; 
Dietrich et al., 2006). Administration of this vaccine promoted a strong and highly 
protective immune response against TB. 
 
Promotion of CD4+ and CD8+ T cell responses against TB can be encouraged by 
using DNA vaccines and protection against TB infection has been observed after 
delivery of mycobacterial antigens, for instance Ag85 and ESAT-6, to mice in the 
form of naked DNA (Kamath et al., 1999; Britton et al., 2003; Olsen et al., 2003). 
Administration of chimeric DNA or co-delivery of multiple DNA plasmids has 
increased the effectiveness of DNA vaccines and proved to reduce the numbers of 
mycobacterial cells in the lungs of aerosol-challenged mice (Tanghe et al., 2000; 
Delogu et al., 2002; Derrick et al., 2004).     
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Whilst designing vaccines that positively influence the immune response, there have 
been attempts to design vaccines that would physically stop the maturation of 
phagosomes containing the mycobacterial bacilli. An example is a urease-deficient 
BCG mutant that would express the listeriolysin O gene from Listeria monocytogenes 
(a bacterium that cannot prevent phagosome maturation because of urease-deficiency) 
(Campos et al., 1996; Grode et al., 2005). There are also attempts to try and attenuate 
M. tuberculosis instead of genetically modified designs of BCG as more human TB 
infections are caused by the former species. 
 
The evaluation strategy for novel TB vaccine candidates is crucial. As well as testing 
the performance of vaccines using standard laboratory control strains like M. 
tuberculosis H37Rv and H37Ra (the avirulent laboratory strain) and M. bovis BCG, it 
is also important to test their efficiency against a representative panel of wild-type M. 
tuberculosis strains that are circulating in the population, as these are the strains that a 
vaccine should ideally protect populations against. 
 
1.2 MOLECULAR TYPING OF M. TUBERCULOSIS STRAINS 
 
1.2.1 The genome – conservation & variability 
The genome size of M. tuberculosis H37Rv is approximately 4.4x106 base pairs (b.p.) 
and is characterised by its very high guanine and cytosine content of 65.6% (Cole et 
al., 1998). In order to use information about the genome effectively it is important to 
identify and understand regions of conservation and variability. There is evolutionary 
conservation in the genome of MTBC and the species within MTBC are closely 
related genetically due to a high degree of DNA homology between strains (Imaeda 
1985). 
 
Frothingham et al., 1994, focused on the 16S-to-23S ribosomal DNA (rDNA) internal 
transcribed spacer (ITS), which has a high rate of nucleotide substitution. However, 
their studies demonstrated that strains from the different MTBC species and M. bovis 
BCG had the same ITS sequence showing that the 16S rDNA sequence was 
conserved, which was corroborated by the identification of conserved domains in the 
16S ribosomal ribonucleic acid (rRNA) molecule (Kirschner et al., 1993; 
Frothingham et al., 1994). Whilst this region remains conserved within the MTBC, 
there are a minimum of seven possible sites within the ITS that are specific for MTBC 
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(Frothingham et al., 1994). Another major factor that contributes to variability in the 
genome of most human pathogens is the degree of horizontal gene transfer, which is 
absent in modern M. tuberculosis strains (Alland et al., 2003). Conversely, it has been 
reported that the M. tuberculosis genome appears to be a composite assembly due to 
horizontal gene transfer that occurred prior to an evolutionary bottleneck 
approximately 35,000 years ago, after which there was a clonal expansion of M. 
tuberculosis strains (Supply et al., 2003; Gutierrez et al., 2005).  
 
Compared to other bacterial pathogens affecting humans, there is a significantly lower 
rate of mutations, more specifically silent nucleotide substitutions, in M. tuberculosis, 
suggesting that evolutionary change in this organism occurs slowly (Sreevatsan et al., 
1997). Although the M. tuberculosis genome is conserved, it does not mean that 
regions of variability or polymorphism do not exist. The polymorphic regions of most 
interest are those that include repeated units of identical sequence. There are 
interspersed repeats (IR), including direct and insertion sequence-like repeats, and 
tandem repeats (TR), including direct repeats that are uninterrupted head-to-tail 
(Mathema et al., 2006). Reorganisation of the genome is more commonly noted with 
unstable transposable elements leading to deletions, inversions, duplications and 
transpositions. Insertion sequences (IS) are transposable elements and although it has 
been identified as being a rare event, transposition of IS elements has been observed 
and these elements are a major contributing factor in producing polymorphisms in the 
genome, which would potentially aid in strain change and differentiation (van 
Soolingen et al., 1991; Cole et al., 1998). 
 
Hermans et al., 1991, identified that a particular IS, IS987, was positioned within a 
direct variable repeat (DVR) containing locus and that the sequence of this locus only 
seemed to be found exclusively in MTBC species (Hermans et al., 1991). This was 
when the true potential of the chromosomal direct repeat (DR) locus was recognised 
as it displayed polymorphism with regard to its length and composition. Each DVR is 
composed of a DR and a spacer region, which is a short non-repetitive sequence. The 
sizes of these are 36 b.p. and 35 to 41 b.p., respectively. Due to particular events 
involving rearrangement of the genes, some spacers may be deleted (van Embden et 
al., 2000). Two such events are homologous recombination between distant or 
adjacent chromosomal DRs, leading to variation in a single or a few DVRs, and 
transposition of an IS, IS6110, which is almost always present in the DR locus.  
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 Supply et al., 1997, reported a new group of repeated sequences, within the 
intercistronic region of the senX3-regX3 mycobacterial two-component system 
encoding operon, called mycobacterial interspersed repetitive units (MIRUs) (Supply 
et al., 1997).  Following on from this identification, Magdalena et al., 1998, amplified 
the senX3-regX3 intergenic region (IR) on various MTBC strains and, based on the 
size of the polymerase chain reaction (PCR) fragment, found that the number of 
MIRUs varied between strains (Magdalena et al., 1998).  
 
Prior to molecular typing techniques, phage typing was the most commonly used 
method for differentiating between strains in the MTBC (Bates et al., 1967). 
However, whilst the technique was useful for typing strains involved in laboratory 
cross-contamination and from outbreaks, the technique was not sufficiently 
discriminative as phage types were limited and the procedure was difficult to perform. 
 
The variations within the M. tuberculosis genome, which have been described briefly, 
in combination with the rapid advancements in molecular techniques, provided the 
foundations for identifying genetic markers that show sufficient variation and 
polymorphism to differentiate between strains belonging to MTBC and broaden our 
understanding of the evolutionary and epidemiological patterns of species within the 
MTBC. 
 
Three molecular techniques, including one requiring prolonged cultivation, that are 
currently widely in use are discussed in detail along with applications of the 
techniques and the advantages and disadvantages of their use with regard to various 
applications. Molecular amplification-based methods seem to be more attractive than 
those requiring prolonged TB cultivation as minimal amounts of DNA are required.  
 
1.2.2 IS6110 restriction fragment length polymorphism 
The IS element, IS6110, which has a sequence of 1355 b.p., is the most commonly 
used element for analysis, usually in a restriction fragment length polymorphism 
(RFLP) format.  This element was first recognised by Thierry et al., 1990, when it 
was also concluded that this element was specific to species belonging to the MTBC 
(Thierry et al., 1990). Thierry et al., 1990 noticed that there were similarities between 
IS6110 and other elements belonging to the enterobacterial IS3 family, and this was 
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supported by McAdam et al., 1990, who identified IS986 as being part of the IS3 
family and noted the high degree of similarity between the sequences of IS986 and 
IS6110, therefore concluding that IS6110 belonged to the IS3 family (McAdam et al., 
1990).  
 
Strains from MTBC have varying numbers of IS6110 copies, ranging from 0 to 25 
copies, that are incorporated into the chromosome at different sites creating a 
combined polymorphism of copy number and position which makes IS6110 a useful 
element for fingerprinting (van Soolingen et al., 1991; van Soolingen et al., 1993). 
The possibility of random integration of the element has been investigated using the 
IS6110-RFLP technique described later in this section, and it was reported that the 
insertions were not completely random i.e. there were preferential insertion sites 
(McHugh et al., 1998). There have been many studies demonstrating that one of the 
preferential sites of integration is the DR region and a study by Legrand et al., 2001 
showed the insertion of an IS6110 copy in between spacers 31 and 32 in the DR 
region (Legrand et al., 2001). The DR region is not the only hotspot as other sites 
such as the genomic region between Rv1754c and Rv1762c and the dnaA-dnaN IR 
have also been recognised as preferential sites of integration (Kurepina et al., 1998; 
Sampson et al., 1999).  
 
The IS6110-RFLP method has been described in great detail by van Embden et al., 
1993 (van Embden et al., 1993). In brief, the method involves a single cleavage of 
each IS6110 element present on the genome using the restriction enzyme PvuII that 
cleaves at the 481 b.p. position of the 1355 b.p. element as shown in Figure 1.4. 
Agarose gel electrophoresis separates the resulting fragments with sizes ranging from 
0.9 to 10 kilobases (kb). Using an IS6110 probe allows visualisation of fragments as 
the probe hybridises to the right of the PvuII cleavage site, as indicated in Figure 1.4. 
This gives a fingerprint of the strain that can be compared to reference fingerprints 
with known band sizes. Currently, IS6110-RFLP remains the gold standard technique 
for typing MTBC strains, which is why it has been discussed in great detail even 
though this technique was not used in the present study. 
 
Figure 1.4 A map of the 1355 b.p. IS6110 region with the cleavage site for PvuII restriction enzyme at the 481 b.p. position and the position at which 
the IS probe hybridises. Taken from Embden et al., 1993 (van Embden et al., 1993).   
 
 
 
 
 
 
 
 
 
1.2.3 Spoligotyping 
As mentioned in Section 1.2.1, species from the MTBC contain a specific 
chromosomal region featuring multiple 36 b.p. DRs interspersed by 35 to 41 b.p. 
spacers, which are unique. The possibility of using the DR region as a tool for typing 
was first pursued by Groenen et al., 1993, using direct variable repeat-polymerase 
chain reaction (DVR-PCR) (Groenen et al., 1993). Their study showed that MTBC 
strains with no epidemiological link could be differentiated effectively using a single 
PCR procedure. Whilst DVR-PCR allowed detection of M. tuberculosis as well as 
typing of strains, another simpler procedure, which was designed for a similar 
purpose, was introduced. Kamerbeek et al., 1997, developed a technique based on the 
hybridization patterns, which were thought to be strain-dependent, of amplified PCR 
product with various spacer oligonucleotides and, for this reason, the method was 
called spacer oligotyping or, more commonly, spoligotyping (Kamerbeek et al., 
1997). 
 
DNA sequence comparison has ultimately led to the discovery of 94 different spacer 
sequences with sequences for each displaying no homology with DNA sequences 
external to the DR region (van Embden et al., 2000). However, only 43 spacers, 
which were identified originally, are used for spoligotyping as the addition of extra 
spacers does not markedly improve discrimination (van Embden et al., 2000; Sebban 
et al., 2002). The polymorphic nature of the DR region is probably due to 
homologous recombination or transposition of the IS6110 element (van Embden et 
al., 2000). Both events would lead to deletion of spacers, which provides the basis for 
spoligotyping. 
 
Spoligotyping as described by Kamerbeek et al., 1997 involves the use of membranes 
that have 43 lines of covalently bound oligonucleotides, to which amplified product 
from the DR region will hybridise depending on which spacers are present and absent 
in the region (Kamerbeek et al., 1997). The hybridisation patterns for each strain are 
visualised using chemiluminescence producing a profile with black rectangles or 
blank spaces representing presence and absence of spacers, respectively. According to 
their studies, Kamerbeek et al., 1997, found that spoligotyping patterns were unique 
for the majority of the strains used in their study and further to this, observations 
showed that strains from particular outbreaks had the same pattern showing the 
potential of spoligotyping. 
 1.2.4 Variable Number Tandem Repeat, Exact Tandem Repeat & 
Mycobacterial Interspersed Repetitive Units  
Variable number tandem repeats (VNTRs) are minisatellites with 10 to 100 b.p. 
repeats and are found in great number in the genome of most bacteria (Mathema et 
al., 2006). VNTRs are found in regulatory and intergenic regions and within open 
reading frames and VNTRs in the human genome are particularly useful tools for 
forensic analysis, paternity testing and genetic mapping and identification. The 
polymorphic nature of this region meant that it would be useful for typing M. 
tuberculosis strains. 
 
Initially, Hermans et al., 1992, identified multiple copies of DNA sequences in the M. 
tuberculosis genome with a 10 b.p. sequence that was repeated tandemly and 
separated by distinctive spacers, 5 b.p. in length (Hermans et al., 1992). As there was 
slight variation in the sequence these repeats were called major polymorphic tandem 
repeats (MPTRs). The same study identified that the polymorphism would be 
especially useful for epidemiological studies as the location of MPTRs was very 
variable. The presence of MPTRs was confirmed by Frothingham and Meeker-
O'Connell, 1998, who reported the existence of 11 loci with tandem repeats in the 
genome of M. tuberculosis (Frothingham et al., 1998). These loci included 5 MPTRs 
and 6 exact tandem repeats (ETRs). The difference being that MPTRs contained 
repeats that were 15 b.p. in length but still had significant sequence variation between 
copies next to each other, whilst ETRs contained longer repeats and the sequences 
between adjacent repeats were identical. All ETR loci displayed length 
polymorphisms that were representative of deletions and insertions of tandem repeats, 
but this degree of polymorphism was not observed with MPTR loci. 
 
As mentioned in Section 1.2.1, MIRUs were found to exist in the region of the senX3-
regX3 mycobacterial two-component system encoding operon and in the study by 
Supply et al., 1997, it was observed that the sizes of MIRU tandem repeats varied 
(Supply et al., 1997; Magdalena et al., 1998). This is the main difference between the 
VNTRs and MIRUs (Mostrom et al., 2002). The length of MIRUs range from 40 to 
100 b.p. and 41 MIRUs have been identified as shown on the M. tuberculosis H37Rv 
genome in Figure 1.5 (Supply et al., 2000). Even though there are many MIRUS, only 
12 showed variations not only in the number of copies of tandem repeats but also in 
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the sequences between MIRUs. From the chosen 12 MIRUs, MIRU-4 and -31 were 
the same as ETR-D and -E, correspondingly, which were identified by Frothingham 
and Meeker-O'Connell, 1998. 
 
Further research into VNTRs yielded the identification of 7 new variable VNTR loci 
designated Queen’s University Belfast (QUB) 5, 11a, 11b, 15, 18, 23 and 26 (Skuce et 
al., 2002). As novel loci were discovered, in an attempt to simplify the situation a 
uniform nomenclature system was proposed by Smittipat et al., 2005 (Smittipat et al., 
2005). Table 1.2 shows the nomenclature system as defined by Smittipat et al., 2005, 
with the alternative names that are given to some of the VNTR loci by different 
researchers. Although not all loci have been included in the table, the selected loci are 
relevant to the present study. MTPRs have not been included in the original table by 
Smittipat et al., 2005, presumably because the original study by Frothingham and 
Meeker-O'Connell, 1998, showed that there was not a significant amount of 
polymorphism in the loci suitable for analysis (Frothingham et al., 1998; Smittipat et 
al., 2005). Table 1.3 shows the three sets of loci that were used along with the 
nomenclature that had been adopted for the present study. 
 
The use of various MIRU and VNTR loci means that the technique is widely known 
as MIRU-VNTR typing. Originally, MIRU-VNTR typing involved the determination 
of number of repeats by using primers specific to each locus to amplify the region in 
separate PCR reactions, after which agarose gel electrophoresis was performed to 
simultaneously confirm presence of PCR products and to determine the molecular 
weight. The number of repeats was calculated using previous knowledge of the 
molecular weight of expected products for various numbers of repeats in specific loci. 
 
The technique can be performed using an automated system, which involves the use 
of fluorescently labelled primers for amplification of loci making performance of 
multiplex PCR reactions possible and allowing large-scale genotyping (Supply et al., 
2001). Using the panel for 12 MIRU-VNTR (see Table 1.3) as an example, the 
number of repeats in each locus would be represented in a 12-digit format. The 
automated system involves the use of capillary electrophoresis (or comparable 
systems) instead of conventional agarose gel electrophoresis and for clustering studies 
capillary electrophoresis has proved to be more useful (Yokoyama et al., 2006). 
 
Figure 1.5 The M. tuberculosis H37Rv genome showing the positions of the 41 MIRU loci, where the black dots represent the 12 variable MIRUs. 
Taken from Supply et al., 2000 (Supply et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
1.2.5 Stability of genetic elements & discrimination power of IS6110-RFLP, 
spoligotyping and MIRU-VNTR typing 
The stability of genetic markers and their discriminatory power are two of the main 
factors influencing the application of IS6110-RFLP, spoligotyping and MIRU-VNTR 
for typing. 
 
Several studies have focused on the stability of IS6110 element with conflicting 
results. IS6110 elements are stable over a short time scale of a few months but when 
looking over longer periods of time, a significant rate of transposition is observed 
(Tanaka et al., 2000). Strains with a larger number of IS6110 copies are more 
polymorphic than strains with low copy number (Tanaka et al., 2000; Tanaka et al., 
2001; Maguire et al., 2002). 
 
In a detailed study carried out in the Netherlands by de Boer, et al., 1999, IS6110-
RFLP fingerprint profiles were different between initial and follow-up isolates; 
changes were more frequent in individuals with extrapulmonary TB than in people 
with both pulmonary and extrapulmonary TB (de Boer et al., 1999). From their study 
they calculated the half-life (t(½)) of IS6110 element as being 3.2 years. In a study, 
which focused on serial isolates (with a known time interval between isolates) from 
patients in San Francisco, the t(½) was 2 years (Yeh et al., 1998; de Boer et al., 1999). 
A suggested explanation for the difference between the results of the IS6110 element 
t(½) in the Netherlands and San Francisco studies was the lack of bias in the serial 
isolates included in the Netherlands study as there was no prior knowledge of the time 
interval between serial isolates. 
 
A study by Warren et al., 2002, showed that  the IS6110 t(½) was 8.74 years (Warren 
et al., 2002). Yeh et al., 1998, suggested that there was a rapid rate of transposition as 
IS6110-RFLP patterns changed in a 3 year time gap (Yeh et al., 1998). A possible 
explanation for the differences in the calculated t(½) between all of the studies is that 
rates were considerably affected by the period between TB onset and the point where 
sputum was sampled, and the potential for re-infection in a high incidence country 
indicated the complexity of estimating the true degree of stability. 
Table 1.2 The nomenclature for VNTR loci, along with the alternative names assigned by different 
researchers. (Produced using Table 2 in Smittipat et al., 2005 (Smittipat et al., 2005). 
 
Tandem repeat locus Alternative nomenclature 
ETR-A 
VNTR-2163A 
VNTR-2163B 
VNTR-1982 
MIRU-40 
loci not included in the table by Smittipat 
et al., 2005 but included in this table for 
the purposes of the present study 
VNTR-2059 MIRU-20 
VNTR-0154 MIRU-2 
VNTR-0577 ETR-C 
VNTR-0580 ETR-D, MIRU-4 
VNTR-0960 MIRU-10 
VNTR-1644 MIRU-16 
VNTR-2347  
VNTR-2461  ETR-B 
VNTR-2531 MIRU-23 
VNTR-2687 MIRU-24 
VNTR-2996 MIRU-26 
VNTR-3007 MIRU-27, QUB-5 
VNTR-3155 QUB-15 
VNTR-3192 ETR-E, MIRU-31 
VNTR-3232 QUB-3232 
VNTR-3239 ETR-F 
VNTR-3336 QUB-3336 
VNTR-4052 QUB-26 
VNTR-4348 MIRU-39 
 
Table 1.3 A table showing the three sets of loci with their nomenclature as used in the present study. 
 
MIRU-VNTR loci 12 MIRU 15 MIRU-ETR Extra 7 loci 
MIRU-2 D D  
MIRU-4 D D  
MIRU-10 D D  
MIRU-16 D D  
MIRU-20 D D  
MIRU-23 D D  
MIRU-24 D D  
MIRU-26 D D  
MIRU-27 D D  
MIRU-31 D D  
MIRU-39 D D  
MIRU-40 D D  
ETR-A  D  
ETR-B  D  
ETR-C  D  
VNTR-2163A   D 
VNTR-2163B   D 
VNTR-1982   D 
VNTR-2347   D 
VNTR-3232   D 
VNTR-3336   D 
VNTR-4052   D 
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Niemann et al., 1999, observed that whilst there was variation in IS6110-RFLP 
patterns between initial and follow-up isolates, there were no changes in the 
spoligotyping patterns indicating that the rate of change is much lower in the DR 
region making this genetic marker more stable than IS6110 (Niemann et al., 1999). A 
similar scenario was reported by Goguet de la Salmoniere et al., 1997, when the same 
spoligotyping pattern was obtained for all strains of M. bovis BCG used in their study 
(Goguet de la Salmoniere et al., 1997). Although rare, coexistence of strains with two 
different spoligotyping patterns in a patient has been observed: the second isolate 
differed from the initial isolate due to a deletion that had occurred during a single 
episode of TB within the patient (Kamerbeek et al., 1997; van Embden et al., 2000). 
However, except for this one deletion, spoligotypes were shown to be stable. The 
existence of an international spoligotyping database, SpolDB4, means that 
comparison studies using this typing technique are possible (Brudey et al., 2006). 
 
As is the case with spoligotyping, MIRU-VNTR is reliable for follow-up of patients, 
in particular in patients that have chronic infection over a long period of time (Savine 
et al., 2002). The in vivo stability of the 12 MIRU-VNTR loci has been observed and 
the estimated length of stability has been reported to be at least 18 months, whilst 
MIRUs are reasonably stable for 30 years in axenic culture environments where only 
one organism is present (Supply et al., 2000; Mazars et al., 2001). In a study 
involving typing of BCG strains that had been cultivated for more than 30 years, there 
was polymorphism in locus MIRU-4, whilst the remaining 11 loci were monomorphic 
indicating that there is slow evolution of these minisatellite-like structures (at least in 
BCG) (Supply et al., 2000). The polymorphisms due to repeat units being added and 
deleted are believed to lead to long term stability of loci. 
 
The MIRU-VNTR loci have a variable range of alleles; for instance, in MIRU-2 and -
24 mostly 1 or 2 copies are observed, therefore, these loci are not very polymorphic in 
comparison with VNTR-3232, -3820 and -4052 (Smittipat et al., 2005). More than 9 
allelic variants have been observed in these loci and VNTR-3820 had the highest 
variability with numbers of repeats varying from 3 to 32. There are external factors 
that influence the variability of particular MIRU-VNTR loci; for instance, MIRU-20 
appears to be more polymorphic in some studies and not in others (Smittipat et al., 
2005). Influential factors may include the source of samples geographically and 
possibly the inherent genetic diversity. Therefore when selecting the panel of loci, 
 - 50 -
factors such as the predominance of certain clones in specific geographical locations 
and the variability within different genetic groups of MTBC strains needs to be taken 
into account (Mathema et al., 2006). 
 
However, selecting different VNTRs for panels with different applications may not be 
ideal as this diminishes advantages of using a universal MIRU-VNTR panel for 
interlaboratory analysis and adopting a technique that is cost effective and 
manageable with regard to labour. An assessment of the reproducibility and 
interlaboratory variation of IS6110-RFLP patterns showed that patterns with smaller 
numbers of bands were reproducible but not for strains with higher numbers of 
IS6110 copies and complex patterns (Braden et al., 2002). In contrast, a comparative 
study showed high reproducibility using MIRU-VNTR demonstrating its potential for 
interlaboratory analysis (Kremer et al., 2005). 
 
There have been numerous studies to compare the results of different molecular 
typing methods and there are clear conclusions on the discriminative abilities of 
techniques (Goguet de la Salmoniere et al., 1997; Kremer et al., 1999; Barlow et al., 
2001; Lee et al., 2002; Hawkey et al., 2003; Gopaul et al., 2006). M. tuberculosis 
isolates with a low IS6110 copy number of 1 to 4 have been excluded because of the 
lower degree of discrimination and where there is a low copy number of IS6110, the 
degree of differentiation offered by spoligotyping is higher than it would be if there 
was a high IS6110 copy number (Goguet de la Salmoniere et al., 1997; Maguire et al., 
2002). Using both of these methods together gives greater discrimination for 
genotyping (Kremer et al., 1999).  
 
The loci included in the 12 MIRU-VNTR panel, described by Supply et al., 2000, 
have varying discriminatory powers with the most discriminative loci being MIRU-
10, -23, -26, -31, -40 and ETR-A (when compared to ETR-B and -C), whilst MIRU-4, 
-16, -24 and -39 were found to be moderately discriminative, and MIRU-2, -20 and -
27 were of poor discrimination (Sola et al., 2003). The discriminative power of 
MIRU-VNTR is proportional to the number of loci in a panel and is similar to that of 
IS6110-RFLP when there is a high copy number of IS6110, but more discriminatory 
when the IS6110 copy number is low (Barlow et al., 2001; Lee et al., 2002; Hawkey 
et al., 2003; Gopaul et al., 2006; Mathema et al., 2006). In a study by Mazars et al., 
2001, the use of 12 MIRU-VNTR yielded 2 to 8 MIRU-VNTR alleles, meaning there 
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were over 16 million different combinations showing that the resolution of MIRU-
VNTR was close to that of IS6110-RFLP (Mazars et al., 2001). However it has been 
reported that 12 MIRU-VNTR is less discriminatory than IS6110-RFLP typing of 
high copy number isolates. Combining 12 MIRU-VNTR and spoligotyping seems to 
provide more discrimination than IS6110-RFLP on its own (Roring et al., 2002). 
Some studies have shown that whilst patterns for 12 MIRU-VNTR are more distinct 
than those obtained by IS6110-RFLP and spoligotyping, specificity is maximised 
when multiple typing methods are used (Cowan et al., 2002).  
 
1.2.6 Deletion mapping 
Differences in the genomes of M. tuberculosis strains H37Rv and CDC1551 have 
been observed and are believed to be caused by SNPs, (i.e. differences in single base 
pairs), and large-sequence polymorphisms (LSPs) that show differences in sequences 
greater than 10 b.p. (Fleischmann et al., 2002). In addition to variation due to SNPs, 
LSPs have been identified as the source of most insertion-deletion events (Brosch et 
al., 2001). Various regions of variability due to insertion and deletion have been 
identified. These deletions occur in aggregations rather than randomly along the 
genome and the irreversible nature of deletions forms the basis of deletion mapping, 
which can be utilised for identifying strains within the MTBC (Brosch et al., 2002; 
Tsolaki et al., 2004).  
 
Such studies have already been performed and yielded very promising results. Brosch 
et al., 2002 investigated 20 variable regions in MTBC strains and results showed that 
these polymorphisms were not independent events but due to genetic occurrences that 
were irreversible in common ancestral strains (Brosch et al., 2002). The main region 
of interest from their study was the M. tuberculosis specific deletion 1 (TbD1). The 
presence or absence of this region was indicative of ancestral and modern strains, 
respectively. Also identified in this study were regions of differences (RDs), one of 
which includes RD9 and if a deletion is recognised in this region it determines that a 
strain is neither ancestral nor modern M. tuberculosis, but one of the other species in 
the MTBC, namely M. africanum, M. microti, and M. bovis. The presence or absence 
of other RD regions allows further sub-speciation within the MTBC as indicated in 
Figure 1.6 (Brosch et al., 2002). 
 
MTBC strain typing using the identified regions of possible deletion is very simple 
and straightforward to perform as it involves amplification of regions of interest using 
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specific primers and running the resulting products on an agarose gel. This reveals 
bands representing larger and lower molecular weights corresponding to the presence 
and absence of the region, respectively. Although deletion mapping was not included 
in the present study it is important to acknowledge its importance in MTBC 
phylogenetic analysis, which will be discussed in Section 1.3.2. 
 
1.3 APPLICATIONS OF MOLECULAR TYPING METHODS 
 
1.3.1 Epidemiological studies 
There are a large range of applications for IS6110-RFLP, spoligotyping and MIRU-
VNTR typing and now deletion mapping. These techniques can give a deeper insight 
into the epidemiology of M. tuberculosis (using IS6110-RFLP, spoligotyping and 
MIRU-VNTR typing) and its phylogeny (using IS6110-RFLP, spoligotyping and 
MIRU-VNTR typing and deletion mapping). The varying discriminatory power of the 
typing techniques makes certain methods more favourable than others for specific 
applications. With regard to MIRU-VNTR, there are applications that are especially 
useful for individual laboratories and will be discussed. 
 
Due to its high discriminatory power, IS6110-RFLP has been the most widely used 
approach for large scale national and international molecular epidemiology studies 
and outbreak investigations. IS6110-RFLP was favoured as the international standard 
procedure that was recognised by all laboratories especially for TB epidemiological 
studies and remains the gold standard technique due to the combination of a very high 
degree of polymorphism and stability of the IS6110 element (van Soolingen et al., 
1991; van Soolingen et al., 1993; Li et al., 2005; Kik et al., 2008; Devaux et al., 
2009). For large scale epidemiological studies, whilst interlaboratory comparison of 
IS6110-RFLP patterns is possible, quality control is essential and has to be carefully 
monitored.  
 
IS6110-RFLP has been used to understand epidemiological transmission of TB all 
over the world. One particular study of interest is that performed by Maguire et al., 
2002, in London to investigate recent transmission events of M. tuberculosis (Maguire 
et al., 2002). Isolates were typed using IS6110-RFLP and patient epidemiological data 
collated. This study demonstrated that TB occurrence in London, in comparison with 
the other cities, was not mainly due to recent transmission. The majority of TB in 
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London was due to either infection being imported by immigrants that moved to 
London recently or by reactivation of previous TB infections (Maguire et al., 2002). 
 
However, there are limitations to the uses of IS6110-RFLP as the fewer bands there 
are within strains the harder it is to interpret, compare patterns and discriminate 
between strains even when using computerised data image analysis. IS6110-RFLP is 
labour-intensive especially when typing large numbers of isolates, making 
spoligotyping and MIRU-VNTR more attractive, and only using IS6110-RFLP to 
confirm the identity of the organism (Kremer et al., 2002). A study investigating the 
potential of IS6110-RFLP and spoligotyping for epidemiological studies showed that 
the discriminatory power of spoligotyping was not sufficient to make it a method that 
could be used on its own and that IS6110-RFLP was more discriminatory for outbreak 
studies (Wilson et al., 1998). 
 
The potential of the loci included in MIRU-VNTR as genetic markers for 
epidemiological studies has been recognised and evaluated (Mazars et al., 2001). 
MIRU-VNTR profiles of isolates that are epidemiologically linked have been shown 
to cluster proving that stability of this genetic marker is sufficient for identifying 
outbreaks. The added advantages of using MIRU-VNTR are the high throughput of 
isolates that can be typed and the ease with which numerical profiles can be 
compared. In some epidemiology studies, a two-step approach has been used with 
IS6110-RFLP as the primary technique followed by MIRU-VNTR (Kwara et al., 
2003). It has even been suggested that using spoligotyping in conjunction with 
MIRU-VNTR would be appropriate for studying epidemiology of TB (Sola et al., 
2001). 
 
When used collectively, molecular typing techniques have proved useful for 
identifying possible sources of outbreaks, which were previously not known, in 
specific social scenarios (Yaganehdoost et al., 1999; Drobniewski et al., 2003). In 
another case study, strain typing was used to recognize and characterise strains, which 
had originated in hospitals, and their transmission. In this particular study molecular 
markers were identified to verify an outbreak of multi-drug resistance (MDR) TB and 
clarifying the history of the order in which drug resistance was acquired as the 
progress of the outbreak could be monitored by molecular typing (Bifani et al., 1996). 
Figure 1.6 A diagram showing the regions that would be deleted (in the boxes) from the genome to identify strains within the MTBC. Taken from 
Brosch et al., 2002 (Brosch et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiology studies using molecular typing has helped to identify the source of 
infection in order to take the most appropriate measures to control TB infection. In 
New York, for instance, the continuous spread of the M. tuberculosis Beijing strain 
led to an escalation in incidence of multiple drug resistance strains of M. tuberculosis 
and as soon as this was recognised, appropriate measures were enforced to curb the 
spread of the strain (Bifani et al., 1996; Moss et al., 1997). Molecular typing is also 
valuable for detected sources of TB infection on a smaller scale, for instance, in 
hospitals as described by Allix et al., 2004 (Allix et al., 2004). This study described a 
scenario in which patients had visited the same hospital during a 1 year period and 
had TB infection in which isolates had identical IS6110-RFLP patterns and 
confirmation was obtained using MIRU-VNTR typing. Their visit to the hospital was 
traced back and it was discovered that they had been to the hospital pneumological 
surgery department for bronchoscopic examination on the same day. The TB infection 
was bronchoscopy-related. 
 
1.3.2 Phylogenetical studies 
Whilst molecular typing techniques are useful for studying the epidemiology of TB 
transmission, there is also significant potential for clarifying phylogenetic 
relationships of clinical isolates and numerous studies have been carried out in an 
attempt to decipher the phylogenetic structure and relationships within MTBC. Before 
continuing, a brief description of SNP has to be included as major breakthroughs in 
phylogenetic studies have resulted from the use of SNP analysis. 
 
M. tuberculosis genome comparisons have yielded polymorphisms at various 
nucleotides, which is a source of more genetic markers to distinguish between M. 
tuberculosis strains. There exists nsSNPs and synonymous SNPs (sSNPs), the main 
difference being that nsSNPs lead to changes in amino acids, whilst sSNPs do not i.e. 
they are neutral. It is the sSNPs that form the basis of studies into evolutionary 
relationships, as sequences of specific regions would help to identify these neutral 
polymorphisms between strains. 
 
Using IS6110-RFLP to assign M. tuberculosis isolates into lineages has shown that 
there are only two specific lineages determined by high and low IS6110 copy number 
(Mazars et al., 2001). Using sSNP has proved otherwise. In the study by Gutacker et 
al., 2002, the phylogenetic relationship of M. tuberculosis isolates from various global 
sources was investigated using 230 sSNP resulting in eight clear-cut lineages 
(Gutacker et al., 2002). Sreevatsan et al., 1997, assigned these eight lineages, I to 
VIII, into three principle genetic groups (Sreevatsan et al., 1997). The largest genetic 
group contained isolates from lineage III to VI, whilst the smallest group was M. 
bovis in a lineage on its own. 
 
Delving deeper into the matter of how important IS6110 copy number is for 
phylogeny studies, Gutacker et al., 2002 has shown that the association between 
IS6110 copy number and phylogenetic lineages is more complex and that the copy 
number alone is not useful for phylogeny studies (Gutacker et al., 2002). This was 
confirmed by Gutacker et al., 2006, which specifically looked at variations in IS6110-
RFLP, spoligotyping and MIRU-VNTR amongst lineages defined by sSNP (Gutacker 
et al., 2006).  
 
In their study, Gutacker et al., 2006, again found a similar phylogenetic trend except 
this time nine genetic lineages were identified, the extra one being II.A (Gutacker et 
al., 2006). When looking for associations between the nine lineages and the number 
of IS6110 copies, IS6110 elements that had been inserted in the mmpS1 gene could be 
genetically associated with lineage IV, showing that these particular strains were 
related by descent. Isolates with less than 6 copies could be associated with different 
lineages, whilst isolates with just 1 copy were distributed amongst lineages I, II.A, 
and IV. This again contradicts the definition of two lineages using the high copy 
number and low copy number categorisation. 
 
Comparison of spoligotypes with phylogenetic lineages shed some light on the genetic 
relationship between principle genetic groups (Gutacker et al., 2006). As a whole, 
population principal genetic group 2/3 isolates were genetically related but could be 
distinguished from principal genetic group 1 organisms as there was no overlap of 
spoligotypes between group 1 and group 2/3. A similar trend was observed when 
MIRU-VNTR profiles for isolates were compared with the phylogenetic lineages. 
This indicates that spoligotyping and MIRU-VNTR typing hold great potential for 
phylogenetic studies. When looking at the data using all three typing methods and 
sSNP, there was a strong indication that strains within the 9 lineages were clonally 
related by descent, as they had a common ancestor (Gutacker et al., 2006). The 
influence of various genetic markers in phylogenetic studies has been confirmed by 
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Warren et al., 2004, who suggested that clonal expansion occurred via sequential 
acquisition of additional IS6110 copies, deletions of specific DR sequences and 
VNTR sequence expansion and contraction (Warren et al., 2004). 
 
Baker et al., 2004, used various typing methods to investigate the phylogeny of 
MTBC including sSNP, TbD1 deletion mapping, IS6110-RFLP and spoligotyping. A 
phylogenetic tree, shown in Figure 1.7a, was produced from data obtained using 
sSNPs and the maximum parsimony method and the different branches of the tree 
represented unique sSNP combinations (Baker et al., 2004). Isolates were defined into 
four distinct M. tuberculosis lineages, I to IV, and a closely related M. bovis lineage. 
 
Correlations and discrepancies between this study and that performed by Gutacker et 
al., 2006 have been identified and reviewed by Mathema et al., 2006 (Mathema et al., 
2006). Lineage I in Baker et al., 2004, corresponds to lineage II in Gutacker et al., 
2006, lineage II is a combination of lineage III, IV, V and VI, lineage III is associated 
with II.A and lineage IV to lineage I. In both studies, M. bovis is a separate lineage. A 
study by Gagneux et al., 2006, showed agreement with lineages I, II, III and IV 
defined by Baker et al., 2004 (Gagneux et al., 2006). In addition to the four lineages, 
two lineages for M. africanum were identified by Gagneux et al., 2006 as there had 
been few M. africanum strains in the study by Baker et al., 2004.   
 
Baker et al., 2004 also looked at the association of the absence and presence of TbD1 
with particular lineages. TbD1 was present in lineage IV and M. bovis, M. microti and 
M. africanum whilst it was absent in the remaining lineages (Figure 1.7b) (Baker et 
al., 2004).  IS6110-RFLP and spoligotyping allowed the assignation of various strain 
families into lineages (Figure 1.7c). The various strains of M. tuberculosis agreed 
with the parsimony tree originally defined using sSNP. The introduction of the 
spoligotyping database, SpolDB4, will contribute greatly towards understanding the 
phylogeny of MTBC as it will allow better identification of isolates to then investigate 
the dissemination of a strain and its history (Brudey et al., 2006).  
 
The possibility of using 12 MIRU and 3 ETR as a rapid tool for phylogenetic 
classification of M. tuberculosis and M. bovis using the five lineages observed by 
Baker et al., 2004 was investigated by Gibson et al., 2005 (Gibson et al., 2005). This 
study generated specific panels of MIRU-VNTR loci that were specific for the 
lineages suggesting that MIRU-VNTR could be used for classification of M. 
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tuberculosis and M. bovis and investigating phylogeny and evolution, whilst 
providing information on sublineages and molecular clocks. 
 
Results from a study that combined MIRU-VNTR and spoligotyping methods 
confirmed a scenario that was proposed by Brosch et al., 2002, from results obtained 
from deletion analysis using TbD1 and various RD regions (Sola et al., 2003). This 
scenario involved a common MTBC ancestor from which the first divergence would 
have led to the species M. canettii followed by the separation of M. tuberculosis East-
African Indian (EAI) strains (Brosch et al., 2002; Sola et al., 2003). M. africanum and 
M. bovis would have been next to be separated proceeded by separation that would 
distinguish M. tuberculosis Beijing, which is distinctive from the Central Asian 1 
(CAS1) family, and non-Beijing strains. Latin-American and Mediterranean (LAM), 
X and Haarlem strains are thought to have deviated later. A similar scenario was 
proposed by Ferdinand et al., 2004, using spoligotyping and MIRU-VNTR, more 
specifically MIRU-24, which the study reported was the most appropriate for 
classification (Ferdinand et al., 2004). 
 
Even though there may be discrepancies between the results obtained from 
phylogenetical studies, it seems to be a general conclusion that distinct lineages can 
be defined and that M. tuberculosis is clonal where horizontal gene transfer does not 
occur. Mathema et al., 2006, suggested reasons for the differences in studies including 
evolutionary convergence that is specific to certain loci which would affect results 
particularly if only one genetic marker is used, or locus-specific transition, which 
would again affect results when using a single marker (Mathema et al., 2006). These 
potential problems can be overcome by using a combination of molecular methods, 
including sSNP, deletion mapping of more than one region, IS6110-RFLP, 
spoligotyping and MIRU-VNTR. 
 
Molecular typing techniques are of great value for phylogenetic analysis of MTBC 
strains as they add further resolution to lineages that have already been defined by 
sSNP. Phylogenetic analysis can help to identify and assign strains that have been 
identified in epidemiological studies to further the knowledge of the association 
between the MTBC strain genotypes. 
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1.3.3 Other applications 
Molecular typing techniques can be applied to clinical situations that are most 
commonly experienced in laboratories, including detection of laboratory cross-
contamination and mixed tuberculosis infection. In order to obtain results rapidly, but 
still ensuring that results are reliable, typing methods based on PCR amplification are 
more suitable. Using a combination of spoligotyping and MIRU-VNTR means that 
results are obtained quicker, whilst still having the discriminatory level of IS6110-
RFLP.  
 
Laboratory cross-contamination is a potential problem when diagnosing TB. Ideally 
the rate of cross-contamination in a laboratory should be less than 1%, but reports 
have shown contamination rates of 0.1 to 65%, i.e. in some laboratories it is a serious 
issue that needs to be addressed (Bhattacharya et al., 1998; de et al., 1999; Ruddy et 
al., 2002). This is where molecular typing techniques come into play as they allow 
reliable detection of cross-contamination. Identifying false-positive cultures of M. 
tuberculosis as early as possible ultimately means the prevention of inappropriate 
treatment of TB in the patient. Whilst IS6110-RFLP can be used to confirm results of 
spoligotyping and MIRU-VNTR, this method is not ideal as it is time consuming and 
would delay detection. 
 
For example, in a study on cross-contamination carried out at the Health Protection 
Agency, Mycobacterium Reference Unit (HPA, MRU), IS6110-RFLP was used to 
confirm results using another technique, rapid PCR-based epidemiological typing 
(RAPET) (Drobniewski et al., 2003). This study showed that there were three types of 
cross-contamination including laboratory cross-contamination, bronchoscopic-related 
and ward-based incidents. In another case study, specimens from 6 different patients, 
which had been decontaminated on the same day, were all positive for M. tuberculosis 
(Allix et al., 2004). Upon MIRU-VNTR typing it was suggested that there was 
possible laboratory contamination as profiles for the majority of isolates were 
identical, whilst isolates from patients that were smear negative had different MIRU-
VNTR profiles. 
 
Although mixed cultures can be detected using IS6110-RFLP and spoligotyping, the 
patterns can be complex to interpret (Pavlic et al., 1999; Allix et al., 2004). MIRU-
VNTR is more appealing for detecting mixed cultures as the simultaneous existence 
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of 2 alleles in individual loci can be more easily identified. In addition, the alleles can 
be distinguished from stutter peaks that are commonly observed. Mixed cultures can 
be differentiated from laboratory cross contamination especially if follow-up isolates 
are obtained from the patient in question (Allix et al., 2004). 
 
1.4 PROJECT AIMS 
 
The aims of the present study were to:- 
• identify the various common and unique clinical M. tuberculosis strains 
circulating within the ethnically diverse population in London 
(http://www.londonshealth.gov.uk/pdf/HINL2004/hilfullreport2004.pdf) by doing 
cluster analysis using molecular typing data for all MTBC isolates from TB cases 
reported within London during a one year time period from the 1st April 2005 to 
31st March 2006,  
• understand the global representation of M. tuberculosis strains in the study 
population of London by performing epidemiological analysis using molecular 
typing and country of birth data, 
• construct a preliminary panel of strains that would be as representative of the 
global population of TB strains as possible and include a broad spectrum of M. 
tuberculosis strains against which any vaccine should be effective; the strains in 
this panel of M. tuberculosis strains would be useful for selecting strains for future 
vaccine evaluation studies and general TB research, 
• understand if TB strains in the preliminary panel are indeed different from each 
other by testing the null hypothesis that strains are phenotypically similar by 
performing a series of initial in vitro experiments followed by in vivo experiments 
on a smaller panel of strains, representing the six MTBC phylogenetic lineages 
defined by Baker et al., 2004 and Gagneux et al., 2006, derived from the 
preliminary panel. 
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Figure 1.7 The phylogeny of M. tuberculosis, where (a) shows a maximum parsimony 
tree of M. tuberculosis and M. bovis lineages based on the combinations of sSNPS, 
(b) shows how absence and presence of TbD1 is related to the lineages, and (c) shows 
the relationship between the defined phylogenies and the various strains including 
Beijing, Harleem, Africa, Latin America-Mediterranean, Delhi, and East Africa-India 
(EA-I). Taken from Baker et al., 2004 (Baker et al., 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 c) b) 
a) 
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CHAPTER 2 
 
MATERIALS & METHODS 
 
2.1 PREPARATION OF SOLUTIONS, MEDIA & REAGENTS 
 
2.1.1 Spoligotyping stock solutions 
20% sodium dodecyl sulphate (SDS) was prepared by dissolving 100 grams (g) SDS 
(BDH Laboratory Supplies, Poole, UK) in molecular grade water (Sigma-Aldrich, 
Poole, UK) to make a final volume of 500 millilitres (ml). 
0.5M Ethylenediaminetetraacetic acid disodium salt dihydrate 99+% (EDTA) (pH 
8.0) was prepared by dissolving 93.0g EDTA (Sigma-Aldrich) in distilled water to 
make a final volume of 500ml. The pH was adjusted to 8.0 using sodium hydroxide 
(NaOH) pellets (BDH Laboratory Supplies). 
All stock solutions were stored at room temperature. 
 
2.1.2 Solutions for spoligotyping that are made fresh each time  
2× saline sodium phosphate EDTA (SSPE)/0.1% SDS was prepared by adding 30ml 
20× SSPE buffer (Sigma-Aldrich), 1.5ml 20% SDS and distilled water to make a final 
volume of 300ml per membrane. SDS was not added to concentrated SSPE as this 
would cause it to precipitate. 
2× SSPE/0.5% SDS was prepared by adding 100ml 20× SSPE buffer, 25ml 20% SDS 
and distilled water to make a final volume of 1000ml per membrane. 
2× SSPE was prepared by diluting 50ml 20× SSPE in distilled water to make a final 
volume of 500ml per membrane.   
1% SDS was prepared by diluting 10ml 20% SDS in distilled water to make a final 
volume of 200ml per membrane. 
20 millimolar (mM) EDTA was prepared by diluting 4ml 0.5 molar (M) EDTA in 
distilled water to make a final volume of 100ml per membrane. 
 
2.1.3 Media for culturing M. tuberculosis strains 
Middlebrook 7H9 medium with 0.05% Tween-80 was prepared by dissolving 4.7g BD 
Difco Middlebrook 7H9 broth (Becton, Dickinson and Company, New Jersey, United 
States of America; USA) in 900ml distilled water and sterilising the medium by 
autoclaving at 121°C for 10 minutes (mins). Tween-80 solution was added after 
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autoclaving. In a Class II cabinet, 5ml 10% Tween-80 solution (Sigma-Aldrich) was 
added to the sterile medium at a final concentration of 0.05% in 1000ml. The 
Middlebrook 7H9 medium with 0.05% Tween was filter sterilised using a 0.2 
micrometre (μm) filter unit (Nalgene Labware, New York, USA) and stored at 20°C. 
Before use, depending on the volume of medium required for an experiment, BD BBL 
Middlebrook OADC Enrichment (Becton, Dickinson and Company) was added at a 
medium:OADC ratio of 9:1. OADC supplement was not added to media when it was 
made initially to give the media a longer shelf life. 
Middlebrook 7H11 agar plates were prepared by dissolving 20.5g Middlebrook 7H11 
Agar Base (Sigma-Aldrich) in 900ml distilled water and adding 5ml glycerol (Sigma-
Aldrich). The medium was sterilised by autoclaving and then left to cool down to 
50°C. Only then was 100ml OADC added to the medium and mixed using a magnetic 
stirrer. The liquid agar was dispensed into OPTILUX Petri Dishes 100×20 millimetres 
(mm) Style (Becton, Dickinson and Company) so that there was approximately 35ml 
medium per plate. 
 
2.1.4 Reagents for DNA extraction  
Tris-EDTA (TE) buffer (10mM Tris, 1mM EDTA pH8.0) was prepared by measuring 
200 microlitres (µl) Tris-EDTA Buffer (Sigma-Aldrich) and using molecular grade 
water to make the volume up to 20ml. This reagent was stored at room temperature. 
Lysozyme (100mg/ml) was prepared by dissolving 1g lysozyme from chicken egg 
white (Sigma-Aldrich) in 10ml molecular grade water, after which 1ml aliquots were 
prepared in 1.5ml microcentrifuge tubes (Alpha Laboratories Limited (Ltd.), 
Hampshire, UK), which were stored at -20°C. 
Buffer AW1 and AW2 from the DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany) were prepared by adding the volume of ethanol 96-100% (Sigma-Aldrich) 
specified on the bottle. These reagents were stored at room temperature. 
 
2.1.5 Media & solutions for tissue culture 
Complete Roswell Park Memorial Institute (RPMI) 1640 medium was prepared 
aseptically in a Class II safety cabinet with a final concentration of 10% Standard 
Quality Foetal Bovine Serum (FBS; PAA Laboratories, Wagram, Austria), 100 units 
(U) Penicillin/ 100 ug Streptomycin (Invitrogen Ltd., Paisley, UK), 20 mM L-
glutamine (Invitrogen), and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
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acid (HEPES) (Gibco Invitrogen, California, USA). Media were stored at 20°C ready 
for use.  
1× DPBS was prepared by diluting 100ml 10× Dulbecco’s phosphate-buffered saline 
(DPBS) without calcium and magnesium (Gibco, Invitrogen) with 900ml distilled 
water. The full volume was filter sterilised using a 0.2μm filter unit and stored at 
20°C ready for use. 
 
2.2 MOLECULAR TYPING OF M. TUBERCULOSIS STRAINS 
 
2.2.1 Preparation of M. tuberculosis DNA extracts 
Culturing of M. tuberculosis specimens and DNA extraction was performed at the 
HPA, MRU. During a 12 month period, between 1st April 2005 and 31st March 2006, 
there were a total of 2363 isolates, which had been received from 30 hospitals and/or 
laboratories situated within the M25 region of London, and had been routinely 
identified as MTBC. 
 
Crude DNA extraction was performed in biological safety cabinets (BSC) within a 
Containment Level 3 laboratory, following all safety guidelines. In brief, 100µl of 
each culture was aliquoted into individually labelled 1.5ml microcentrifuge tubes. An 
equal volume of chloroform (VWR International, Leicestershire, UK) was added to 
each tube. After ensuring the cap was screwed on tightly, each tube was vortexed for 
30 seconds (secs). Tubes were not opened at this stage due to aerosol production 
during vortexing. Tubes containing culture/chloroform mixture were heated at 80°C 
for 20 mins after which tubes were stored at -20°C ready for use. 
 
2.2.2 DNA amplification for MIRU-VNTR typing 
Typing was performed on the crude DNA extracts from all isolates, analysing the 15 
MIRU and 3 ETR minisatellite regions spanning the M. tuberculosis genome and 
included the loci MIRU-2, -4, -10, -16, -20, -23, -24, -26, -27, -31, -39, -40, and ETR-
A, -B, -C. WellRED dye labelled forward primers (Sigma Proligo, Poole, UK) and 
unlabelled reverse primers (Invitrogen Ltd.) were already in use within the laboratory 
and were designed using previous studies by Frothingham and O’Connell, 1998 and 
Supply et al., 2001 with some modifications during optimisation (Frothingham et al., 
1998; Supply et al., 2001). Sequences of all primers and labelling dyes are included in 
Table 2.1. 
Table 2.1 The sequences for all primers used for MIRU-VNTR typing. 
 
Primer Forward sequence Reverse sequence Dye used for labelling 
MIRU-2  5’- CAG GTG CCC TAT CTG CTG ACG-3’ 5’-GTT GCG TCC GGC ATA CCA AC-3’ WellRED D3 
MIRU-4  5’-GTC AAA CAG GTC ACA ACG AGA GGA A-3’ 5’-CCT CCA CAA TCA ACA CAC TGG TCA T-3’ WellRED D2 
MIRU-10  5’-ACC GTC TTA TCG GAC TGC ACT ATC AA-3’ 5’- CAC CTT GGT GAT CAG CTA CCT CGA T-3’ WellRED D4 
MIRU-16  5’-CGG GTC CAG TCC AAC TAC CTC AAT-3’ 5’-GAT CCT CCT GAT TGC CCT GAC CTA-3’ WellRED D2 
MIRU-20  5’-CCC CTT CGA GTT AGT ATC GTC GGT T-3’ 5’-CAA TCA CCG TTA CAT CGA CGT CAT C-3’ WellRED D2 
MIRU-23  5’-CGA ATT CTT CGG TGG TCT CGA GT-3’ 5’-ACC GTC TGA CTC ATG GTG TCC AA-3’ WellRED D4 
MIRU-24  5’-GAA GGC TAT CCG TCG ATC GGT T-3’ 5’-GGG CGA GTT GAG CTC ACA GAA C-3’ WellRED D3 
MIRU-26  5’-GCG GAT AGG TCT ACC GTC GAA ATC-3’ 5’- TCC GGG TCA TAC AGC ATG ATC A-3’ WellRED D4 
MIRU-27  5’- TCT GCT TGC CAG TAA GAG CCA-3’ 5’-GTG ATG GTG ACT TCG GTG CCT T-3’ WellRED D3 
MIRU-31  5’-CGT CGA AGA GAG CCT CAT CAA TCA T-3’ 5’- AAC CTG CTG ACC GAT GGC AAT ATC-3’ WellRED D3 
MIRU-39  5’- CGG TCA AGT TCA GCA CCT TCT ACA TC-3’ 5’- GCG TCC GTA CTT CCG GTT CAG-3’ WellRED D2 
MIRU-40  5’-GAT TCC AAC AAG ACG CAG ATC AAG A-3’ 5’-TCA GGT CTT TCT CTC ACG CTC TCG-3’ WellRED D3 
ETR-A  5’-AAA TCG GTC CCA TCA CCT TCT TAT-3’ 5’-CGA AGC CTG GGG TGC CCG CGA TTT-3’ WellRED D2 
ETR-B  5’-GCG AAC ACC AGG ACA GCA TCA TG-3’ 5’-GGC ATG CCG GTG ATC GAG TGG-3’ WellRED D4 
ETR-C  5’-GTG AGT CGC TGC AGA ACC TGC AG-3’ 5’-GGC GTC TTG ACC TCC ACG AGT G-3’ WellRED D4 
VNTR 2163b  5’-CGT AAG GGG GAT GCG GGA AAT AGG-3’ 5’-CGA AGT GAA TGG TGG CAT-3’ WellRED D2 
VNTR 2347  5’-GCC AGC CGC CGT GCA TAA ACC T-3’ 5’-GCC AGC CGC CGT GCA TAA ACC T-3’ WellRED D2 
VNTR 3232  5’-CAC TAG TTG TTG CGG CGA TGG T-3’ 5’-AGC CAC CCG GTG TGC CTT GTA TGA C-3’ WellRED D3 
VNTR 2163a  5’-CCC GGG GCG CTC GTG ATG-3’ 5’-CAC TAG TTG TTG CGG CGA TGG T-3’ WellRED D4 
VNTR 1982  5’-GGA ATG GCT ACG GAA GGA ATA CTC-3’ 5’-AAG GGC GGC ATT GTG TTC C-3’ WellRED D2 
VNTR 3336  5’-GAT CGG GTG CAG TGG TTT CAG GTG-3’ 5’-CCC GGG GCG CTC GTG ATG-3’ WellRED D3 
VNTR 4052  5’-AAC GCT CAG CTG TCG GAT-3’ 5’-CGG CGG CAC CCT GGA GTC TGG-3’ WellRED D4 
All forward primers were labelled for capillary gel electrophoresis and unlabelled for agarose gel electrophoresis; reverse primers were unlabelled 
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A 10ml 2× reaction buffer was prepared using 10× ammonium (NH4) reaction buffer, 
50mM magnesium chloride (MgCl2) and 100mM deoxynucleotide triphosphates 
(dNTPs), (all from Bioline, London, UK) and molecular grade water. Final 
concentrations were 2× NH4 reaction buffer, 3mM MgCl2 and 0.4mM of each dNTPs. 
Aliquots of 1.5ml were stored at -20°C ready for use. 
 
PCR were set up as either simplex or duplex reactions so 9 primer sets, containing 
forward and reverse primers for each locus, were prepared using molecular grade 
water giving a final concentration of each primer of 0.5 µM. Primer set 1 contained 
MIRU-4 and -16 primers; set 2 contained MIRU-39 and ETR-A primers; set 3 
contained MIRU-20 primers; set 4 contained MIRU-2 and-24 primers; set 5 contained 
MIRU-31 and -40 primers; set 6 contained ETR-C primers; set 7 contained MIRU-10 
and -23 primers; set 8 contained MIRU-27 and ETR-B primers; set 9 contained 
MIRU-26 primers. Primer mixes were stored at -20°C ready for use. 
 
Amplification of the different loci in each DNA extract was conducted as follows: 
10µl PCR reactions were prepared in 0.2ml 96 well Thermal Cycler Plates (Alpha 
Laboratories), for each primer set, and contained 4.33µl 2× reaction buffer, 0.08µl 
99.9% dimethyl sulphoxide (DMSO) (Sigma-Aldrich), 4.50µl primer set, and 0.09µl 
5U/µl BIOTAQ DNA polymerase (Bioline). For optimisation and amplification of 
MIRU-4 and –16 loci, 0.27µl 50mM MgCl2 was added to each reaction. Crude DNA 
extracts were allowed to thaw and any debris was spun down by centrifugation at 
8050×g for 2 mins and then 1µl was mixed into each reaction by pipetting up and 
down. 
 
All reactions were spun down by centrifuging plates at 250×g for 1 minute in an IEC 
Centra CL3R (Thermo Life Sciences, Basingstoke, UK). A GeneAmp PCR System 
9700 (Applied Biosystems, Warrington, UK) was used to amplify each locus. The 
following cycle was used for amplification: 95°C for 180 secs; 35 cycles of 95°C for 
30 secs, 60°C for 30 secs, and 72°C for 60 secs; 72°C for 300 secs. During 
amplification, PCR fragments were labelled with dyes so fragment sizes could be 
detected using capillary electrophoresis. 
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For agarose gel electrophoresis, DNA amplification procedures were exactly the same 
except simplex PCR reactions were set up to amplify loci individually using 
unlabelled forward and reverse primers with the same primer sequences. 
 
2.2.3 Capillary gel electrophoresis 
Capillary gel electrophoresis allowed identification of amplified product according to 
their molecular weight and the dye with which products were labelled during 
amplification. Analysis of PCR products was performed using Beckman Coulter CEQ 
8000 Genetic Analysis System (Beckman Coulter, Fullerton, USA). MIRU and ETR 
loci were analysed together in three separate capillaries. For each DNA extract, 
amplified products from MIRU-2, -4, -10, -16, -23, -24 were analysed in capillary A, 
products from MIRU-27, -31, -39, -40, ETR-A and -B were analysed in capillary B 
and products from MIRU-20, -26 and ETR-C were analysed in capillary C. 
 
Due to the varying intensities of labelling dyes, PCR products were diluted and 
pooled so resulting intensities of peaks on the chromatogram, following 
electrophoresis, were similar. PCR products that were labelled with Dye 2 were 
diluted 1 in 10 using molecular grade water in the PCR plate. PCR products labelled 
with Dye 3 and 4 were diluted 1 in 100 using the diluted Dye 2 fragments as the 
diluent. Pooled PCR products were mixed by pipetting up and down and centrifuged 
for 1 minute at 250×g. 
 
A Sample Microtiter plate (Beckman Coulter) was prepared so each well contained 
25µl sample loading solution (Beckman Coulter) and 0.1µl DNA Size Standard 600 
(Beckman Coulter) for analysing MIRU and ETR loci. For each DNA extract, 1µl of 
pooled PCR product was added to separate wells. The prepared sample plate was 
loaded onto the analysis system according to the manufacturer’s instructions along 
with a Beckman Coulter 96 well plate filled with Separation buffer (Beckman 
Coulter) and a 10ml CEQ Separation gel cartridge (Beckman Coulter). 
 
After capillary gel electrophoresis was completed, the automatically generated raw 
data traces, displaying peaks for each locus, were analysed using the calling tables in 
Appendix 1 and 2, to generate corresponding traces displaying peaks that were 
annotated with the locus name, molecular weight and calculated number of repeats. 
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Manual agarose gel electrophoresis was performed if there was an absent peak for any 
of the loci. 
 
Reproducibility of data was verified by repeating MIRU-VNTR typing for all loci on 
randomly selected isolates. 
 
2.2.4 Agarose gel electrophoresis 
For those isolates with loci that had missing peaks after capillary gel electrophoresis, 
the loci were amplified from the isolate as described in Section 2.2.2, using unlabelled 
forward primers; DMSO was not used in the PCR reactions and a negative control for 
each locus primer set was included using 1µl molecular grade water instead of DNA 
template. 
 
A 1.2% weight/volume (w/v) agarose gel (Agarose LE Analytical grade; Promega, 
Southampton, UK) was used to resolve 5µl of each PCR product against a 1000 b.p. 
HyperLadder IV (Bioline). The gel was viewed on an ultraviolet transilluminator 
(UVP inc, Cambridge, UK) and an image captured using a digital camera (Canon 
PowerShot A620, Surrey, UK). Product sizes were determined by comparing bands 
with the ladder and using the calling tables (Appendix 1 and 2) to calculate the 
number of repeats in the locus of interest. 
 
In some cases, amplified ETR-A fragments had to be resolved against the 2000 b.p. 
ladder or a custom size ladder comprised of amplified ETR-A fragments as the 
molecular weight of some products exceeded 1000 b.p. Also, during capillary gel 
electrophoresis of amplified MIRU-4 fragments, there were peaks with molecular 
weights considerably lower than expected indicating that MIRU-4 was more 
polymorphic with possible deletions. Whilst these polymorphisms were detected by 
capillary electrophoresis, detection was not as easy with agarose gel electrophoresis as 
the latter method provides lower resolution. Therefore, a custom size ladder for 
MIRU-4 and another ladder for MIRU-4 with the various deletions was prepared. 
 
2.2.5 Preparation of custom size ladders for ETR-A and MIRU-4 
From the data obtained after capillary gel electrophoresis, extracts with a known 
number of repeats in ETR-A, MIRU-4 and MIRU-4 with the various deletions were 
identified. Seven extracts were selected for each of the three ladders with different 
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numbers of repeats to give a broad range of values and ensure that there were not too 
many bands close together during electrophoresis. 
 
The locus, MIRU-4 or ETR-A, was amplified from each isolate in separate 40µl 
reactions, containing 20µl 2× reaction buffer, 10µl unlabelled primer mix for either 
ETR-A or MIRU-4, 1µl BIOTAQ polymerase and 2µl DNA. Amplification 
conditions were as follows: 95°C for 180 secs; 30 cycles of 95°C for 30 secs, 55°C for 
30 secs, and 75°C for 60 secs; 72°C for 300 secs. After amplification, 5µl of each 
product was resolved against a 1000 b.p. ladder, as described in Section 2.2.4, to 
confirm the presence of PCR products and to approximate product sizes. The full 
volume of PCR product was combined to produce three separate custom size ladders 
for ETR-A, MIRU-4 and MIRU-4 with deletions that were stored at -20°C. When 
ladders were loaded onto gels, HyperLadder IV was also loaded in adjacent wells. 
 
2.2.6 MIRU-VNTR typing using more discriminative VNTR loci 
All MIRU-VNTR typing data was entered into a Microsoft Access database, which 
was designed by Dr. Tim Brown and Dr. Vladyslav Nikolayevskyy, HPA, MRU, and 
was directly linked to BioNumerics version 3.00. Firstly MIRU-VNTR profiles 
produced by capillary gel electrophoresis were exported directly into Microsoft Excel 
format. Scripts within BioNumerics were used to create a table with one row per 
extract and columns for extract identification and each locus. The table format was 
used to export data into a Microsoft Access database, where additional typing data 
from agarose gel electrophoresis were manually added. Cluster analysis was 
performed in BioNumerics, using the n-1 method, to identify all DNA extracts whose 
MIRU-VNTR profiles were identical and formed clusters, which by definition 
contained 2 or more isolates, and which would be typed using the additional 7 VNTR 
loci. 
 
The more discriminatory 7 VNTR loci which were evaluated included VNTR-2163B, 
-2347, -3232, -2163A, -1982, -3336 and -4052. Serial isolates were also typed using 
these VNTR loci as part of another smaller study investigating the reproducibility of 
the VNTR loci, which will be described in Section 2.2.8 and in Chapter 4. Each locus 
was amplified from the DNA extracts as described in Section 2.2.2 and six primer sets 
were prepared as follows. Set 1 contained VNTR-2163B and -2347 primers; set 2 
contained VNTR-3232 primers; set 3 contained VNTR-2163A primers; set 4 
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contained VNTR-1982 primers; set 5 contained VNTR-3336 primers; set 6 contained 
VNTR-4052 primers. Sequences of all primers and dyes used for labelling are 
included in Table 2.1. PCR reactions were set up as described previously, except 
Diamond DNA polymerase (Bioline) was used instead, as VNTR loci seemed to 
require a polymerase with higher specificity for effective amplification. The 
amplification cycle was: 95°C for 180 secs; 35 cycles of 95°C for 30 secs, 60°C for 
30 secs, and 72°C for 120 secs; 72°C for 300 secs. 
 
Capillary gel electrophoresis was performed as described in Section 2.2.3 and VNTR 
loci analysed in two separate capillaries where VNTR-2163B, -2347, -3232, -2163A 
were analysed in capillary A and VNTR-1982, -3336, -4052 were analysed in 
capillary B. When loading the Sample Microtiter plate, as well as using 0.1µl DNA 
Size Standard 600, 0.1µl MapMarker D1 labelled 640-1000 (BioVentures, Inc., 
Murfreesboro, USA) was added to each well as some VNTR fragment sizes were 
expected to exceed 600 b.p. As for MIRU and ETR loci, if there were any missing 
peaks after capillary gel electrophoresis, agarose gel electrophoresis was performed as 
described in Section 2.2.4, but using a 2000 b.p. HyperLadder II standard (Bioline) 
instead. The calling table for the VNTR loci can be found in Appendix 2. The 
additional typing data were entered into the same Access database.   
 
2.2.7 Spoligotyping  
Spoligotyping was performed on all of the 2363 crude DNA extracts as follows: 
firstly, 1ml mastermix containing 5% DMSO, 2× NH4 reaction buffer, 3mM MgCl2, 
0.4mM of each dNTP and 0.5nmol/ml of each primer, biotinylated DRa (5’-CCG 
AGA GGG GAC GGA AAC-3’) and DRb (5’-GGT TTT GGG TCT GAC GAC-3’) 
was prepared and stored at -20°C ready for use. Primers were obtained from Isogen 
Life Science, Maarssen, The Netherlands, and sequences were as described by Goguet 
de la Salmoniere et al., 1997 (Goguet de la Salmoniere et al., 1997). 
 
Spoligotyping was performed as described in Kamerbeek et al., 1997 (Kamerbeek et 
al., 1997). Each spoligo-membrane (Isogen Life Science) accommodated forty 
samples including two positive controls, M. tuberculosis strain H37Rv and M. bovis 
BCG P3 (Isogen Life Science), which were included for each membrane. PCR 
reactions, containing 18μl diluted mastermix and 2μl DNA, were set up in 0.2ml 96 
well Thermal Cycler Plates. The DR region was amplified using the following 
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conditions: 94°C for 300 secs; 30 cycles of 94°C for 30 secs, 55°C for 60 secs, and 
72°C for 60 secs; 72°C for 300 secs. As DNA was amplified, reverse strands were 
biotin labelled. During amplification, solutions required for hybridisation and 
detection steps were made up as described in Section 2.1.1 and 2.1.2. 
 
Hybridised DNA was detected using chemiluminescence: equal volumes of enhanced 
chemiluminescent (ECL) Detection Reagents 1 and 2 (Amersham Biosciences) were 
mixed to make a total volume of 20ml for each membrane. Membranes were 
incubated with ECL reagent for 1 minute before being transferred into clear plastic 
covers ensuring there were no air bubbles. A light sensitive Hyperfilm ECL 
(Amersham Biosciences) was exposed to the membrane for 2 mins, before it was 
developed and fixed using GBX developer and replenisher and GBX fixer and 
replenisher (Kodak, New York, USA). Depending on whether the intensity of the 
signal was faint or too dark, membranes were used again to expose another film for a 
longer or shorter period of time, respectively. 
 
Membranes were re-used for more spoligotyping by stripping PCR products from the 
previous analysis using stringent washing conditions. Membranes were washed twice 
in 100ml 1% SDS in the hybridisation bottles at 80°C for 30 mins and then once in 
100ml 20mM EDTA at room temperature on the rocker. Each membrane was stored 
in 100ml 20mM EDTA ready for the next hybridisation. Both solutions were prepared 
as described in Section 2.1.1 and 2.1.2. 
 
Each spoligotype profile was scanned into specifically formatted strips with 
corresponding black and white dots for present and absent spacers, respectively, and 
since BioNumerics was directly linked to the main Microsoft Access database, 
spoligotyping data automatically appeared in the Access database as a 43 digit binary 
code. In BioNumerics, the binary codes were converted into 15 digit octal codes using 
a script within BioNumerics, which was based on the study by Dale et al., 2001, to 
make the spoligotyping digital profiles easier to use for further analysis (Dale et al., 
2001). The octal codes,  were used to assign a spoligofamily to each isolate using an 
online tool (http://cgi2.cs.rpi.edu/~bennek/SPOTCLUST.html), based on the 
SpolDB3-based probabilistic approach described by Vitol et al., 2006 (Vitol et al., 
2006).  
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2.2.8 Evaluation of MIRU-VNTR typing using VNTR-1982 and -3232 
The stability of VNTR-1982 and -3232 and the reproducibility of typing data, under 
different amplification and fragment detection conditions, were investigated. The 
details of this study, including the optimised methodology, are described in greater 
detail in Chapter 4. In brief, DNA extracts from 16 MTBC isolates, which had been 
included for quality control purposes during MIRU-VNTR typing and had complete 
data for 12 MIRU, 3 ETR and 7 VNTR loci, were selected to cover a range of repeats 
in MIRU-26, ETR-B and VNTR-1982 and -3232 loci. These loci were amplified 
using different polymerases including Bioline BIOTAQ and Diamond polymerase and 
Qiagen HotStartTaq DNA polymerase and HotStartTaq Plus DNA polymerase. 
Products were resolved on a 1.2% (w/v) agarose gel to ensure PCR products were 
present, and then analysed using capillary gel electrophoresis. During this analysis the 
effect on detected fragment sizes was evaluated using different parameters that 
involved changes in capillary temperature and the time allowed for the denaturing and 
separation steps. 
 
Reproducibility of typing using all MIRU, ETR and VNTR loci, which were included 
for this study, was also investigated in a blinded study, by checking for consistency 
between MIRU-VNTR profiles of serial isolates (i.e. multiple isolates from the same 
patient taken at successive time intervals). 
 
2.3 SELECTING STRAINS OF PARTICULAR INTEREST 
 
2.3.1 Epidemiology  
Demographic data, including gender, date of birth and country of birth, was available 
from the London TB Register for the patients included in the present study. We had 
ethical approval to use the demographic data of patients for the purposes of research. 
To perform epidemiological analysis in the present study, the country of birth data 
was used and was available for the majority of extracts. In addition, the drug 
sensitivities for the first line drugs, including isoniazid, ethambutol, rifampicin, 
pyrazinamide and streptomycin, were available at the HPA, MRU. 
 
In order to understand the degree to which London TB isolates reflected the global TB 
burden, the number of isolates in each spoligofamily was plotted onto a global map 
using the country of birth data to assign region of origin for each patient. The global 
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regions were as defined by WHO; to avoid any bias, serial isolates were not taken into 
consideration i.e. one isolate per patient was included for analysis. 
 
2.3.2 Selection of strains for phenotypic analysis 
The molecular typing, cluster analysis and epidemiology data were used to select 
strains for Panel A. For further details of the selection analysis see Section 3.2.4. 
Clusters containing more than nine isolates were included for selection of strain and 
an algorithm was designed to select particular strains of interest and is shown in 
Figure 2.1. This algorithm selected strains based mainly on correlations, within the 
cluster, between the most common spoligofamily, the most common country of birth 
and the most common sub-cluster, which were identified using profiles for the more 
discriminatory 7 VNTR loci that split the MIRU and ETR clusters. 
 
Strains were also selected if they did not fit any general trends observed within the 
MIRU and ETR clusters. Should there be any isolates within the cluster that had a 
different spoligofamily to other isolates within the cluster, the MIRU and ETR profile 
of this isolate was compared to isolates of the same spoligofamily from other clusters. 
If the profiles differed by more than 2 copies in any of loci, the isolate was included in 
the panel. Isolates taken from patients that had a country of birth and did not fit the 
general country of birth and spoligofamily identification trend in the cluster, were also 
included in the panel. If isolates had the same spoligofamily identification as strains 
already selected for the panel but with a different country of birth, it was also included 
in the panel to broaden the range of different M. tuberculosis strains. 
 
Using the selection criteria described, 42 strains that had particular properties were 
selected. This panel will be referred to as Panel A from here onwards and details of 
the strains in this panel can be seen in Table 3.2. 
   
 
 
Figure 2.1 The algorithm that was applied to 12 MIRU and 3 ETR profile clusters to select particular strains of interest for inclusion in Panel A. 
Compare 15VNTR profiles, corresponding to family Y that has been identified as 
being different in cluster X, with another cluster where family Y represents the 
majority. Exclude isolates with no Country of Birth (COB) data. 
Are there subtle changes of 1 or 2 copies in the loci that differ? (Subtle 
differences may mean that the profile happened to fall into cluster X)  
 
 
 
 
 
 
Does the isolate come from the same 
COB/22VNTR cluster as an isolate that 
has already been included in the panel 
from cluster X? 
Yes No 
Exclude from 
further analysis 
Include in panel to 
compare with isolates 
from the same cluster 
Is the spoligofamily ID in 
cluster X the same or different? 
Isolates with different 
spoligofamily ID to the majority 
Include in panel to compare with isolates 
from same cluster with different family ID 
Is the strain in cluster X localised to a particular country/region to identify a possible source of the 
strain? 
To determine this, calculate number of patients 
a) in each country of birth (COB) within the cluster 
b) in the regions, based on COB, defined by World Health Organisation 
If there is insufficient data no conclusions can be drawn about the possible source of the strain. 
Identify the most common COB and 22VNTR cluster. 
Does most common COB correlate with the largest 22VNTR 
cluster? (If there is only 1 isolate with COB data then include in the 
panel) 
Yes No 
Calculate ratio of patients born in UK against 
those born in the niche (country/region) area 
to give indications of degree of success for 
local transmission of strain in UK. 
Low ratio: successful strain for transmission 
High ratio: not as successful strain  
May indicate a very successful 
strain in its transmission ability 
as it affects patients worldwide. Yes
No 
Include in panel 
Yes
No 
Isolates with same spoligofamily 
identification (ID) to the majority 
There are no clusters with this spoligofamily ID
Has an isolate from cluster X already been included? No 
YesAre there any isolates with the most common COB that are in the 
same 22VNTR cluster as the other isolates selected for the panel? 
Yes 
No 
End of analysis Include in panel to compare with 
isolates from the same cluster 
End of analysis 
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2.3.3 Phenotypic analysis 
The 42 Panel A strains were analysed in vitro for the following properties: immune 
response and growth of strains in tissue culture models and growth rates of strains in 
Middlebrook 7H9 culture systems. 
 
As part of the preparation of a panel of strains representing the maximum diversity 
against which a vaccine would provide protection, in vivo phenotypic experiments 
were planned in guinea pig models. So that sufficient reproducibility could be 
achieved to critically test the null hypothesis that TB strains were fundamentally the 
same, a smaller number of strains derived from the original 42 strains in Panel A were 
selected to create a core second panel (Panel B) based on the different phylogenetic 
lineages within MTBC. The selection of strains for Panel B is described in more detail 
in Section 3.3. Also included in Panel B was a wild-type M. africanum strain. 
Laboratory strains, included M. tuberculosis H37Rv (one from HPA, MRU and the 
other from HPA, Centre for Emergency Preparedness and Response; CEPR, Porton 
Down), M. tuberculosis H37Ra and the vaccine strain M. bovis BCG. All Panel B and 
laboratory strains were included for phenotypic experiments. 
 
2.4  PREPARATION OF MYCOBACTERIAL STOCK CULTURES 
 
2.4.1 Culturing M. tuberculosis strains 
In order to have sufficient uniform seed-stock for all phenotypic experiments, a stock 
of frozen cultures was prepared of the Panel B strains (obtained from the HPA, MRU 
archives), and all laboratory strains (both M. tuberculosis H37Rv strains, and M. 
tuberculosis H37Ra, and M. bovis BCG). All manipulations with cultures were carried 
out in Class I biological safety cabinets following safety guidelines. 
 
Using 1ml graduated sterile plastic pasteur pipettes (Alpha Laboratories) for each 
strain, a pyruvate and glycerol slope (Media for Mycobacteria, Cardiff, UK) and a 
50ml Falcon conical tube (Becton, Dickinson and Company) containing no more than 
10 sterile 5mm diameter glass beads (Sigma-Aldrich) and 10ml Middlebrook 7H9 
with 0.05% Tween-80 medium, were each inoculated with 2 drops of the original 
culture from archive. The medium was prepared as described in Section 2.1.3. Even 
though Tween would reduce clumping of the mycobacteria, the liquid cultures were 
vortexed so the glass beads would break up clumps as well (after vortexing, it was 
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important NOT to open the tubes as there was aerosol production during the process). 
All slopes and liquid cultures were incubated at 37°C. The liquid cultures were 
vortexed every 2 days to ensure that clumping was reduced as much as possible. 
 
After 2 weeks the liquid cultures were sub-cultured, except 15ml Middlebrook 7H9 
with 0.05% Tween-80 medium was used. The fresh liquid cultures were incubated at 
37°C for 3 weeks, vortexing the cultures every 2 days.   
 
2.4.2 Archiving M. tuberculosis cultures 
After 3 weeks, when mycobacterial cells should potentially still be in the logarithmic 
phase of the bacterial growth curve, the cultures were removed from incubation and 
1.5ml of each culture was transferred into labelled sterile 2.0ml cryovial tubes 
(Simport, Beloeil, Canada) so there were 10 cryovial tubes per strain, which were then 
stored at -80°C, ready for use in phenotypic experiments. 
  
2.5 QUANTIFICATION OF M. TUBERCULOSIS 
 
2.5.1 Developing a quantification assay for MTBC cultures 
The accuracy of quantification of MTBC cultures using colony forming units (c.f.u.) 
is compromised by the tendency for mycobacterial cells to form clumps; the process 
is also relatively slow but considered the gold standard quantification procedure. An 
alternative methodology was sought to accurately quantify MTBC cultures and the 
development of the MTBC DNA quantification assay is described in detail in Section 
5.2. 
 
The detailed procedure for preparation of the M. tuberculosis DNA standard is 
described in Section 5.2. Briefly, after 4 weeks, the mycobacterial growth on slopes 
inoculated with M. tuberculosis H37Rv was re-suspended in TE buffer and incubated 
in an 80oC waterbath for 50 mins to kill the mycobacteria. Bacterial cells were lysed 
with lysozyme. Proteinase K and Buffer AL (both provided in the Qiagen DNeasy 
Blood & Tissue kit) was added to the lysed bacterial cells, to help break down any 
cell debris, after which 96-100% ethanol (Sigma-Aldrich) was added to the tube. 
Purification of the extracted DNA was performed using the protocol and reagents 
provided with the Qiagen DNeasy Blood & Tissue kit. 
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The concentration of double-stranded DNA, in ng/μl, was calculated at 260nm, which 
was then used to calculate the number of genomes per μl in the DNA extract. Using 
this value, DNA standards containing 1×107, 1×106, 1×105, 1×104, 1×103, 1×102, 
1×101 genomes/μl were prepared and stored at -20°C ready for use. 
 
2.5.2 Comparing quantification methods for MTBC cultures 
Liquid cultures of 30ml volume were prepared, as described in Section 2.4.1, for the 
Panel B strains and incubated at 37°C. At regular intervals of 3 or 4 days, the optical 
density at 600nm (OD600) was measured for all cultures, and the number of 
mycobacteria was quantified using real-time PCR and c.f.u. The details of these 
procedures are described in Sections 5.3. For real-time PCR, primers amplifying the 
ribonucleic acid polymerase β-subunit-encoding gene (rpoB) region of the M. 
tuberculosis genome were used (refer to Section 5.2.2 for details on evaluation of 
primers that could be used for real-time PCR). The results of the comparison of these 
quantification methods is detailed in Section 5.3.4, but briefly, it was concluded that 
OD600 of 0.2 could be used to indicate mycobacterial cells being within the 
logarithmic phase of the growth curve and real-time PCR could be used as a more 
rapid method for quantifying MTBC cultures.       
 
2.6 IN VITRO TISSUE CULTURE EXPERIMENTS 
 
2.6.1 Preparation of mycobacteria cells for infection experiments 
Tissue culture experiments were performed using the ten Panel B strains selected in 
Section 2.3.3 (refer to details of strains in Section 3.3), including M. tuberculosis 
Beijing, M. tuberculosis LAM10, two M. tuberculosis CAS, M. tuberculosis EAI5, 
and M. africanum, M. tuberculosis H37Rv (MRU), M. tuberculosis H37Rv (Porton 
Down), M. tuberculosis H37Ra, and M. bovis BCG. These experiments were 
performed to provide some insight into how human macrophage-like cells are affected 
after infection with the different strains. 
 
Ten days before setting up a tissue culture infection experiment, one of the archived 
tubes of frozen cultures for each of the strains was thawed at room temperature and 
the full volume used to inoculate a 50ml falcon tube, containing 15ml Middlebrook 
7H9 with 0.05% Tween-80 media and beads. After vortexing, the cultures were 
incubated at 37°C for eight days, but every two days the cultures were vortexed. 
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 Two days before the tissue culture infection experiment, the OD600 was measured for 
each of the cultures using the procedure described in Section 2.5.2 and detailed in 
Section 5.3.1 and recorded on the falcon tube. At the same time, a drop was placed on 
a section of Columbia blood agar (CBA) plate (Oxoid Ltd., Cambridge, UK) and 
spread using a plastic loop to ensure the purity of cultures. If OD600 was above 0.2 for 
any of the cultures, then an aliquot of the culture was diluted accordingly, using fresh 
media, in new 50ml falcon tubes containing glass beads, so that the final volume of 
sub-culture was 15ml (OD600 0.2). All cultures and CBA plates were incubated at 
37°C. 
 
After overnight incubation, the CBA purity plates were checked for contamination 
and then re-incubated. If there was contamination, a culture from any previous 
experiment was used to prepare 15ml culture at OD600 0.2. A drop of all cultures that 
had been diluted the previous day was also plated onto CBA plates. Cultures and 
plates were incubated until required for the infection experiment on the following day. 
 
2.6.2 Preparation of monocytic THP-1 cells for infection experiments 
The human monocytic cell line, THP-1, was obtained from the American Type 
Culture Collection (ATCC, Virginia, USA). All tissue culture procedures were carried 
out under aseptic conditions in a Class II safety cabinet, which was decontaminated 
with a 30-minute ultraviolet exposure before use and sprayed with 70% ethanol before 
and after use. All items, including safety gloves, were decontaminated by spraying 
70% ethanol before going inside the cabinet. Sterile consumables were used for all 
procedures including all 5ml, 10ml, and 25ml pipettes (Sarstedt Ltd., Nümbrecht, 
Germany), all 75ml cell culture flasks (Becton, Dickinson and Company), and 50ml 
falcon tubes. Cell culture flasks were sprayed carefully with ethanol ensuring no 
ethanol spray went on the vented cap.  
 
The THP-1 cells were thawed on arrival and cultured in complete RPMI 1640 
medium, pre-warmed to 37°C, in 75ml cell culture flasks. Complete RPMI medium 
was prepared as described in Section 2.1.5. Cells were incubated at 37°C, 5% carbon 
dioxide (CO2). The THP-1 cells were not activated therefore the cells were 
proliferative and non-adherent. Every 2 or 3 days, depending on the density of the 
cells in the culture flasks, the THP-1 cells were sub-cultured by firstly pooling all 
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THP-1 cells from all flasks by centrifuging cells down in a single 50ml polystyrene 
conical centrifuge tube (Becton, Dickinson and Company) for 5 mins at 1100×g and 
then resuspending cells in 10ml fresh complete RPMI medium. Five culture flasks 
containing 10ml fresh complete RPMI medium were inoculated aseptically with 2ml 
of the pooled THP-1 cells. 
 
Two days prior to setting up an infection experiment, THP-1 cells were counted, 
activated and plated. Firstly, all cells were pooled in a small volume of fresh complete 
RPMI medium as described above. For cell counting, 30µl of cell culture was diluted 
1 in 2 using Trypan blue solution (Sigma-Aldrich). After Trypan blue staining, live 
THP-1 cells looked bright, clear and round when observed under a Motic Inverted 
Microscope (Motic Incorporation Ltd., Richmond, Canada), whilst dead THP-1 cells 
took up the stain and were blue. Trypan blue/THP-1 cell mixture was transferred to 
fill one of ten chambers of a KOVA Glasstic Slide 10 with Grid Chamber (Hycor 
Biomedical, Ltd., Penicuik, UK), holding approximately 6.6µl. One well of the slide 
contained a large 3 by 3 grid and in each square of this grid was a smaller 3 by 3 grid. 
The full calculation for establishing the number of THP-1 cells per ml is detailed in 
Appendix 3. The calculated value was used to dilute or concentrate the THP-1 culture 
accordingly so there were 300,000 cells per ml. In this study, 6ml of THP-1 cells, at 
the correct concentration, were required for each of the ten strains, and for uninfected, 
lipopolysaccharide (LPS) and IFN-γ controls. 
 
THP-1 cells were activated by adding phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich) at a final concentration of 500ng/ml, so the cells differentiated from 
monocytic, proliferative, non-adherent THP-1 cells into macrophage-like, non-
proliferative, adherent cells. A volume of 1ml PMA-activated THP-1 cells 
(corresponding to 300,000 cells) was plated into 12 wells in each of seven Costar 24-
well flat bottom cell culture plates (Corning, New-York, USA), leaving a column of 
empty wells between the two strains per plate to avoid cross-contamination during 
further experimental procedures. The plates were incubated at 37°C, 5% CO2 for 48 
hours (hrs). 
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2.6.3 Infection of THP-1 cells with M. tuberculosis 
On day 0, two days after the mycobacterial cultures and macrophage-like THP-1 cells 
were prepared, the THP-1 cells were infected with MTBC at a ratio of 1:1; numbers 
of MTBC were quantified using real-time PCR. 
 
The tubes containing the culture for each strain were vortexed, and left to stand for 5 
mins. The OD600 was measured for each of the cultures and two aliquots of 500µl 
from each culture were transferred into two labelled 1.5ml microcentrifuge tubes. The 
microcentrifuge tubes were centrifuged at 12,000×g for 10 mins, the supernatant from 
each tube safely discarded and the pelletted mycobacterial cells were resuspended in 
100µl TE buffer. DNA extraction and purification procedures were then performed as 
described in Section 2.5.2 and detailed in Section 5.2 and the volume of Buffer AE for 
eluting DNA was 40µl. 
 
Real-time PCR reactions were set up using rpoB primers, DNA standards (ranging 
from 1×101 to 1×107 genomes/μl) and the two DNA extracts of unknown 
concentration per strain, and then the number of genomes/ml culture was calculated 
(the detailed procedures for setting up PCR and calculating genomes/ml is described 
in Section 5.2.2, except DNA had been extracted from 500µl culture instead of 1ml). 
As there were duplicate DNA extracts per culture, the final number of genomes/ml 
was an average of the duplicates. In order to infect THP-1 cells with bacteria at a 
multiplicity of infection (MOI) of 1, the volume of each culture required to infect 
300,000 THP-1 cells with 300,000 mycobacterial cells was calculated. During the 
PCR step, Middlebrook 7H11 plates were inoculated with serial dilutions of each 
culture and all plates incubated at 37°C for 3 to 4 weeks, to obtain c.f.u. data (refer to 
Section 5.3.3 for the detailed procedures for the serial dilution and plating). 
 
Once the volume of culture required was established for each strain culture, the 
original cultures in the 50ml falcon tubes were vortexed and the tubes left to stand for 
5 mins. During this time, the 24-well tissue culture plates containing activated THP-1 
cells were observed under the inverted microscope to ensure that the cells had adhered 
to the bottom of the wells and that the RPMI medium was not contaminated. As there 
were 6 wells per strain, the appropriate volume of each of the 10 strain cultures was 
added to each of the 6 wells of the labelled 24-well plate aseptically. A drop of each 
culture was also plated onto CBA plates. 
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 As well as infecting activated THP-1 cells with each of the ten different strains, three 
sets of controls were prepared. The first control was uninfected activated THP-1 cells. 
For this control, each of the 6 wells were inoculated with a volume of Middlebrook 
7H9 medium (with OADC) equivalent to the largest volume of culture that was used 
for infecting THP-1 cells. This control enabled the identification of any effects that 
the medium may have on the THP-1 cells. The second control was set up by adding 
25µl of 50µg/ml LPS from Escherichia coli 055:B5 (Sigma-Aldrich) to each of the 6 
wells. The third control was prepared by adding 25µl of 50µg/ml IFN-γ (Miltenyi 
Biotech, Bergisch Gladbach, Germany) to each of the 6 wells. Using LPS and IFN-γ 
to activate THP-1 cells can potentially act as positive controls as they induce the 
production of certain cytokines and these controls are particularly important for 
measuring cytokine production using assays such as Enzyme-Linked ImmunoSorbent 
Assay (ELISA). All of the plates were incubated at 37°C, 5% CO2, overnight, for 
infection of the THP-1 cells. 
 
The following morning, day 1 post-infection, any unincorporated mycobacterial cells 
were removed by washing the infected THP-1 cells. The RPMI medium from each 
well was transferred into separate sterile microcentrifuge tubes. Each well was 
washed by adding 500µl 1× DPBS (prepared as described in Section 2.1.5) gently 
against the side of the well and then transferring the full volume into corresponding 
microcentrifuge tubes containing the old RPMI medium. The infected THP-1 cells in 
the wells were kept wet by gently adding 1ml 1× DPBS to each well. 
 
Any THP-1 cells that may have become detached from the bottom of the well and 
aspirated were spun down by centrifugation at 300×g for 10 mins, (which avoids 
spinning down bacterial cells). The supernatant was discarded safely and the 1ml 1× 
DPBS was transferred from the 24-well plate and into corresponding microcentrifuge 
tubes. Again, THP-1 cells were spun down, during which time 1ml fresh complete 
RPMI was added to each of the wells. THP-1 pellets at the bottom of microcentrifuge 
tubes were resuspended by taking a small volume of RPMI, approximately 80µl, from 
the appropriate well and transferring the resuspended cells back in the well. The 24-
well plates were incubated for 5 to 6 hrs, allowing the intracellular mycobacteria to 
elicit an effect, if any, before samples were taken for the day 1 time point. 
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2.6.4 Sample collection of mycobacteria infected THP-1 cells  
Samples were taken at day 1, 4 and 7 post-infection. At every time point, for each 
strain and control, RPMI medium was transferred from two wells and into separate 
1.5ml microcentrifuge tubes. All THP-1 and mycobacterial cells were spun down by 
centrifugation at 8000×g for 10 mins, during which time 300µl 1× DPBS was added 
to each of the wells from which RPMI had been removed. After centrifugation, the 
supernatant was transferred into separate microcentrifuge tubes, which were then 
stored at -80°C ready for ELISA. 
 
The 300µl 1× DPBS was transferred from the wells and into the microcentrifuge tubes 
containing the pelletted cells. Addition of 100µl of 0.25% Trypsin, 0.25% (1×) with 
EDTA (Invitrogen Ltd.) for 3 mins allowed the THP-1 cells to detach from the bottom 
of the wells. The trypsin-EDTA was then inactivated by adding 500µl RPMI. The full 
volume was transferred into the appropriate microcentrifuge tubes and if some cells 
could still be seen at the bottom of the well, a small volume of liquid from the 
microcentrifuge tube was used to scrape the cells and aspirate them back into the 
microcentrifuge tubes. The cells in the microcentrifuge tubes were spun down by 
centrifugation, this time discarding the supernatant and centrifugation was repeated. 
The tubes containing the dried pellets of cells were stored at -80°C ready for analysis. 
 
The experimental procedures described in Sections 2.6.1 to 2.6.4 were repeated two 
more times so there were supernatants and pelletted cells, stored at -80°C, from three 
independent experiments. 
 
2.6.5 Measuring cytokine levels in supernatant 
The levels of human TNF-α, human IL-10, human IL-1β, and human IL-6 cytokines 
were measured in all of the supernatants, using ELISA Ready-SET-Go! Kits 
(eBioscience, California, USA). The assay was performed using the protocols 
provided with the kits, which included the 96-well ELISA plates and all reagents 
except wash buffer, which was a solution of 1× DPBS (without calcium and 
magnesium) with 0.02% Tween-20 solution (Sigma-Aldrich). 
 
In a single day, the assays for each of the 4 different cytokines could be performed 
using supernatant from one independent THP-1 infection experiment as the 96-well 
ELISA plate could accommodate these supernatants and all recommended standards. 
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The day before performing the assay, ELISA plates (one plate per cytokine) were 
coated with capture antibodies, which were diluted as directed in the protocols using 
Coating Buffer that was prepared as directed using the powdered buffer provided. 
Aliquots of 100µl diluted capture antibody were dispensed into each well of the 
plates, which were then sealed and incubated overnight at 4°C. If there was any 
cytokine in the supernatant that was complementary to the capture antibody it would 
specifically bind to it. 
 
The following morning, supernatant from one of the three independent experiments 
was left at room temperature to thaw. The capture antibody was aspirated from all of 
the plates, which were washed 5 times with 300µl Wash Buffer per well, allowing 1 
minute for soaking between washes to wash away excess capture antibody. All plate 
washes were performed using a plate washer (Wellwash 4 Mk2; Thermo Scientific). 
Afterwards, 200µl 1× Assay Diluent, prepared by diluting 5× Assay Diluent with 
distilled water, was added to each of the wells and all plates incubated at room 
temperature for 1 hour. The 1× Assay Diluent was aspirated from the wells and the 
plates washed as described previously. 
 
The top concentration of standards, which were specific to each cytokine assay, were 
prepared by diluting the stock standard from the kit with 1× Assay Diluent using the 
volumes detailed in the protocol, as these vary between cytokine assay and also 
between kits for the same cytokine. For the standard curve, six 2-fold serial dilutions 
of the top standards were prepared so the final volume of diluted standards was 400µl. 
For each cytokine plate, there were seven standards and a blank, which was the 1× 
Assay Diluent. 
 
One plate was set up at a time to minimise the time gap between the addition of 
standards and the last sample in the final well. Firstly, 100µl of the top standard was 
added to each of the top two wells of the first two columns, so there were duplicate 
wells for each standard. Two 100µl aliquots of the next dilution down from the top 
standard were added into the next two wells and so forth with the remaining 
standards. Aliquots of 1× Assay Diluent were added to the bottom two wells. In the 
remaining wells, 100µl of the supernatant was added with 1 well per sample, so all 
supernatants from one experiment could be analysed simultaneously. All plates were 
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sealed and incubated for 2 hrs at room temperature to allow any cytokine in the 
supernatant to bind to the capture antibody. 
 
After incubation, standards and supernatants were aspirated from the wells and 
washed 5 times as described previously to leave only the bound cytokine molecules. 
These molecules were detected by adding 100µl cytokine specific Detection antibody, 
which was diluted in 1× Assay Diluent as directed in the protocol, to each of the 
wells. ELISA plates were sealed and incubated for 1 hour at room temperature. The 
Detection antibody was then aspirated and the plates washed as before. 
 
A detection enzyme was added to each well to bind to the Detection antibody. For this 
assay Avidin-horseradish peroxidase (Avidin-HRP) was used and this reagent was the 
same for all cytokine assays. Avidin-HRP was diluted using 1× Assay Diluent and the 
volumes detailed in the protocol, after which 100µl was quickly added to each well, 
as the enzyme was light sensitive. The plates were sealed and incubated in the dark at 
room temperature for 30 mins. The Avidin-HRP was aspirated and washed as before 
except there were 7 washes instead of 5 to make sure any unbound Avidin-HRP was 
washed away completely. 
 
A volume of 100µl Substrate solution was added to each well and the plate incubated 
in the dark at room temperature for 15 mins. As any bound Avidin-HRP reacted with 
substrate it caused a colour change from colourless to blue if the cytokine was 
present. The extent to which there was colour development showed how much 
cytokine there was present initially. As the reaction between the Avidin-HRP and 
substrate is light sensitive, as soon as the 15 mins incubation was over, 50µl Stop 
Solution was added to each well to stop the reaction and to avoid false readings. The 
Stop solution caused a colour change from blue to yellow. The OD at 450nm (OD450) 
was measured for each well in all cytokine plates using a Multiskan Microplate 
Reader (Thermo Scientific). 
 
The logarithm (log) of OD450 values was calculated. The mean log OD450 value was 
taken for each of the standards, as there were duplicate readings, to produce the 
standard curve of log OD450 value of standards versus the corresponding log 
concentration values, which were calculated using the top standard concentration, in 
picogram/millilitre (pg/ml), provided in the kit’s protocol. The top standard 
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concentrations varied between cytokine assays and between kits. The log cytokine 
concentration in the supernatants was established by extrapolation against the 
standard curve and then the actual concentration calculated using 10log concentration. 
During the initial experiment, when samples were taken at each time point, there were 
duplicate samples per time point. Therefore, the mean cytokine concentration was 
taken. The cytokine concentrations for each of the ten strains and the three controls 
were plotted against days post infection to identify any trends. 
 
The ELISA assays were repeated using the same protocol for supernatant collected 
from the two repeated independent infection experiments described in Section 2.6.4. 
If there were any supernatants in which the calculated cytokine concentration was 
above the concentration of the top standard, the ELISA had to be repeated as the 
standard curve was only valid for the concentration stated in the protocol and any 
OD450 values above this could not be reliably extrapolated. The supernatants were 
diluted 1 in 4 using complete RPMI as the diluent before being added to the ELISA 
plate well. When calculating the cytokine concentration, the dilution factor was taken 
into account. 
 
2.6.6 Measuring fold enhancement and growth of mycobacteria in THP-1 cells 
Real-time PCR was used to calculate the growth of mycobacteria inside THP-1 cells 
at the three different time points. Firstly, DNA was extracted from the dried pellets of 
cells that were prepared during sample collection. The DNA extraction protocol 
differed from previous protocols, as DNA was extracted from both THP-1 and 
mycobacterial cells that had initially been taken up by THP-1 cells. 
 
The pellets of cells were resuspended in 200μl 1× DPBS by pipetting up and down 
gently after which 20μl proteinase K, 22μl 100mg/ml lysozyme and 200μl Buffer AL 
was added to the cells and mixed thoroughly by vortexing. The tubes were incubated 
in a 56oC waterbath for 15 mins, after which 200μl ethanol (96-100%) was added to 
each tube and mixed thoroughly to make a homogenous solution. The DNA 
purification steps were performed using the Qiagen DNeasy Blood & Tissue Kit and 
the procedures described in Section 5.2.1. The DNA was stored at -20°C ready for 
real-time PCR. 
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Real-time PCR reactions were set up using the volumes detailed in Section 5.2.2. The 
set up was slightly different because no DNA standards were used. For each DNA 
extract two sets of three reactions were set up, one set of reactions was prepared using 
rpoB primers and the other set of reactions was set up using primers for actin 
(forward: 5’-TCA CCC ACA CTG TGC CCA TCT ACG A-3’; reverse: 5’-CAG 
CGG AAC CGC TCA TTG CCA ATG G-3’). Setting up reactions with these primers 
meant that the threshold cycle (Ct) values could be used to calculate the amount of 
mycobacteria relative to the THP-1 cells present as it is not known to what extent the 
THP-1 cells would survive after infection with mycobacteria. However, it is important 
to note that as DNA levels are being assayed there would be no discrimination 
between viable and dead mycobacteria and also between dead or living THP-1 cells. 
 
After real-time PCR, the fold enhancement relative to day 1, for each strain, was 
calculated using the 2-ΔΔCt mathematical model (Pfaffl 2001): 
i. calculating ΔCt for each time point 
= Ct (rpoB) - Ct (actin) 
ii. calculating ΔΔCt between day 1 and all other time points 
= ΔCt (day 4) - ΔCt (day 1) and 
= ΔCt (day 7) - ΔCt (day 1) 
iii. calculating fold enhancement (the efficiency of both pairs of the primers is 2 
so this value was used for calculations) for each ΔΔCt 
= 2-[ΔΔCt(dy4 - dy1)] and 
= 2-[ΔΔCt(dy7 - dy1)]  
The fold enhancement at day 4 and 7 for each strain was plotted as a bar graph to 
make comparisons of the fold enhancements between strains. 
 
2.7 IN VITRO GROWTH EXPERIMENTS 
 
2.7.1 Inoculation of MGIT tubes 
As well as studying the growth of mycobacteria in tissue culture systems, the growth 
of the ten strains was investigated using another in vitro system, which allowed real-
time observation of growth curves. The MTBC cultures that were used for infecting 
activated macrophage-like THP-1 cells, had already been quantified using real-time 
PCR, therefore the BBL Mycobacteria Growth Indicator Tube (MGIT) 7ml tubes 
(Becton, Dickinson and Company) were inoculated with the same cultures on the 
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same day as the tissue culture experiments were set up. The MGIT tubes contained 
7ml modified Middlebrook 7H9 medium and, before inoculation, 800μl OADC was 
added to each of the tubes required for each experiment. 
 
As there were no previous data on the number of mycobacteria that should be used for 
inoculation, MGIT tubes were set up with 10 fold differences in the number of 
mycobacteria, with the highest number being 600,000 genomes and the lowest 6 
genomes. In order to inoculate a MGIT tube with 600,000 mycobacteria, two times 
the volume of culture required per well for the tissue culture experiments was added 
to the tube. The same volume of culture was then used to complete a set of five 10-
fold serial dilutions, before inoculating MGIT tubes with 60,000, 6,000, 600, 60 and 6 
mycobacteria. For each strain, two sets of six MGIT tubes were inoculated with the 
different number of mycobacteria so there were duplicate sets of MGIT tubes. 
Negative controls were set up in exactly the same way, using the same Middlebrook 
7H9 medium that had been used to inoculate the non-infected THP-1 cells. 
 
After inoculation, MGIT tubes were registered onto the EpiCenter that was the 
dedicated computer linked to the BACTEC MGIT 960 Mycobacterial Detection 
System (Becton, Dickinson and Company), which was an automated system into 
which the tubes were placed for incubation. The temperature inside the MGIT 960 
was controlled and maintained at 37oC to allow mycobacteria to grow. Fixed to the 
bottom of each tube was silicone, embedded with a fluorescent growth indicator, 
which was sensitive to dissolved oxygen in the medium. As the mycobacteria grew 
during incubation in the MGIT 960, the oxygen in the tubes was utilised and this 
oxygen depletion caused an increase in fluorescence. Every hour, the MGIT 960 took 
fluorescence readings from all of the tubes simultaneously. The algorithm within the 
software (TB eXiST version 5.53) automatically calculated the growth units in 
accordance to the detected fluorescence. Real-time growth curves displaying growth 
units versus time, in hrs, were automatically generated using the TB eXiST software. 
 
2.7.2 Analysis of growth curves 
Once all of the growth curves had reached a plateau, the raw growth unit data for all 
of the strains and negative controls, at each of the different inoculation sizes, was 
exported into Microsoft Excel, where growth curves were plotted again. These plots 
were used to identify the two time points between which the growth curve was at 
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logarithmic phase (i.e. the time point between which the diagonal line of the curve 
was the straightest). Once these time points had been established, the raw data for the 
relevant curve were used to find the exact growth unit at the two time points. 
 
The growth rate at mid-logarithmic phase was then calculated by dividing the 
difference in growth units at each time point by the difference between the two time 
points. In each experiment, for every strain, the mean growth rate of the duplicate 
values at the different inoculum sizes was calculated.      
 
2.8 AEROBIOLOGY STUDIES 
 
2.8.1 Preparation of cultures 
The stability of the core five Panel B M. tuberculosis strains as circulating aerosols 
was tested using an all-glass impinger-30 (AGI-30) sampling device. Cultures with 
1×107 c.f.u. were required. One frozen aliquot of archived culture for M. tuberculosis 
Beijing, M. tuberculosis LAM10, two M. tuberculosis CAS, and M. tuberculosis 
EAI5 was thawed at room temperature and the full volume used to inoculate a CBA 
plate to check for purity, and 50ml falcon tubes, containing 15ml Middlebrook 7H9 
medium with 0.05% Tween-80 media and glass beads. After vortexing, the cultures 
and CBA plates were incubated at 37°C. Every day the plates were checked for 
growth and the cultures were vortexed to break up the clumps. After a week, 
subcultures were prepared by inoculating fresh Middlebrook medium and CBA plates 
(to check for purity) and incubated for 10 days to ensure that the bacteria were in the 
exponential phase of growth. 
 
Instead of using c.f.u., quantification of mycobacteria in each culture was performed 
using real-time PCR procedures as previously described in Section 2.6.3. For each 
strain, two aliquots of the volume of culture required to obtain 1×107 mycobacterial 
genomes were transferred into 2.0ml microcentrifuge tubes and the bacterial cells 
pelletted by centrifugation at 12,000×g for 10 mins to remove media containing 
Tween. Tween is a detergent and may affect the aerosolisation of the cultures. For this 
reason, bacterial cells were resuspended in 1.5ml Middlebrook 7H9 media without 
Tween and without OADC, as the cultures were used immediately. All culturing 
procedures were performed at HPA, MRU. 
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2.8.2 AGI-30 sampling 
The AGI-30 sampling was performed in collaboration with HPA, CEPR, based in 
Porton Down, UK, and the procedures for actual AGI-30 sampling were performed by 
Simon Clark and colleagues in CEPR using a Class III flexible film isolator (Bell 
Isolation Systems Ltd, Scotland, UK).  
For each strain, the full volume of culture, was diluted 1 in 10 using sterile distilled 
water, so the final 15ml diluted culture contained 1×106 genomes. The cultures were 
aerosolized using a 3-jet collison nebulizer (BGI, Incorporated, Massachusetts, USA) 
and then fed through the Henderson apparatus (CEPR), through which air was 
circulated. The diameter of the aerosol particles was on average 2.0μm, with a range 
of 0.5-7.0μm. The aerosols traveled through the apparatus and whilst the Henderson 
apparatus is usually used to deliver aerosols to animals, for the purposes of this 
experiment the aerosols were delivered to four AGI-30 samplers (Ace Glass, 
Incorporated, New Jersey, USA), which were effectively glass vessels, containing 
5ml sterile distilled water, that draws air containing TB bacilli from the Henderson 
apparatus via an inlet and then captures the aerosols in the water. Each strain was 
tested separately and the apparatus was washed through with sterile distilled water 
between strains. Comparing the numbers of mycobacteria in the collison and the AGI-
30 samplers for each strain would allow to identify any differences in the stability of 
strains following aerosolisation. 
 
For safety reasons, all further procedures were conducted at the HPA, CEPR facilities. 
Therefore, to ensure all quantification was performed using the same method, 
colleagues at CEPR and I plated out mycobacteria from the collison and AGI-30 
samplers, a second aliquot of culture that had been prepared in Section 2.8.1 was also 
plated onto Middlebrook 7H11 agar plates (Biomerieux UK Ltd., Hampshire, UK). 
For all collison and AGI-30 samples, 100μl of neat and diluted samples were plated; 
two 10-fold serial dilutions in duplicate were prepared. All plates were incubated at 
37°C for four weeks after which the c.f.u. was counted. The number of c.f.u. per ml 
was calculated by multiplying the c.f.u. count by 10 (as 100µl was plated) and this 
value was multiplied by the dilution factor.   
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2.9 IN VIVO GUINEA PIG EXPERIMENTS 
 
2.9.1 Infecting guinea pigs with TB aerosol 
The phenotypes of core Panel B M. tuberculosis strains, were tested using an in vivo 
model of guinea pigs. Similar experiments had been performed previously at HPA, 
CEPR, using laboratory-adapted strains, so it was of particular interest to compare the 
effects of infecting guinea pigs with wild-type strains. Simon Clark and colleagues 
from CEPR carried out the procedures for infection of guinea pigs. 
 
Sixteen female Dunkin-Hartley guinea pigs, weighing between 650g and 750g 
(Harlan Laboratories, Inc., Loughborough, UK) were infected with each strain. For 
infection, the diluted cultures that had been used for aerobiology testing were used 
again. The AGI-30 sampler components were exchanged for a sow, which 
accommodated 8 guinea pigs per challenge. This meant there were 2 separate 
challenges per strain and between each challenge a sample of the collison was taken 
for c.f.u. counts to monitor the numbers of mycobacteria throughout the challenge. 
 
The diluted culture was aerosolised in the collison nebulizer and as the aerosols 
travelled through the Henderson apparatus, they were delivered straight to the snout 
of the guinea pigs. Guinea pigs were challenged for 5 mins under the controlled 
conditions of the apparatus; meaning approximately 10 mycobacteria should be 
retained in the lungs of the guinea pigs. After 16 guinea pigs had been infected with 
one strain, the apparatus was washed through with sterile distilled water before 
another 16 animals were infected with the second strain and so forth. 
 
After infection, all animals were kept under controlled and contained conditions. 
Their health was monitored and all guinea pigs were weighed every 5 days. Post-
challenge, guinea pigs were culled after 16 days post-challenge (8 guinea pigs per 
strain), and then 56 days post-challenge. All animals were euthanised with overdoses 
of sodium pentabarbitone. 
    
2.9.2 Tissue preparation for viable c.f.u. counts 
After culling, the lung and spleen were aseptically dissected. These procedures were 
performed by Simon and colleagues at CEPR. All other lungs and spleens were stored 
at -20°C immediately ready for processing, but day 56 lungs and spleens were 
weighed, in grams, and a small segment of the organs was removed prior to storage, 
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for histopathology. A rotating blade macerator system (MSE homogeniser; Ystral 
GmbH, Ballrechten-Dottingen, Germany) was used to homogenise lung tissue in 10ml 
sterile distilled water and spleen tissue in 5ml water, and colleagues at CEPR and I 
plated out 100μl aliquots of neat homogenized lung and spleen tissue onto 
Middlebrook 7H11 plates. Appropriate dilutions were plated for the day 16 and 56 
lung and spleen tissues. All plates were inoculated in duplicate. Plates were incubated 
at 37°C for four weeks after which the c.f.u. was counted. The number of c.f.u. per ml 
was calculated as described in Section 5.3.3.  
 
2.9.3 Tissue preparation for histopathology 
For histopathology, all slide preparation procedures were performed by colleagues at 
CEPR. Day 56 lung and spleen tissue segments, which had been removed before 
storing the rest of the tissue at -20°C, were fixed in 10% volume/volume (v/v) 
formalin (Surgipath Europe Ltd., Peterborough, UK). A 1cm3 section was taken from 
one end of each spleen and the top left, top right and bottom right lobe sections from 
each set of lungs were used for histopathological analysis. Tissue samples were 
processed to paraffin wax after which 5µm sections for all lung and spleen tissues 
were stained for routine examination with haematoxylin and eosin; encapsulated and 
calcified lesions were detected using van Giesen and Alizarin Red staining, 
respectively. All stains were provided by Surgipath Europe Ltd.  
 
The examination of slides was blinded and the extent to which lesions were present 
was objectively evaluated semi-quantitatively by a CEPR board-certified veterinary 
pathologist, Dr Graham Hall. The slides for all lung and spleen tissues were scored 
according to the size of the lesions present and the degree of consolidation. 
Consolidation was observed by microscopy and showed a specific change in the 
morphology of the lesion. The greater the number of areas of consolidation, the higher 
the score. The criteria for scoring were as detailed in Table 2.2. For tissues in which 
lesions were detected, the degree to which lymphocytes had infiltrated these lesions 
was also subjectively scored. Numerical data were obtained by recording the number 
of encapsulated lesions, the number of foci of caseation and the number of calcified 
lesions. 
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Table 2.2 The criteria used to score the histopathology slides taken from guinea pig lung and 
spleen after infection with M. tuberculosis.  
 
Score Lesion size Degree of consolidation 
0 lesions not detected 
1 very few or very small 0-10 % 
2 few or small 10-20 % 
3 medium sized 20-33 % 
4 moderate sized; areas of pneumonia 33-50 % 
5 large; moderately extensive pneumonia 50-80 % 
6 extensive pneumonia > 80 % 
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CHAPTER 3 
 
MOLECULAR TYPING, EPIDEMIOLOGY, PHYLOGENETIC ANALYSIS & 
SELECTION OF STRAINS FOR PHENOTYPIC EXPERIMENTS 
 
3.1 INTRODUCTION 
 
In 2007 there were 8417 reported cases of tuberculosis in the UK, with 92% of cases 
being reported in England alone (HPA 2008). London accounted for 39% of cases in 
England and 72% of TB patients in London were born outside of the UK, mainly in 
the Indian sub-continent and sub-Saharan Africa countries, with the highest TB rates 
being seen amongst the ethnic Pakistani, Indian and Bangladeshi groups and black 
Africans (HPA 2008). 
 
According to an earlier study by Dale et al., 2005, in London using IS6110 RFLP and 
spoligotyping data, there are clear differences in the distribution of MTBC families 
amidst patients from different countries (Dale et al., 2005). For instance, in patients 
originating from East Africa and East Asia, the M. tuberculosis African and Beijing 
strains were most common and strains observed in Indian and Pakistani patients were 
markedly different from those observed in patients from Bangladesh. Despite the 
noticeable differences in the M. tuberculosis strains, which seem to predominantly 
infect specific ethnic communities in London, previous studies revealed limited 
transmission from infected immigrants to individuals from other communities in the 
London population (Dale et al., 2005). It is hypothesised that higher transmission had 
occurred either in the country from the immigrant country of origin before entering 
London or within the communities where immigrants are in very close proximity to 
each other causing dissemination of particular strains within specific communities. 
 
The main aim of the present study was to construct a preliminary panel of strains 
(Panel A) representative of the global TB population which would span a broad 
spectrum of M. tuberculosis strains that would be useful for future vaccine evaluation 
studies and general TB research. In addition to designing an algorithm to select M. 
tuberculosis strains for the preliminary panel, the present study also aimed to test the 
null hypothesis that M. tuberculosis strains are phenotypically similar to each other 
using a smaller panel of strains (Panel B derived from the preliminary panel A) to 
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represent the six MTBC phylogenetic lineages defined by Baker et al., 2004 and 
Gagneux et al., 2006. This chapter focuses on the selection process of strains for the 
preliminary panel A and then goes into detail to describe the rationale used to select 
the smaller panel of strains for Panel B. 
 
3.2 MOLECULAR TYPING & EPIDEMIOLOGY 
 
3.2.1 MIRU-VNTR typing 
All cultures received by HPA, MRU between 1st April 2005 and 31st March 2006 
from 30 hospitals and/or laboratories situated within the M25 boundary of London, 
and which had been identified as belonging to M. tuberculosis complex, were 
included for initial MIRU-VNTR typing. Typing, which included the analysis of the 
15 MIRU and 3 ETR loci, was performed on crude DNA extracts from 2363 isolates, 
which all fitted the above criteria for selection. 
 
The 15 loci were amplified in each of the extracts, and molecular weights of amplified 
fragments were calculated as described in Section 2.2. Molecular weight data were 
displayed as a raw data trace, in which red peaks represented the size standard and 
blue, black or green peaks represented molecular weights of different loci according 
to the dye with which they were labelled during amplification. Figure 3.1a shows a 
raw data trace, as displayed by the Genetic Analysis System, from capillary A in 
which MIRU-2, -4, -10, -16, -23, -24 were analysed (refer to Section 2.2.3). Raw data 
were automatically analysed to produce a second trace, in which each peak was 
annotated with the locus and number of repeats corresponding to the detected 
molecular weight. The analysed data trace in Figure 3.1b corresponds to the raw data 
trace in Figure 3.1a. 
 
For some isolates, if after capillary gel electrophoresis no amplified product was 
detected and peaks were absent for certain loci; these loci were re-amplified 
individually and molecular weights identified manually by resolving products against 
a DNA ladder using agarose gel electrophoresis. The number of repeats was 
calculated using the calling tables in Appendix 1 and 2. 
 
The methodology was modified for certain loci: during capillary gel electrophoresis, 
there were missing peaks for ETR-A possibly because fragment sizes exceeded 640 
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b.p., which was the highest molecular weight of the size standard. Whilst extending 
the separation time for electrophoresis meant higher molecular weight peaks were 
included in traces, a locus specific custom size ladder was prepared in order to make 
analysis easier using agarose gel electrophoresis for those extracts in which ETR-A 
peaks were absent. A custom size ladder for MIRU-4 was also prepared because 
during data analysis, there were some MIRU-4 fragments with molecular weights that 
were lower than expected, indicating deletions at this locus.  
 
Extracts that had been successfully analysed by 15 MIRU-VNTR typing were used to 
select extracts that would be used to make locus specific custom size standards. For 
MIRU-4, seven extracts containing repeats ranging from 1 to 9, three extracts with 1, 
2 and 3 repeats and a 49 b.p. deletion, and an extract with 5 repeats with a 50 b.p. 
deletion were selected. Seven extracts containing repeats in ETR-A ranging from 1 to 
9 were selected. Loci were amplified and products were resolved on gels to ensure 
PCR product was present. PCR products were pooled to produce three custom size 
ladders, ETR-A, MIRU-4 and MIRU-4 with deletions. The ladders were used if it was 
difficult to determine the number of repeats when using commercial Hyperladders. 
 
All 15 MIRU-VNTR profiles were collated into a Microsoft Access database that was 
linked to BioNumerics version 3.00, which contained the program for cluster analysis. 
Isolates were analysed blinded and for 265 patients there were multiple isolates. Only 
one profile per patient was included, to avoid bias during analysis, by removing 
profiles of serial isolates (i.e. isolates taken from the same patient more than once). 
The profiles for serial isolates were included as part of another smaller study to 
investigate the reproducibility of particular loci (see Chapter 4). Similarly, during 
capillary gel electrophoresis, some extracts had been included more than once for 
quality control purposes. These profiles were also removed. A total of 102 profiles 
were removed to leave 2261 profiles for cluster analysis. From these 2261 profiles, 
there was complete data for 2046 isolates. 
 
The dendrogram produced after performing the cluster analysis is included as 
supplementary data on the compact disc. The dendrogram was produced using the 
profiles from 12 MIRU, 3 ETR and 7 VNTR typing (NOTE: MIRU-4 and -31 are 
referred to as ETR-D and –E in the dendrogram). Also included are the octal codes of 
isolates after spoligotyping along with the family identification. The dendrogram 
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revealed that 1225 profiles were placed into one of 235 clusters, whose cluster sizes 
varied from 2 to 53 profiles. There were 1036 profiles that did not fall into any cluster 
and were termed unique isolates. All isolates with 15 MIRU-VNTR profiles that fell 
into clusters were further analysed using the more discriminatory loci, including, 
VNTR-2163B, -2347, -3232, -2163A, -1982, -3336 and -4052 (see Section 4.1.5). 
The dendrogram in the supplementary data disc includes the results of cluster analysis 
using the profiles from 12 MIRU and 3 ETR typing and also from the 7 VNTR 
typing. 
 
3.2.2 Spoligotyping 
The crude DNA extracts from the 2363 isolates were subjected to spoligotyping and 
the resulting octal codes used to identify which family isolates of M. tuberculosis 
belonged to, as described in Section 2.2.7. Figure 3.2 shows a scanned image of a film 
after spoligotyping. Altogether, there were complete spoligotyping profiles for 2233 
isolates (94.5% of the total). From these profiles, 656 different spoligotypes were 
observed, and included 198 clustered spoligotypes, with cluster sizes varying from 2 
to 221 profiles, and 458 unique spoligotyping profiles. 
 
To identify which family the octal codes belonged to, profiles were entered into the 
online SPOTCLUST program, which was based on the SpolDB3 model. This model 
included profiles for M. africanum, M. bovis-BCG, M. microti, and nine main M. 
tuberculosis families. Within some M. tuberculosis family groups there were sub-
families denoted with a number after the family name. In total, there were 32 families 
in the SpolDB3 database and four additional groups, Family 33-36. Figure 3.2 shows 
a scanned image of a spoligotyping membrane with the corresponding family 
designations for spoligotyping profiles. From the 2233 profiles, all, except 4, were 
assigned to one or more of the families, with a probability greater than 0.5. From the 
assigned profiles, 88.4% were assigned to a single family with a probability of more 
than 0.9. Remaining profiles could not necessarily be assigned to a single 
spoligotyping family i.e. there was ambiguity leading to their assignment to more than 
one family with probabilities ranging from 0.5 to 0.9; 88% (n = 231) of these profiles 
were assigned to one of the following four groups: i) all profiles identified as M. 
tuberculosis Haarlem 3 all had secondary designations, ii) all strains assigned to M. 
tuberculosis LAM1 were also assigned to LAM9, iii) all profiles assigned to M. 
tuberculosis S family, except for 1, had secondary designations and iv) all profiles 
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assigned to M. tuberculosis X, except 1, were assigned to M. tuberculosis Tuscany-1 
(T1).  
  
Figure 3.3a shows a bar graph of the numbers of profiles that were assigned to each of 
the major MTBC families. There were no M. microti in this study population. From 
Figure 3.3a, it could be seen that the most prevalent family was the CAS family, 
which accounted for 24.7% of the total number of DNA extracts that were genotyped. 
Other major families included T, EAI, LAM and Haarlem. From those extracts 
identified as belonging to the T family, the majority, 84.7%, belonged to the T1 sub-
family, whilst 57.6% of isolates identified as belonging to EAI family were assigned 
to the EAI5 sub-family. From isolates identified as belonging to the LAM families, 
the predominant sub-family was LAM10 and the most predominant sub-family in the 
Haarlem family was Haarlem3. There was a lower prevalence of M. tuberculosis 
Beijing and X families, comprising 5.7% and 4.6% of the total number of isolates, 
respectively, and even fewer members of other families including M. tuberculosis 
H37Rv, S, M. bovis-BCG, M. africanum and the additional unclassified families 33-
36. 
 
3.2.3 Epidemiology 
There was country of birth data for 1381 patients, which constituted 61% of all 
patients included in the study. Apart from the UK, patients were born in 89 different 
countries, which were categorised into global regions, as defined by the WHO. Figure 
3.3b shows the proportions of patients that were born in each region. Altogether, there 
were 1157 patients born outside of the UK; one group of 501 patients was born in the 
African countries, with Somalia contributing the majority of cases (n = 179), and 463 
patients were born in the Indian subcontinent, with the majority of patients being born 
in India (n = 247). The remaining migrant TB patients were from Western Africa, 
Eastern and South East Asia, South-Central Asia, Middle Africa, Western, Northern 
and Southern Europe, and Southern Africa (7.3%, 5.0%, 2.9%, 2.6%, 2.5%, and 2.4%, 
respectively). Each of the other global regions contributed less than 2.0%. 
 
The geographical distribution of the major M. tuberculosis complex families, defined 
by spoligotyping, was investigated and the results are illustrated in Figure 3.4. From 
this diagram, geographical associations were seen between families such as M. 
tuberculosis CAS, EAI, and Beijing, and particular global regions. The patients born 
in the Indian subcontinent were infected mainly with M. tuberculosis CAS and EAI 
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families. The CAS strains isolated from patients born in the Indian subcontinent 
comprised approximately 60% of all CAS strains.  
 
From the 58 patients born in Eastern and South-East Asia, the majority were infected 
with M. tuberculosis Beijing (27 patients) and EAI (21 patients) families. The EAI 
family was also primarily found in immigrants to the UK originally born in the Indian 
Subcontinent and Eastern Africa. Isolates that had been identified as belonging to the 
M. africanum family were predominantly isolated from patients born in the Western 
African countries. 
 
There was no specific association of isolates identified as belonging to the M. 
tuberculosis T family and a particular global region as 40, 67 and 48 isolates (from 
the 366 isolates identified as M. tuberculosis T) were isolated from patients originally 
born in the UK, Eastern Africa and the Indian Subcontinent, respectively. There were 
fewer M. tuberculosis T isolates from patients born in South Africa (4 isolates), 
Western Asia (5 isolates), Northern Africa (2 isolates) and South-Central Asia (4 
isolates). There was underrepresentation of M. tuberculosis LAM and Haarlem 
families, first in the Indian Subcontinent with 4.5% and 3.4%, respectively, and 
secondly in South-East Asia comprising 5.4% and 6.9%, respectively. 
 
3.2.4 Selection of strains for preliminary Panel A 
As it was not possible to perform further phenotypic experiments on all 2363 isolates, 
a series of analyses were conducted to create preliminary panels of strains resulting in 
a final panel of MTBC strains that would be as representative of the global TB strain 
population as possible and against which any vaccine should prove effective. For this, 
we examined a number of genotypic and phenotypic criteria, selecting strains initially 
based on:  
1) frequency in an unselected metropolitan strain family population setting (London, 
UK), with an ethnically diverse population, with representatives from most of the 
global regions (refer to Section 1.4) 
2) supplemented with more infectious strains as demonstrated by greater success e.g. 
higher clustering rates, in unselected regional/national settings in London UK, 
Samara  Region (Russia) and Estonia (Kruuner et al., 2001; Ruddy et al., 2004; 
Drobniewski et al., 2005), and strains infecting individuals outside their typical 
ethnic groups. Our logic was that strains found commonly in a particular 
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population, e.g. Somalis, would tend to spread amongst other Somalis in their 
country of origin and where Somalis develop active TB in the UK any 
transmission would be more likely to spread within their own ethnic groups and so 
to other Somalis. Where such strains are seen to spill over into the host or other 
non-Somali migrant communities (e.g. into an East European patient) it may be 
more likely to be the consequence of more transient exposure and suggest that the 
strain might be more infectious 
3) strains were added from our population-based phylogenetic analysis (refer to 
Section 3.3) to ensure that all the globally-identified phylogenetic groups were 
fully represented  
4) strains were added if phylogenetic analyses suggested that strains were of 
enhanced virulence compared to standard laboratory strains or clinical isolates. 
 
An initial panel (A) reflecting the global population of strain families was selected to 
include a broad spectrum of M. tuberculosis strains. Firstly, in order to gain a better 
understanding of the most common profiles, cluster analysis was performed on all 
isolates (one isolate per patient) using only the MIRU and ETR profiles as described 
in Section 3.2.1 giving 235 clusters altogether, with cluster size varying from 2 to 53 
profiles (see supplementary data on disc). In clusters containing 9 isolates and less, 
the country of birth data was more limited and in some clusters there was only data 
for one or two of the patients, meaning no correlations would be identified when 
applying the algorithm in Figure 2.1. Following the application of this cluster 
inclusion criterion, there were 24 clusters from the initial 235 clusters containing 
more than 9 profiles. 
 
Using spoligotyping data, the proportion of each cluster accounted for by different 
strain families was determined. Many clusters were dominated by one spoligotype 
family. The proportions of isolates, in each cluster, with the family assignations are 
detailed in Table 3.1. In 21 of the 24 clusters over 80% of isolates belonged to a 
single M. tuberculosis spoligofamily. From these 21 clusters, there were 11 clusters in 
which all isolates came from a single strain family strongly supporting a common 
transmission among the individuals in the group at some time point. Five of the 24 
clusters, contained sub-families of the same family (e.g. cluster 18 comprised of T 
family strains, but there were sub-families of T1 and T3). For these 5 clusters 
containing sub-families, the design of the selection algorithm would be different to 
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that in Figure 2.1 because in order to have the ideal representative panel of strains, 
isolates from each sub-family would need to be selected. The algorithm in Figure 2.1 
was designed specifically to select a representative panel of strains from clusters that 
did not contain isolates from sub-families. 
 
An algorithm was constructed to select strains of interest from the 19 clusters (refer to 
Figure 2.1). The algorithm was designed to help select strains based on correlations 
between the most common family in a cluster, the most common country of birth and 
the most common sub-cluster, which was assigned using the 7 VNTR profiles within 
the initial clusters. The common patterns that were considered were family 
designations and country of birth within a cluster. 
 
Using the designed selection criteria, 42 strains of interest were selected from 16 of 
the 19 clusters (refer to Table 3.2). It was not possible to select strains from MRU 
clusters 8 and 38 as the initial cluster using 15 MIRU and ETR profiles were split by 
subsequent analysis using additional 7 VNTR profiles. When looking at the full 22 
VNTR profiles for isolates in Cluster 8 and 38, 53.1% and 46.2% of isolates had 
different profiles to other isolates in their cluster, respectively, and were unique. This 
meant there were no correlations between the most common country of birth and 22 
VNTR cluster designations in Cluster 8 and 38. Even though initially clusters with 
more than 9 isolates were included, there was country of birth data for only 1 of the 
11 isolates in Cluster 148, which meant an isolate from this cluster could not be 
selected. Cluster 28 had to be included for analysis as there was country of birth data 
for 50% of the 10 isolates in this cluster, which had all been identified as M. 
tuberculosis X2. These 42 strains formed the first step toward a globally 
representative panel (Panel A). 
 
The 42 strains selected for Panel A included 10 different families from patients born 
in 17 different countries. Two of the larger groups included in the panel were M. 
tuberculosis CAS (14 strains isolated from patients born in 8 countries) and Beijing (9 
strains also isolated from patients born in 8 countries although different countries to 
the CAS strains). Strains belonging to M. tuberculosis Haarlem or S families, M. 
africanum or Families 33-36 were not included in Panel A because clusters containing 
these families did not fit the initial criteria for inclusion. 
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Figure 3.1 (a) A raw data trace produced by the Beckman Coulter CEQ 8000 Genetic 
Analysis System, for capillary A, in which MIRU-2, -4, -10, -16, -23, -24 loci (identified by the 
labels) were analysed, and (b) a corresponding trace of analysed data in which the 
corresponding peaks to Figure 3.1a are labelled and which were automatically annotated 
with the molecular weight, locus name and number of repeats. 
(Red peaks represent the size standard) 
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Figure 3.2 A scanned image showing spoligotyping profiles that were obtained for the 
controls (profile 1 and 2) and 38 of the 2363 extracts (profiles 3 to 40). Absence and presence 
of spacers were displayed as empty spaces (binary code 0) and black squares (binary code 1), 
respectively. After converting binary codes to octal codes, the M. tuberculosis family for each 
profile was identified using an online SPOTCLUST program. Below are examples of some of 
the identifications that were made.  
 
Profile 1   M. tuberculosis  H37Rv control 
Profile 2   M. bovis BCG P3 control 
Profile 3, 7   M. tuberculosis  EAI5 
Profile 6, 17, 20  M. tuberculosis  EAI3 
Profile 8, 10, 11, 13, 15  M. tuberculosis  CAS 
Profile 12   M. tuberculosis  EAI4 
Profile 14   M. tuberculosis  LAM9 
Profile 16, 37   M. tuberculosis  Beijing 
Profile 18, 19, 22  M. tuberculosis  T1 
Profile 21   M. tuberculosis  LAM10 
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Figure 3.3 (a) Histogram showing the number of spoligotyping profiles that were 
assigned to each of the main families; the numbers for M. tuberculosis T, Haarlem, X, 
EAI and LAM includes all sub-families, and (b) the proportion of patients born in 
global regions defined by the World Health Organisation. 
a) 
b) 
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Figure 3.4 The geographical distribution, using the global regions, defined by the World Health Organisation, of the major M. tuberculosis complex families that had 
been assigned to isolates using spoligotyping. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 105 -
If our underlying hypothesis was correct that these strains were more common or 
dominant in a population because of some underlying advantage compared to other 
strains of M. tuberculosis we would predict that in a range of experiments 
investigating different phenotypes we would be able to determine a difference or 
enhancement in the phenotype of one or more strain.  An alternative way of 
considering this was for us to take a statistical approach in stating a null hypothesis 
that all TB strains are the same phenotypically and to then prove or disprove this null 
hypothesis. 
 
The null hypothesis would be tested by comparing differences in phenotype or 
virulence in vivo. However, this could not be evaluated using all of the 42 strains in 
Panel A as this number would be impractical, too costly and was not necessary to 
prove or refute the underlying hypothesis.  Previous studies had shown that the global 
phylogeny of TB strains fell into 6 major groups (including M. bovis and M. 
africanum) and so we determined whether the 42 strains in Panel A included strains 
spanning all the 6 phylogenetic groups.  The in vivo experiments would need to 
include representatives of all of those groups. 
 
3.3 PHYLOGENETIC ANALYSIS & SELECTION OF STRAINS 
 
3.3.1 Phylogenetic analysis 
Globally, TB strains can be ordered into 6 phylogenetic lineages (if M. bovis and M. 
africanum are included) (Baker et al., 2004; Gagneux et al., 2006). A study by Gibson 
et al., 2005, demonstrated that MIRU and ETR codes could be used to classify M. 
tuberculosis and M. bovis strains into one of the five M. tuberculosis lineages (I, II, 
III, IV and M. bovis), initially defined by Baker et al., 2004, and subsequently 
validated by Gagneux et al., 2006. Phylogenetic analysis involved assigning each of 
the 2261 isolates into each of the lineages based on the number of repeats in specific 
loci as detailed in Table 3.3. The proportion of families identified by spoligotyping 
was calculated within each of the lineages to check for any correlations between 
lineage and family. The results from this analysis are displayed in Figure 3.5. 
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Table 3.1 The 24 clusters containing more that 9 profiles, after performing cluster analysis 
with MIRU and ETR profiles. The table includes details of the proportions of each of the M. 
tuberculosis families observed in each cluster. ∗ indicates the clusters containing sub-families 
and which were exempt from further analysis.             
MRU cluster number Cluster size MTBC spoligofamily % of cluster  
14 53 CAS 100 
CAS 87.8 
Family35 4.1 
Beijing 4.1 
Haarlem 1 2.0 
8 49 
S 2.0 
LAM10 95.3 
T1 2.3 1 43 
No identification 2.3 
T1 57.6 18 ∗ 33 T3 42.4 
CAS 93.8 3 32 
No identification 6.2 
LAM8 87.1 
LAM9 9.7 27 ∗ 31 
T1 3.2 
Haarlem 1 21.4 
Haarlem 2 7.1 
Haarlem 3 60.7 
T1 3.6 
X1 3.6 
2 ∗ 28 
No identification 3.6 
LAM10 96.3 42 27 
X3 3.7 
CAS 87.0 
Beijing 8.7 6 23 
EAI5 4.3 
10 22 Beijing 100 
201 21 M. bovis BCG 100 
LAM1 95.0 125 20 
No identification 5.0 
36 17 LAM3 100 
100 16 T1 100 
41 15 Beijing 100 
Haarlem 1 28.6 
Haarlem 3 57.1 
T2 7.1 12 ∗ 14 
X1 7.1 
192 14 Beijing 100 
38 13 EAI3 100 
72 13 CAS 100 
112 13 LAM10 100 
LAM8 83.3 130 ∗ 12 LAM9 16.7 
CAS 90.9 31 11 
No identification 9.1 
LAM3 81.8 148 11 
X2 18.2 
28 10 X2 100 
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Table 3.2 The 42 strains that were included in Panel A, and strains that were then included in 
Panel B. 
 
MRU Cluster /Sub-cluster M. tuberculosis spoligofamily Country of Birth Panel B 
/1 CAS Somalia D 
/unique CAS Bulgaria  14 
/5 CAS Hungary  
/1 T1 UK  
/1 LAM10 UK D 1 
/1 LAM10 Nigeria  
/1 CAS Jamaica  3 
/unique CAS Qatar  
/1 LAM10 Nigeria  
/2 X3 Nigeria  42 
/1 LAM10 UK  
/4 Beijing India  
/4 EAI5 India D 
/4 CAS Pakistan  
/unique CAS Somalia  
/6 CAS India  
6 
/unique CAS Mozambique  
10 /unique Beijing China  
201 /unique M. bovis-BCG UK  
/1 LAM1 India  
/1 LAM1 Poland  
/unique LAM1 Angola  
125 
/unique LAM1 Gambia  
/1 LAM3 UK  
/2 LAM3 Nigeria  36 
/1 LAM3 Iran  
100 /1 T1 Jamaica  
/1 Beijing UK  
/3 Beijing India  
/unique Beijing Poland  41 
/1 Beijing Uganda  
/unique Beijing Hong Kong  
/2 Beijing Jamaica  192 
/unique Beijing Malaysia  
/1 CAS India D 
/2 CAS Somalia  72 
/1 CAS Pakistan  
112 /1 LAM10 Pakistan  
/1 CAS Somalia  31 
/1 CAS India  
/1 X2 UK  28 
/unique X2 Nigeria  
  Beijing Estonia D 
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Table 3.3 The defined MIRU loci and number of repeats that would define isolates into the 
five lineages, M. tuberculosis lineage I, II, III, IV and M. bovis according to Gibson et al., 
2005. 
Lineage Locus associated with lineage (number of repeats) 
I MIRU-39 (3) ETR-A (4) ETR-C (4) 
II MIRU-16 (1, 2, 3) MIRU-39 (2) ETR-B (1, 2) 
III MIRU-23 (5) ETR-C (2)  
IV MIRU-24 (2) MIRU-26 (2)  
M. bovis MIRU-10 (2) MIRU-40 (2) ETR-C (5) 
 
 
In total, 1223 isolates were ordered into the 5 M. tuberculosis lineages (lineages I to 
IV, which corresponded to East Asian, Euro-American, East African-Indian, and 
Indo-Oceanic lineages, respectively, and the M. bovis lineage) and 210 isolates, 
constituting 14.7%, remained undefined using the algorithm by Gibson et al., 2005.  
From the 1223 isolates, 1174 isolates were assigned to a single lineage, whilst the 
remaining isolates were assigned to two lineages. Lineage II contained the largest 
proportion of isolates (38.5% of the total number of isolates), while lineage III and IV 
were assigned 20.4% and 18.6% of isolates, respectively. The smaller lineages, 
lineage I and M. bovis, had similar proportions of isolates, 2.2% and 2.3%, 
respectively. From those isolates assigned to two lineages, lineage II overlapped with 
three other lineages including lineage III (17 strains), lineage IV (7 isolates) and M. 
bovis lineage (2 strains), whilst 23 isolates were assigned to both lineage I and IV. 
Using the algorithm, isolates identified as M. africanum by spoligotyping could not be 
assigned to any of the five lineages.  
 
There was good correlation between families identified by spoligotyping and the 
lineages, especially for lineages I, III, IV, and the M. bovis lineage, which were 
primarily made up of isolates identified as M. tuberculosis Beijing, CAS, EAI and M. 
bovis-BCG, respectively. Lineage II was more diverse in the different families that 
were found in this lineage. Within lineage II were isolates belonging to T, LAM, 
Haarlem, X, and S families, which together constituted over 90% of isolates assigned 
to lineage II. 
 
As the approach identified in Gibson et al., 2005 was unable to ascribe the appropriate 
lineage in 259 isolates, lineage designations were completed by performing SNP 
analysis, using genes described by Baker et al., 2004, including oxyR C37T, katG 
C87A, rpoB T2646G, and rpoB C3243T. This was performed by colleagues in HPA, 
MRU. From the 49 isolates originally assigned to more that one lineage, all strains 
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were assigned to one of the two lineages using SNP analysis. From the 210 isolates 
that were not defined at all, isolates identified as M. tuberculosis Beijing, CAS, and 
M. bovis BCG by spoligotyping were assigned to lineage I, III and M. bovis, 
respectively, by SNP analysis. The recently evolved modern families, Haarlem, LAM, 
X, T, and S were assigned to lineage II, and all but 3 isolates identified as EAI family 
were assigned to lineage IV. All M. africanum isolates, except one, were assigned to 
lineage I. 
 
3.3.2 Selection of strains for Panel B 
After performing the phylogenetic analysis it was decided to select strains primarily 
from Panel A but also to include some strains of interest identified in the scientific 
literature. M. tuberculosis Beijing, CAS and EAI strains were selected to represent 
lineages I, III, and IV. A LAM strain was chosen to represent lineage II because it 
was one of the larger families within this lineage. The final strains included in Panel 
B, the details of which can also be found in Table 3.2, were: 
1) M. tuberculosis Beijing strain. Although Beijing strains had been included in 
Panel A, the Estonian Beijing IX strain was of more clinical significance as the 
MDR strain had appeared in the Estonian population and had come to dominate 
the population after a period of 10 years (data not published). A Beijing IX strain 
isolated from a patient in Estonia and fully sensitive to all first line drugs, 
isoniazid, streptomycin, rifampicin, ethambutol and pyrazinamide, was used to 
avoid bias if there are phenotypic changes related to resistance. This strain had the 
same MIRU and ETR profile as that of isolates in one of the larger clusters, cluster 
10 (refer to Table 3.1). 
2) M. tuberculosis LAM strain. A LAM10 strain, from Panel A, belonging to cluster 
1 that had been isolated from a patient born in the UK was selected. This strain 
had been shown to be responsible for the largest outbreak of isoniazid resistant TB 
in London and, subsequently, in the UK (Ruddy et al., 2004). The selected strain 
was resistant to isoniazid, but sensitive to streptomycin, rifampicin, ethambutol 
and pyrazinamide. 
3) M. tuberculosis CAS strain. The CAS strain constituted approximately 25% of the 
population that was studied and, therefore, was essential for inclusion in Panel B. 
After performing cluster analysis using only the MIRU and ETR profiles, the 
largest cluster was Cluster 14 with 53 isolates all belonging to CAS family. A total 
of 53.1% of patients, for whom country of birth data were available, were from 
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4) M. tuberculosis CAS strain. From epidemiology analysis (Section 3.2.3), it was 
observed that most patients from the Indian subcontinent were infected with M. 
tuberculosis CAS and EAI strains, and India was the country of origin for most 
patients in this region infected with CAS. Therefore, a CAS strain was selected 
from Panel A, belonging to Cluster 72, which apart from Cluster 14, was the only 
other cluster in which all isolates had been identified as belonging to the CAS 
family. In Cluster 72, 44.4% of patients were born in India. The selected strain 
was sensitive to all first line drugs. 
5) M. tuberculosis EAI strain.  An EAI strain was selected to represent lineage IV. 
This family is of epidemiological interest because this strain was also isolated 
from most patients that were born in the Indian subcontinent. In Panel A there was 
only one EAI5 strain, which belonged to cluster 6 and isolated from a patient born 
in India. This strain was fully sensitive to all first line drugs. 
6) Wild-type M. africanum. Besides lineages I, II, III and IV defined by Baker et al., 
2004, a separate key lineage for M. africanum had been defined by Gagneux et al., 
2006 (Baker et al., 2004; Gagneux et al., 2006). As the initial rationale for 
selecting Panel B was identifying a strain from each of the major MTBC lineage, a 
strain was selected at random from the study population of 41 M. africanum 
strains.   
 
Laboratory control strains M. tuberculosis H37Rv (supplied by HPA, MRU), M. 
tuberculosis H37Rv and M. bovis BCG (supplied by HPA, Porton Down), and M. 
tuberculosis H37Ra (HPA, National Collection of Type Cultures; NCTC) were 
included for phenotypic analysis. 
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Figure 3.5 The numbers of isolates assigned to each of the M. tuberculosis complex lineages, 
defined by Baker et al., 2004, and Gagneux et al., 2006, using MIRU and ETR codes defined 
by Gibson et al., 2005. The diagram also shows the proportions of families, identified by 
spoligotyping, which made up each lineage.  
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3.4 DISCUSSION 
 
The initial part of the present study involved identification of the various circulating 
strains and London provided the most appropriate setting with such an ethnically 
diverse population, so isolates from all 30 hospitals and/or laboratories situated in 
London were included prospectively for molecular typing. Patients were born in 89 
countries, which included some of the high-TB burden countries defined by the 
WHO, and provided a significant global biodiversity of M. tuberculosis strains. 
 
Isolates were typed using 12 MIRU and 3 ETR loci primarily, which grouped all 
profiles that were the same (clustered) and filtered all unique isolates. The clustered 
isolates were included for secondary analysis using the more discriminatory panel of 7 
additional VNTR loci to identify isolates that were truly identical to each other. The 
usefulness of the 7 VNTR loci was demonstrated by the reduction in clustering rates 
from 54.5%, when using the MIRU and ETR loci, to 22.2%.  
 
Although typing using the MIRU, ETR and VNTR loci allowed identification of the 
various common and unique molecular types circulating within London, 
spoligotyping was performed to identify which M. tuberculosis family each isolate 
belonged to and to understand the biodiversity of MTBC isolates. The online 
SPOTCLUST tool was used to assign spoligotyping profiles to MTBC families 
(Filliol et al., 2002) and all but four strains were assigned to one of 32 families in the 
database and four additional families, Family 33 to 36. 
 
During analysis of profiles it was observed that two different octal code profiles could 
be identified as the same M. tuberculosis family and it was determined that the 
recognition rules were based on deletions in specific spacers (Filliol et al., 2002). For 
some octal code profiles there were two family identifications and it was realised that 
the rules were sometimes not sufficiently specific to some families. For instance, 
strains that had been identified as belonging to M. tuberculosis LAM1 family were 
also given an identification of LAM9, but at a lower probability, as the recognition 
rules involved deletions in spacers 21 to 24 and 33 to 36 for both families, and the 
tool could not distinguish between the codes. 
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After all of the molecular typing was completed, the global representation of M. 
tuberculosis strains in the study population of London was investigated. This was 
fulfilled by performing epidemiological analysis, which involved plotting proportions 
of identified MTBC families on a global map using the country of birth data that was 
available for 1381 patients. There were strong associations between country of birth 
of patients and M. tuberculosis families: for example the Beijing family was 
associated with patients born in South and South-East Asia, whilst the CAS strains 
were more predominant amongst patients originally from the Indian subcontinent and 
South-Central Asia. The EAI strain was slightly more widespread as it was commonly 
found in patients from the Indian subcontinent, South-East Asia and Eastern Africa, 
whilst the M. africanum strains were significantly associated with patients born in 
Western Africa. 
 
Similar associations have been previously reported in recent studies and provide 
evidence of a clonal MTBC population in some high TB-burden countries and suggest 
higher TB transmission rates within these countries (Behr et al., 2004; Filliol et al., 
2002; Vitol et al., 2006; Gagneux et al., 2007). The lack of any definite association 
between country of birth and M. tuberculosis families S, T, Haarlem, and X, in this 
study, may suggest that the distribution of these families is fairly uniform globally. 
However, a more realistic explanation may be the poor definition of these families 
with the present recognition rules, as these families are still evolving and have a fairly 
recent origin, perhaps from the Indian subcontinent (Singh et al., 2004; Gutierrez et 
al., 2006; Vitol et al., 2006). This epidemiological analysis demonstrated that the 
population of isolates included representatives from all MTBC families and almost all 
global regions, although there were few representatives from North and South 
America. 
 
The clusters produced when using the MIRU and ETR profiles, along with the 
country of birth, family assignations and 7 VNTR profiles attached to the isolates 
within clusters, were used to select the strains for Panel A. The cluster analysis 
identified the more prevalent strains circulating within London and it seemed logical 
to base part of the selection of strains for vaccine evaluation on prevalence of strains 
as there is likely to be higher success in the transmission of these strains. The clusters 
that would be used for further analysis were selected by including clusters with more 
than 9 isolates. Whilst the main reason for these criteria was to include the more 
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prevalent strains, the decision was also influenced by limited country of birth data for 
clusters smaller than 10 isolates. 
 
As strain prevalence was a factor for selection, clusters containing sub-families were 
excluded. In order to select which particular isolate from each cluster would be 
selected, an algorithm was designed to take into account important factors such as the 
country of birth of patients and the most prevalent 7 VNTR cluster within the main 
MIRU and ETR profile based cluster.  
 
The country of birth data provided a very good indication of possible sources of 
strains and has been demonstrated previously by Dale et al., 2005 (Dale et al., 2005). 
The strong association between the MTBC family identification and country of its 
origin may offer valuable information for vaccine development because, whilst the 
ideal option would be to have one universal vaccine, a niche vaccine providing 
significant efficacy against certain TB families, like M. tuberculosis CAS and Beijing, 
in regions where they are found at high incidence may offer protection to a substantial 
proportion of the population. For the purposes of selecting strains for Panel A, the 
strain was selected if there was a correlation between the most common country of 
birth and the most prevalent 7 VNTR cluster. 
 
Using the algorithm, 42 strains of interest were selected. It was important to establish 
if there were any phenotypic differences between circulating M. tuberculosis strains 
using in vitro experiments initially, with the subsequent possibility of performing in 
vivo experiments. It was not possible to perform statistically valid in vivo experiments 
on all of the 42 strains in Panel A, so 6 wild-type strains were selected after 
performing phylogenetic analysis to represent the major M. tuberculosis lineages 
defined by Baker et al., 2004 and Gagneux et al., 2006 (Baker et al., 2004; Gagneux 
et al., 2006) (refer to Section 3.3). When assigning isolates into the lineages defined 
by MIRU and ETR codes, whilst the vast majority of isolates were assigned to a 
single lineage a small proportion were assigned to two lineages or not assigned at all 
(Gibson et al., 2005). Therefore, SNP analysis was used to complete the designation 
of isolates successfully. 
 
Phylogenetic analysis revealed families that made up the vast majorities of each of the 
lineages with M. tuberculosis Beijing, CAS and EAI strains representing lineages I, 
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III, and IV, respectively. Even though lineage II was made up of multiple families it 
was decided to select a LAM strain because it was one of the larger families within 
this lineage and, as mentioned previously, there was a LAM10 strain that was of 
particular interest. The final panel of strains comprised M. tuberculosis Beijing IX 
strain from a patient born in Estonia (this strain was selected as a result of 
unpublished data reporting its clinical significance as the strain has gone from first 
appearance to dominating the TB strains found in the Estonian population within a 
decade), M. tuberculosis LAM10 strain from a patient born in the UK (this isoniazid 
resistant strain was selected as it was responsible for the London TB outbreak), two 
M. tuberculosis CAS strains from clusters that contained isolates all identified as 
CAS, M. tuberculosis EAI5 strain isolated from a patient born in India, and a 
randomly selected M. africanum strain. 
 
In addition, laboratory control strains were included (two M. tuberculosis H37Rv 
strains, M. tuberculosis H37Ra, and M. bovis BCG). An M. tuberculosis H37Rv strain 
from HPA, Porton Down, was included as the data from in vivo experiments would be 
compared to data from similar experiments previously carried out using the H37Rv 
strain from Porton Down. Therefore, phenotypic in vitro experiments would be 
performed using H37Rv strains from both laboratories.  
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CHAPTER 4 
 
REPRODUCIBILITY OF NOVEL M. TUBERCULOSIS MINI-SATELLITE 
VNTR LOCI 
 
4.1 GENOTYPING USING VNTR LOCI 
 
4.1.1 Introduction 
Molecular genotyping can be used to investigate suspected outbreaks and detect 
laboratory cross-contamination in low to middle TB incidence areas. The highest level 
of discrimination is required for population-level genotyping when identifying 
clustered cases that are not apparently linked and if there is limited epidemiological 
data (Gopaul et al., 2006). In order to differentiate between re-infection and 
reactivation of infection, to detect laboratory cross-contamination and to establish 
epidemiological links between patients, IS6110-RFLP has been used routinely, 
sometimes in conjunction with spoligotyping (Supply et al., 2006). 
 
Typing using multiple VNTR loci, which had been previously proposed by 
Frothingham and Meeker-O'Connell, 1998, has been modified to increase 
discrimination by including additional loci (Frothingham et al., 1998; Supply et al., 
2001; Kwara et al., 2003; Supply et al., 2006). Discrimination, which is very 
important for prospective molecular epidemiological studies, depends considerably on 
the number of loci used and their selection. 
 
Despite the proposal of a standardised VNTR typing panel of 12 MIRU, 3 ETR and 9 
VNTR (VNTR-424, -2401, -3690, -4156, -2163B, -1955, -4052, -2347 and -3171) 
loci, it was not clear if this panel provided sufficient discriminatory power in regions 
where homogeneous MTBC families were prevalent (Kam et al., 2006; 
Nikolayevskyy et al., 2006; Supply et al., 2006; Oelemann et al., 2007). There are 
reports of additional VNTR loci with improved discrimination for prospective routine 
typing and to distinguish isolates within particular homogeneous groups of strains 
with highly conserved genes, such as the M. tuberculosis Beijing family (Gopaul et 
al., 2006; Kam et al., 2006; Nikolayevskyy et al., 2006). In the previous chapter, the 
additional seven VNTR loci had been useful due to their increased discriminatory 
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power to identify isolates that were the same as each other when applying the 
algorithm in Figure 2.1 to the 12 MIRU and 3 ETR clusters. 
 
Concerns about the stability and reproducibility of some hypervariable and 
discriminative loci such as VNTR-3232, -2163A, -3336, and -1982 have resulted in 
their exclusion from MTBC multilocus VNTR typing panels proposed for 
international standards (Kremer et al., 2005; Supply et al., 2006). For these reasons, it 
was decided to conduct a study to examine the stability of hypervariable loci and the 
parameters associated with reproducibility. 
 
4.1.2 Evaluation of conditions affecting analysis of VNTR loci 
Factors affecting reproducibility, including optimisation of enzyme choice, PCR and 
fragment analysis conditions to ensure reproducibility of results of the two 
hypervariable loci, VNTR-3232 and -1982, were analysed using a panel of 16 MTBC 
isolates, which had been previously characterised (refer to Section 2.2) and for which 
there was complete data for the 12 MIRU, 3 ETR and 7 VNTR loci. Isolates were 
selected to cover a range of repeats in MIRU-26, ETR-B and VNTR-1982 and -3232 
loci. 
 
As primers were labelled with the same dye, a single primer mix was prepared with 
forward and reverse primers for MIRU-26 and ETR-B so the final concentration of 
each primer was 0.5 µM. Separate mixes were prepared for VNTR-1982 and -3232 as 
they were labelled with different dyes. For each of the 16 extracts, MIRU-26, ETR-B, 
VNTR-1982 and -3232 were amplified exactly as described in Section 2.2.2 and 2.2.6 
using 0.2ml 8-strip tubes (Alpha Laboratories) instead. Each locus was amplified 
using BIOTAQ and Diamond polymerase, with their respective amplification cycles 
(refer to Section 2.2.2 and 2.2.6). Loci were also amplified using HotStartTaq DNA 
polymerase and HotStartTaq Plus DNA polymerase (both supplied by Qiagen). Each 
10µl reaction contained 1× PCR Buffer (Qiagen), 0.25U/µl of the relevant 
polymerase, 0.2µM dNTPs, 0.125µM of relevant primer, 5% DMSO. For HotStartTaq 
DNA polymerase, the DNA amplification cycle was as follows: 95°C for 15 mins; 
35 cycles of 94°C for 30 secs, 60°C for 30 secs, and 72°C for 60 secs; 72°C for 10 
mins. The amplification cycle was the same when using HotStartTaq Plus DNA 
polymerase, except the initial 95oC activation time was reduced to 5 mins. The 
number of repeats at loci in PCR products was calculated manually by resolving 4µl 
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of each product on a 1.2% (w/v) agarose gel as described in Section 2.2.4 against a 
2000 b.p. HyperLadder II standard. 
 
Molecular weights of PCR products and the corresponding number of repeats were 
then calculated by denaturing capillary electrophoresis. PCR products were pooled 
and resolved against DNA Size Standard 600 and MapMarker D1 labelled 640-1000 
as described in Section 2.2.3 and 2.2.6, except three different parameter sets were 
used to analyse fragments, as detailed in Table 4.1. Method 1 (Table 4.1) shows the 
original parameters used for MIRU-VNTR analysis and the other methods included 
variations of the different parameters, including changes in capillary temperature, and 
in durations of denaturation and separation steps. Raw data were automatically 
analysed and the peaks in analysed data traces were automatically annotated with the 
molecular weights, in base pairs, and the calling tables (Appendix 1 and 2) were used 
to manually calculate the number of repeats in each locus. 
 
Table 4.1 The parameters used to analyse each set of sixteen pooled PCR products on the 
Beckman Coulter CEQ 8000 Genetic Analysis System. 
  Method 1* Method 2 Method 3 
Capillary Temperature (oC) 60 60 50 
Temperature (oC) 90 90 90 Denature 
Duration (secs) 120 180 180 
Voltage (kV) 2.0 2.0 2.0 Inject Duration (secs) 30 30 30 
Voltage (kV) 6.0 6.0 6.0 Separate Duration (mins) 60 60 70 
* this was the original method used for 15 MIRU-VNTR 
 
 
Reproducibility of typing using all of the 12 MIRU, 3 ETR and 7 VNTR loci, which 
were used for the larger study, was also investigated in a blinded study, by checking 
for consistency between MIRU-VNTR profiles of serial isolates, within the 2363 
isolates that had been originally typed (refer to Section 2.2.6). There were 265 sets of 
serial isolates (i.e. multiple isolates from the same patient taken at successive time 
intervals), where each set contained 2 to 6 isolates from the same patients at different 
time points with intervals varying from 3 days to 11 months. 
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4.1.3 Optimised VNTR loci typing conditions 
The 16 isolates selected for this study had repeats in MIRU-26 ranging from 1 to 8; 
ETR-B ranging from 1 to 6; VNTR-1982 ranging from 2 to 13; VNTR-3232 ranging 
from 1 to 16. Factors potentially influencing the performance of hypervariable VNTR 
loci were evaluated by amplifying loci using four different polymerase enzymes and 
resolving PCR fragments under non-denaturing (agarose gel electrophoresis) and 
denaturing conditions (automated capillary electrophoresis using three different sets 
of separation conditions; Table 4.1). 
 
The ability to correctly amplify different VNTR loci was dependent on the enzyme 
used (Table 4.2). These results were the average of data from 2 repeated experiments. 
All polymerases were efficient for amplifying MIRU-26 and ETR-B, indicated by the 
presence of bands on agarose gels and peaks during capillary gel electrophoresis. All 
polymerases except Bioline BIOTAQ were able to amplify VNTR-1982 and longer 
fragments were amplified more efficiently by Bioline Diamond and QIAGEN 
polymerases. Effective amplification of VNTR-3232 was achieved only with Bioline 
Diamond (15/16 strains, i.e. 93.8%); therefore, Diamond polymerase was used for the 
amplification of additional VNTR loci. 
 
Table 4.2 The number of DNA extracts (out of the selected 16) for which peaks were detected 
by different conditions for capillary electrophoresis after amplifying the loci with different 
polymerases. The figures in brackets represent the number of extracts whose calculated 
number of repeats were [higher] and (lower) than the expected value. 
Bioline polymerases Qiagen polymerases Locus Method (Refer to Table 2.1) BIOTAQ Diamond HotStartTaq HotStartTaq Plus 
1 16 16 16 [1] 16 [1] 
2 15 16 16 [1] 16 [1] MIRU-26 3 16 16 16 16 
1 16 16 16 (1) 16 (1) 
2 15 16 16 (1) 16 (1) ETR-B 
3 16 16 16 (2) 16 (2) 
1 8 13 14 14 
2 9 13 12 14 VNTR-1982 
3 6 11 12 14 
1 11 15 13 14 
2 10 15 14 14 VNTR-3232 
3 11 (3) 15 (7) 13 (6) 13 (4) 
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Three different methods were evaluated for capillary gel electrophoresis, including 
Method 1 (Table 4.1), which is normally used in the laboratory for analysis. Methods 
2 and 3 (Table 4.1) were included to investigate the effects of increasing the time for 
denaturing PCR products at 90°C and decreasing the capillary temperature. For each 
locus, the detected molecular weights of products, which had been amplified using 
each of the four polymerases and then resolved using the different capillary gel 
electrophoresis conditions, were plotted and compared with expected molecular 
weights, which were also plotted on the same graphs. The graphs for each locus, 
MIRU-26, ETR-B, VNTR-1982 and -3232 are shown in Figure 4.1a to 4.1d. 
 
Molecular weights of the MIRU-26 fragments were as expected for all but 2 repeats. 
For this allele, the molecular weight of fragments amplified using BIOTAQ and 
Diamond polymerases were approximately 344 b.p., as expected, but higher than 
expected when using the Qiagen polymerases meaning that the interpreted number of 
repeats was 1 repeat more than expected. The smaller ETR-B fragments with 1 and 2 
repeats all had molecular weights of expected sizes when using Methods 1 and 2, but 
were lower than expected when the capillary temperature was decreased (Method 3); 
this did not affect the interpreted number of repeats. For the higher number of repeats 
(4, 5 and 6 repeats), independent of the polymerase used to amplify them, molecular 
weights of fragments when resolved using capillary gel electrophoresis Method 3, 
were lower than expected, which in some cases affected the interpretation of the data. 
 
Irrespective of the polymerase used for amplification and the method used for 
capillary gel electrophoresis, the molecular weights of amplified VNTR-1982 
fragments were all similar to expected values as were the interpreted numbers of 
repeats. Analysis using Methods 1 and 2 for capillary gel electrophoresis generated 
the expected molecular weights for VNTR-3232 fragments, whilst lower molecular 
weights were detected when using Method 3. The lower molecular weights for 
VNTR-3232 fragments with an expected 1 to 6 repeats did not influence the 
interpreted number of repeats, but for fragments with more than 7 repeats, the lower 
molecular weights produced, gave a lower repeat number than expected. 
Figure 4.1 The detected molecular weights of (a) MIRU-26, (b) ETR-B, (c) VNTR-1982, and (d) VNTR-3232 fragments (amplified using different polymerases) when capillary gel 
electrophoresis analysis was performed under the different conditions outlined in Table 2.1. 
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Figure 4.1 continued 
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Figure 4.1 continued  
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Figure 4.1 continued  
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4.1.4 Reproducibility of MIRU-VNTR typing 
The stability and reproducibility was further investigated by performing MIRU-
VNTR typing, using all 22 loci (12 MIRU, 3 ETR and 7 VNTR) on serial isolates 
(refer to Section 2.2.8). There were 265 sets of serial isolates with a total of 367 
isolates. MIRU and ETR loci had been amplified using Bioline BIOTAQ polymerase 
and VNTR loci had been amplified using Bioline Diamond polymerase. Fragment 
analysis was performed using the optimised capillary gel electrophoresis conditions 
detailed in Method 1 (Table 2.1). Analysis was blinded. 
 
There were no discrepancies in the MIRU-VNTR profiles between isolates in each set 
of serial isolates. In a proportion of serial isolates, genotyping results were validated 
by a colleague using both agarose and capillary gel electrophoresis and again no 
differences were found between different runs and different methods of fragment 
separation (Figures 4.2 and 4.3). 
 
4.1.5 Genotyping using the additional 7 VNTR loci 
Initially, for the main study, 2363 MTBC isolates were typed using 12 MIRU and 3 
ETR loci. Cluster analysis was performed using the 12 MIRU and 3 ETR profiles. A 
cluster was defined as containing two or more isolates with the same 12 MIRU and 3 
ETR profiles. All clustered isolates were then including for typing using the 7 
additional VNTR loci (refer to Section 2.2.6). There was a clustering rate of 54.5% 
when using the MIRU and ETR profiles (refer to Section 3.1.1 for details). This 
clustering rate suggested that high rates of active TB transmission might currently be 
occurring in London.  
 
From the 1225 isolates that had been clustered using MIRU and ETR profiles, 1196 
isolates were subjected to secondary typing using the additional 7 VNTR loci (VNTR-
2163B, -2347, -3232, -2163A, -1982, -3336 and -4052) and the optimised conditions 
described above. Improved resolution was achieved as strains that had been clustered 
initially were subdivided into new groups: 1730 isolates had unique genotyping 
patterns and the remaining 502 isolates were grouped into 158 clusters giving a new 
substantially lower clustering rate of 22.2% (see supplementary data on the disc for 
the dendrogram produced after cluster analysis). The addition of the 7 VNTR loci 
demonstrated that when using the 12 MIRU and 3 ETR loci there was an over-
estimation in the transmission rate of strains. 
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Figure 4.2 An agarose gel showing the stability of the locus VNTR-3336 and reproducibility 
of typing data by amplifying the locus in 2 serial isolates from 4 different patients, A, B, C 
and D, and then resolving products using non-denaturing agarose gel electrophoresis. 
 
 
1 – Patient A, Isolate 1, isolated 20/06/05; 8 copies 
2 – Patient A, Isolate 2, isolated 11/07/05; 8 copies 
3 – Patient B, Isolate 1, isolated 08/07/2005; 9 copies 
4 – Patient B, Isolate 2, isolated 08/08/2005; 9 copies 
5 – Patient C, Isolate 1, isolated 11/11/2005; 7 copies 
6 – Patient C, Isolate 2, isolated 16/11/2005; 7 copies 
7 – Patient D, Isolate 1, isolated 16/05/2005;  6 copies 
8 – Patient D, Isolate 2, isolated 25/05/2005; 6 copies 
 
 
       1   2    3    4    5    6     7   8  
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Figure 4.3 Analysed data traces produced by the Beckman Coulter CEQ 8000 Genetic 
Analysis System. All traces were produced after amplifying the additional 7 VNTR loci from 
two isolates taken from the same patient at different time points with an 11-month interval. 
Traces A and B are from the first isolate and traces C and D from the second isolate. The 
data demonstrate the stability of these VNTR loci in serial isolates from the same patient and 
the reproducibility of typing using the optimised protocol for amplification and fragment 
analysis. 
 
 
 
 
Traces A & C – peaks representing VNTR-2163B, -2347, -3232, -2163A  
Traces B & D – peaks representing VNTR-1982, -3336; -4052 
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The discriminative ability varied between all 22 loci with the Hunter-Gaston 
Discrimination Index (HGDI) values of MIRU loci ranged from 0.134 (MIRU-2 with 
4 allelic variants) to 0.727 (MIRU-40 with 11 allelic variants). The HGDI values were 
calculated manually for all MIRU, ETR and VNTR loci using the principles described 
by Hunter and Gaston, 1988 (Hunter et al., 1988). For the ETR loci, values ranged 
from 0.551 (ETR-B with 9 allelic variants) to 0.813 (ETR-A with 14 allelic variants). 
The HGDI values of VNTR loci were considerably more with values for VNTR-
2163B, -2347, -3232, -2163A, -1982, -3336, and -4052 being more than 0.900 (0.985, 
0.954, 0.994, 0.992, 0.989, 0.992, and 0.987, respectively). The allelic variants were 
higher for the VNTR loci indicative of their higher polymorphic nature (13, 6, 19, 18, 
14, 15 and 10, respectively). As expected, none of the 22 loci were monomorphic in 
the current study. Loci included in the additional panel displayed higher variability 
than the panel of 12 MIRU and 3 ETR loci indicating their potential usefulness for 
prospective molecular genotyping. 
 
4.2 DISCUSSION 
 
Polymorphisms in rapidly evolving repetitive sequences like minisatellite VNTR are 
usually considered a valuable tool for practical epidemiological studies providing a 
very high degree of discrimination, which is an essential pre-requisite for prospective 
epidemiology where there would be little prior epidemiological data available. There 
are conflicting views about using hypervariable VNTR loci for typing, even though 
VNTR-3232 has been reported to have a particularly high discriminatory power in 
comparison with most VNTR, MIRU and ETR loci (Roring et al., 2002; Gopaul et 
al., 2006; Nikolayevskyy et al., 2006). 
 
The converse argument against its use is supported by the study of Supply et al., 
2006, who experienced problems when using VNTR-3232, including amplification of 
multiple alleles, the absence of PCR amplification products, data interpretation and 
interlaboratory reproducibility; due to the hypervariability experienced, this locus was 
excluded from their panel (Supply et al., 2006). Amplification issues with this locus 
have also been reported by Kremer et al., 2005 (Kremer et al., 2005). Another locus 
with great potential for genotyping and for differentiating between strains is VNTR-
1982, but this locus was excluded for similar reasons (Nikolayevskyy et al., 2006; 
Supply et al., 2006). Therefore, by identifying the conditions giving good 
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discrimination and those responsible for lack of reproducibility, optimal conditions 
were defined, which would enable molecular epidemiologists to use VNTR-1982 and 
-3232. 
 
In the present study, the variability and reproducibility of these two loci was 
addressed, and MIRU-26 and ETR-B were included as controls because amplified 
fragments are stable during agarose and capillary gel electrophoresis and were also 
used as controls by Supply et al., 2006 in their inter-laboratory analysis (Supply et al., 
2006). 
 
The quality of bands and peaks for MIRU-26 and ETR-B were not affected by the 
polymerase used and the performance of all enzymes was 100%. However, peaks for 
VNTR-1982 and -3232 repeats were absent, particularly when using BIOTAQ 
polymerase and for fragments with an expected larger molecular weight. An improved 
performance was gained when using Diamond (VNTR-3232) and Diamond or Qiagen 
HotStart (VNTR-1982) polymerases (93.8% and 87.5%, respectively). For this 
reason, Bioline Diamond was recognised as the most suitable for amplifying the 
VNTR loci.  
 
The variations in performance of polymerases for amplifying specific loci can be 
explained by their properties. BIOTAQ polymerase is a standard Taq, normally used 
for a wide variety of templates, whereas Diamond polymerase is a modified enzyme 
with a point mutation in its active site meaning it can amplify regions such as 
microsatellites, secondary structures, and templates with expected high guanine-
cytosine percentage (G-C%) regions more effectively. The latter target for 
amplification is of particular interest when amplifying regions of the M. tuberculosis 
G-C rich genome. The Qiagen polymerases are chemically modified with a specificity 
similar to that of Diamond polymerase, which possibly explains their similar abilities 
in amplifying both VNTR loci. The buffer used with the Qiagen polymerases 
increases the specificity of binding of primers to the region of interest making these 
polymerases ideal for complex genomic DNA. HotStartTaq Plus polymerase is 
actually recommended by the supplier for typing studies. 
 
Conditions influencing the detected sizes of PCR fragments that would influence 
interpreted copy number during capillary electrophoresis, namely parameters 
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affecting denaturation of PCR products, were investigated. Capillary temperature and 
the duration for DNA denaturation were altered as it was hypothesised that these 
parameters would affect the separation of DNA strands, therefore influencing how 
linear the DNA was, ultimately affecting the accuracy to which molecular weights of 
fragments are detected. Increasing the duration of the separation step allowed time for 
fragments larger than 1000 b.p. to be detected. 
 
The parameters normally used for MIRU-VNTR analysis in the laboratory are 
detailed in Method 1 (Table 2.1). Method 2 was designed to examine the effects of 
increasing the time for denaturation. The molecular weights of fragments for each 
locus, obtained when using the original and modified Method 2, were similar and the 
offset values (differences between expected and experimental molecular weights) 
were similar. 
 
Differences were observed when capillary temperature was decreased (Method 3; 
Table 2.1). Independent of the locus investigated and polymerase used, molecular 
weights of fragments were lower than expected, with offset values significantly larger 
in some cases, to the point where the calculated number of repeats differed from the 
expected values. Proof that the decreased detected molecular weights were the effects 
of decreased capillary temperature was obtained by amplifying a single locus from the 
same extract using each polymerase and then visually inspecting the fragments on an 
agarose gel; bands were at the same level when compared to each other and had the 
same molecular weights when compared to the molecular weight markers. 
 
The denaturing conditions and capillary temperature were critical for reliable MIRU-
VNTR analysis. So whilst optimised amplification of MIRU and ETR loci was with 
BIOTAQ polymerase, and Diamond polymerase for amplifying the VNTR loci, 
optimised conditions for analysis of PCR product were as detailed in Method 1; Table 
2.1. The reproducibility and stability of the VNTR loci was also demonstrated by 
comparing 22 MIRU-VNTR profiles from serial isolates. The consistency between 
profiles of serial isolates from same patients showed that the amplification and 
fragment analysis conditions were indeed ideal for typing these loci and that these loci 
could be used for routine genotyping. 
 
 - 131 -
Using all 22 loci for typing gave the lowest clustering rate of 22.2% in MTBC strains 
obtained over one year from a single metropolitan setting (London), which is similar 
to proportions established in previous studies conducted in London in 1993 and 1995-
1997, and similar to population-based studies in areas of low to middle TB incidence 
where RFLP was used alongside molecular genotyping methods (Maguire et al., 
2002; Oelemann et al., 2007). This suggests, from the public health point of view, that 
TB transmission in London has remained stable over the last decade.  
 
This present study determined that the MIRU and ETR panel are not sufficiently 
discriminative for tracking TB transmission. The higher allelic variation in the VNTR 
loci has also been observed in a previous study by Roring et al., 2002 (Roring et al., 
2002). For the purposes of genotyping and epidemiological analysis, this particular 
study was of interest as it suggested that using VNTR and ETR loci in combination 
could increase the discriminative power of a panel of loci (Roring et al., 2002). The 
current observations regarding the applicability of the hypervariable VNTR loci, 
especially VNTR-3232, -3336, -2163A, and -1982, are in agreement with 
observations from previous studies, some of which demonstrated the use of VNTR 
loci for distinguishing between strains within the M. tuberculosis Beijing family 
(Drobniewski et al., 2005; Iwamoto et al., 2007; Wada et al., 2007). 
 
Our study suggests that hypervariable VNTR loci can be both discriminating and 
reproducible and, therefore, could be potentially be used successfully at multiple 
laboratories with consistent results providing that there is strict adherence to proposed 
reaction and PCR fragment separation conditions and the use of specific DNA 
polymerases. 
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CHAPTER 5 
 
DEVELOPMENT OF A RAPID PCR-BASED QUANTIFICATION ASSAY OF 
M. TUBERCULOISIS COMPLEX CULTURES 
 
5.1 INTRODUCTION 
 
In cultures, mycobacteria tend to grow as clumps and when plating out bacteria for 
c.f.u. there is no certainty that a single colony has grown from a single mycobacterial 
cell, as might be the case with Escherichia coli, for example. Hence, there could be a 
huge margin for error in knowing how many mycobacteria are being used in 
experiments. Although it is a gold standard method for quantifying bacteria, there is a 
disadvantage with performing a conventional c.f.u. count with slow growing 
mycobacteria as it takes at least 3 weeks for colonies to grow meaning there would be 
a delay in setting up experiments. Whilst waiting for these colonies to grow, cultures 
are frozen and after thawing there would be loss of viability meaning the c.f.u. data 
may not necessarily be accurate. If the cultures were used directly after thawing, 
mycobacteria may not be in the exponential phase of the growth curve, meaning there 
would be a lag in the growth of bacteria during experiments. 
 
For this reason it was decided to investigate the use of a potentially more accurate and 
quicker method to quantify the number of individual mycobacteria, so as to be able to 
set up phenotypic assays on the same day as quantification, without having to freeze-
thaw cultures. The method under investigation was real-time PCR. 
 
Real-time PCR is increasingly used because data are reproducible; it is a highly 
sensitive method and has the ability to perform quantification over a wide range 
(Chini et al., 2007). This method has many applications including quantifying gene 
expression as demonstrated by Chini et al., 2007, where the expression of the tst gene 
responsible for producing toxic shock syndrome toxin-1 in methicillin-resistant 
Staphylococcus aureus was investigated (Chini et al., 2007). This PCR assay has also 
been used for quantifying complementary DNA (cDNA) and measuring levels of 
various cytokines in a system (Whelan et al., 2003). 
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In M. tuberculosis, the melting points of end PCR product, which is a feature of the 
real-time PCR cycles, were used to detect mutations in rpoB and the katG gene that 
encodes for the catalase-peroxidase enzyme (Garcia de Viedma et al., 2002). In 
addition to genotyping assays already available for detecting rifampin and isoniazid 
resistance by focussing on the rpoB and inhA regions, the mutations in rpoB and katG 
genes conferred rifampin and isoniazid resistance, respectively, and real-time PCR 
have provided another genotypic system by which resistance to these drugs could be 
detected rapidly (Garcia de Viedma et al., 2002; Miotto et al., 2006; Miotto et al., 
2008).      
 
More importantly, for the purposes of this study, real-time PCR has great potential for 
calculating the initial DNA levels, which would be equivalent to bacterial load. The 
IS6110 region of the M. tuberculosis genome has been used to quantify bacteria in 
paraffin-embedded and formalin-fixed biopsy sections from lymph nodes and to 
positively prove that levels of M. tuberculosis DNA in sputum correlated with the 
numbers of acid-fast bacilli calculated by microscopy (Desjardin et al., 1998; Ishige et 
al., 1999). The use of other IS elements have been used to rapidly quantify 
mycobacterial DNA, including IS900, which enabled quantification of M. avium 
subspecies paratuberculosis in milk, and IS2404, which specifically quantified M. 
ulcerans in tissue excised from patients with Buruli ulcer (Rondini et al., 2003; 
O'Mahony et al., 2004). 
 
For quantification of mycobacteria at the HPA, MRU, it was decided to perform the 
real-time PCR assay using the rpoB and katG genes as they are present as single 
copies, and they have been used in such assays previously (Garcia de Viedma et al., 
2002). In addition, as the present study was including all isolates belonging to the 
MTBC, the rpoB gene would be of most use, as this gene is present in all MTBC 
strains and other PCR assays have demonstrated that this gene can differentiate 
between mycobacteria belonging to MTBC and non-tuberculous mycobacteria (Kim 
et al., 2004). The oxyS gene was also included in the analysis as this gene was not 
used as a target in any of the other PCR-based assays performed at the HPA, MRU, 
thereby reducing any chances of future cross-contamination problems. 
 
This small study attempted to validate real-time PCR quantification data by 
comparing the growth curves from real-time PCR data with growth curves from 
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OD600 and c.f.u. data. In order to use real-time PCR, a DNA standard, containing a 
known number of M. tuberculosis H37Rv genome copies, had to be prepared and the 
performance of different primers evaluated using the DNA standard as the template. 
 
5.2 DEVELOPMENT OF PCR-BASED QUANTIFICATION ASSAY 
 
5.2.1 Preparation of M. tuberculosis H37Rv DNA standard  
After 4 weeks, there was growth of mycobacteria on all pyruvate and glycerol slopes 
that had been inoculated whilst preparing frozen archive cultures (refer to Section 
2.4). Bacterial growth from one of the pyruvate slopes that had been inoculated with 
M. tuberculosis H37Rv was transferred into a 1.5ml microcentrifuge tube and re-
suspended in 100µl TE buffer (10mM Tris, 1mM EDTA pH8.0; prepared as described 
in Section 2.1.4). The re-suspended culture was incubated in an 80oC waterbath for 50 
mins to kill the mycobacteria. Even though this method of killing is effective, the 
remaining procedures for DNA extraction were still performed under the biological 
safety cabinet. 
 
Bacterial cells were lysed by adding 5µl 100mg/ml lysozyme (prepared as instructed 
in Section 2.1.4) to the tube, which was vortexed and incubated for 2 hrs in a 37oC hot 
block. After incubation, 25µl proteinase K and 200µl Buffer AL (both provided in the 
Qiagen DNeasy Blood & Tissue kit) was added to the lysed bacterial cells, to help 
break down any cell debris. The contents of the tube were mixed by vortexing and 
then the tube was incubated in a 56oC hot block for 30 mins. Before the purification 
of extracted DNA, 200µl 96-100% ethanol (Sigma-Aldrich) was added to the tube and 
it was important to make sure that the contents were thoroughly mixed together by 
vortexing. 
 
After this step it was safe to work with the extracted DNA on the bench. For the 
purposes of real-time PCR, DNA had to be as pure as possible. DNA purification was 
performed using the consumables, reagents, and protocol provided with the Qiagen 
DNeasy Blood & Tissue kit. Firstly, the DNA extract was transferred into a DNeasy 
Mini spin column that was resting in a 2ml collection tube. During centrifugation at 
6000×g for 1 min, the DNA bound to the membrane within the column, whilst the 
flow-through was collected in the collection tube. After centrifugation, the flow-
through was discarded and the column transferred into a new collection tube. 
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 In order to purify the DNA, 500µl Buffer AW1, prepared as described in Section 
2.1.4, was added to the tube, which was then centrifuged at 6000×g for 1 min. Again 
the flow-through was discarded and the column transferred into another clean 
collection tube. The second purification step involved adding 500µl Buffer AW2, 
prepared as described in Section 2.1.4, and centrifuging at 6000×g for 3 mins to 
ensure that the membrane in the column was dry. After the flow-through was 
discarded, the column was transferred into a clean 1.5ml microcentrifuge tube and left 
open so any residual ethanol could evaporate as the ethanol could affect the 
performance of the PCR. The initial pellet of harvested cells was large; therefore, 
150µl Buffer AE was added directly onto the membrane and the tube was incubated 
for 1 min at room temperature. DNA was eluted and collected in the 1.5ml 
microcentrifuge tube by centrifugation at 6000×g for 1 min. Agarose gel 
electrophoresis was performed using 5µl DNA to ensure that extraction and 
purification was successful. The DNA could be seen as a smear when the agarose gel 
was viewed under the ultraviolet light.  
 
The resulting concentration of double-stranded DNA, in ng/μl, was calculated at 
260nm using a NanoDrop 1000 Spectrophotometer (Thermo Scientific) and its 
attached software. The number of genomes per μl in the DNA extract was calculated 
using the DNA concentration. The details of the calculation can be found in Appendix 
4. Once the number of genomes/μl was established, Buffer AE, which had been used 
to elute the DNA during purification, was used to dilute a small volume of the 
standard DNA to obtain a 1×107 genomes/μl standard. Still using Buffer AE as the 
diluent, 10-fold serial dilutions were prepared, resulting in standards containing 
1×106, 1×105, 1×104, 1×103, 1×102, 1×101 genomes/μl. The DNA standards were 
stored at -20°C ready for use. 
 
5.2.2 Evaluation of rpoB, katG and oxyS primers 
The simplest way to calculate the number of genomes in a DNA extract using real-
time PCR was to quantify the number of single copy genes in a sample. Unlabelled 
forward and reverse primers were designed for three different genes, spanning the M. 
tuberculosis genome, which existed as single copies. As all real-time PCR was 
performed using the iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad 
Laboratories, California, USA), primers were designed for rpoB, katG and oxyS genes 
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using the guidelines in the instruction manual. The primer sequences were: rpoB 
(forward: 5’-CCG CGA TCA AGG AGT TCT TC-3’; reverse: 5’-GCC GAT CAG 
ACC GAT GTT G-3’), katG (forward: 5’-GAC AAG GCG AAC CTG CTT AC-3’; 
reverse: 5’-CCC AGG TGA TAC CCA TGT C-3’) and oxyS (forward: 5’-CGA AGG 
TGC AAG TCT GTT CC-3’; reverse: 5’-CAT CAC TGT CTT GGG TCT CG-3’). 
Primers were supplied by Invitrogen Ltd. and their performance evaluated. 
 
The rpoB, katG and oxyS genes were amplified in separate reactions using the DNA 
standards, prepared in Section 5.2.1, ranging from 1×101 to 1×107 genomes/μl in 10-
fold increments, as the template. The reaction for each primer set and DNA standard 
was prepared in triplicate in iQ 96-Well PCR Plates (Bio-Rad Laboratories) at a final 
volume of 20µl, which contained 10µl 2× iQ SYBR Green Supermix (Bio-Rad 
Laboratories), 0.1µl each of 200µM forward and 200µM reverse primers, 1µl DNA 
and 8.9µl molecular grade water. The SYBR Green Supermix contained 100mM 
potassium chloride, 40mM Tris-hydrochloric acid (pH8.4), 0.4mM of each dNTP, 
iTaq DNA polymerase (50 units/ml), 6mM MgCl2, SYBR Green I, and 20nM 
fluorescein. Non-template controls were also set up for each primer set, using 1µl 
Buffer AE instead of DNA. 
 
Reproducibility of the values obtained from the replicates was optimised by preparing 
master mixes of reagents wherever possible to reduce the amount of pipetting. Also, 
when dispensing the reagents into the wells of the PCR plate, it was important not to 
produce bubbles as they would affect the fluorescence readings during real-time PCR. 
Evaporation during amplification was reduced, as the tiniest change in volume could 
affect the readings, by using a clear Microseal 'B' Adhesive Seal (Bio-Rad 
Laboratories) to seal the plate being careful not to get any fingerprints on the seal as 
the fluorescence is read from the top through the seal. The reactions in the wells were 
spun down by centrifuging the plate at 250×g for 1 minute. 
 
The following cycle was used for real-time PCR: 95°C for 180 secs; 50 cycles of 
95°C for 30 secs, 65°C for 30 secs; 55°C for 60 secs. The cycle was programmed so 
fluorescence readings were acquired at the end of each of the 50 cycles because as the 
DNA is amplified the number of fluorescent labelled PCR product increases and this 
increase can be plotted using the fluorescence values. After the 55°C step, an 
additional step was inserted to obtain a melt curve. This step involved a 0.5°C 
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increase from 55°C to 95°C and at each increment a fluorescence reading was 
acquired. 
 
After real-time PCR was complete the iQ5 Optical System Software version 2.0 (Bio-
Rad Laboratories) was used to analyse the fluorescence readings. Graphs were 
automatically plotted for the amplification and melt-curve steps. Threshold cycle (Ct) 
values were automatically calculated by the software for all reactions and indicated 
the point at which there was enough DNA amplification to produce a detectable 
amount of fluorescence from the PCR product. Hence, if there was a lot of DNA in 
the initial reaction the Ct value would be lower as fewer amplification cycles would 
be needed for fluorescence to reach the detectable level. Conversely, if the DNA 
concentration was initially lower it would take more cycles to produce the same 
detectable level of fluorescence. The melt-curve graphs indicated whether or not there 
was a single PCR product in the reactions, which would be indicated by a single peak 
at the temperature when the double-stranded DNA separated. The temperature at 
which this occurred was dependent on the size of the DNA. 
 
The graphs that were plotted during the amplification and melt-curve steps for each of 
the primers can be seen in Figure 5.1. There were clear differences in the quality of 
the primers that were used to amplify each of the genes. The replicates for rpoB were 
well defined so the average Ct value of replicates was calculated reliably. The curves 
representing the more concentrated DNA standards were separated from each other at 
regular intervals and this was corroborated numerically by the fact that there was a 
difference of 4 between Ct values for each DNA concentration. 
 
Although the difference between Ct values for the more concentrated DNA standards 
was similar for the katG and oxyS primers, the curves for the replicates were not 
grouped together as clearly as for rpoB. This meant that the calculated average Ct 
value when using katG and oxyS primers was not reliable. The replicates for the DNA 
standard containing 1×101 genomes/μl were not reproducible when using all of the 
primer sets for amplification. 
 
The graphs for melt-curves were good for all of the primer sets as there were clearly 
single peaks at the same temperature. The rpoB PCR products separated at 
approximately 92°C, katG products at approximately 89°C and oxyS products at 
 - 138 -
approximately 88°C. The differences in temperatures reflected the sizes of the PCR 
products as the amplified rpoB fragments were larger than the katG and oxyS 
products. The standard curves generated with the serially diluted standard DNA was 
linear over the data points with gradients of 3.79, 3.54, and 3.57 for primer sets rpoB, 
katG and oxyS, respectively, as shown in Figure 5.2. The efficiency of all primers was 
over 90%, which is supported by the coefficient of correlation (R2) values that were 
above 0.99 for all standard curves. Similar R2 values were observed in previous 
studies evaluating the use of real-time PCR using other primer targets (Desjardin et 
al., 1998; Rondini et al., 2003; O'Mahony et al., 2004).    
 
It was decided to use the forward and reverse primers for the rpoB gene for 
quantification of mycobacteria because the replicate reactions were more reproducible 
and the small difference in Ct values between the DNA concentrations meant that the 
assay would be more sensitive. Even though the replicates for lower DNA 
concentrations were not reproducible, the concentration of DNA that would be used 
for subsequent experiments would be higher, therefore this would not pose a problem. 
The quality of the standard curve, when using rpoB primers in the assay, further 
confirmed the decision to use these primers. 
 
Using primers to amplify a gene that was present in the M. tuberculosis genome as a 
single copy meant that quantifying the number of rpoB copies in a DNA extract 
would be equivalent to quantifying the number of genomes. However, before using 
real-time PCR for quantifying the number of mycobacteria in cultures that would be 
used in phenotypic experiments, the technique had to be validated against current 
quantification methods, OD600 and c.f.u., both of which are influenced by the 
clumping of mycobacteria. 
 
5.3 COMPARISON OF MTBC QUANTIFICATION METHODS  
 
5.3.1 Quantification of MTBC cultures using OD600 
An archive tube of frozen culture for each of the 5 M. tuberculosis strains in Panel B 
(refer to Section 2.4) was thawed at room temperature and 2 drops were used to 
inoculate two 50ml falcon tubes, containing 30ml Middlebrook 7H9 with 0.05% 
Tween-80 medium and beads in each, so there were duplicate liquid sub-cultures for 
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each strain (refer to Section 2.4.1). After vortexing, the cultures were incubated at 
37°C. 
 
The day of inoculation was day 0. At day 3, 1ml of each culture was transferred into 
separate disposable plastic cuvettes (Alpha Laboratories Ltd.) and OD600 was 
measured with a cell density meter (WPA Biowave, Cambridge, UK), using 1ml 
medium as the blank to tare the density meter. The OD600 was plotted on a graph of 
time (days) versus OD600 (Figure 5.3a). The OD600 was measured regularly, every 3 or 
4 days until the growth curves for each of the strains reached the stationary phase 
indicated by the plateux of the bacterial growth curve. 
 
5.3.2 Quantification of MTBC cultures using real-time PCR assay 
Each time the OD600 was measured at the various time points, a separate 1ml aliquot 
of each culture was transferred into a 1.5ml microcentrifuge tube. The bacterial cells 
were pelletted by centrifugation at 12,000×g for 10 mins and the supernatant was 
safely discarded. The pellet of mycobacteria was resuspended in 100µl TE buffer. The 
DNA extraction and purification procedure was as described in Section 5.2.1 except 
the volume of Buffer AE for eluting DNA was reduced to 30µl as the initial pellet of 
bacterial cells was much smaller. The DNA was stored at -20°C ready for 
quantification with real-time PCR. 
 
Using the standards prepared in Section 5.2.1, ranging from 1×101 to 1×107 
genomes/μl, and the DNA of unknown concentration, real-time PCR reactions were 
set up using the rpoB primers exactly as described in Section 5.2.2. Just like for the 
standards and non-template control, three replicate reactions were prepared for each 
of the unknown samples. After the PCR and melt curve was complete, iQ5 software 
automatically analysed the data to calculate the starting concentration of genomes/μl 
in the unknown samples by extrapolating the Ct value of unknown samples against 
those of the DNA standards. The DNA standards were included in each real-time PCR 
run, as the Ct value of DNA standards in a previous run could not be used for 
extrapolation in subsequent runs. 
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Figure 5.1a Graphs produced by the iQ5 Optical System Software after analysing 
fluorescence readings obtained during real-time PCR when using DNA standards ranging 
from 1×101 to 1×107 genomes/μl as templates and each of the three primer sets for the genes, 
i) rpoB, ii) katG and iii) oxyS. For each set of primers and DNA standards there were 3 
replicate reactions. The replicate curves for each of the DNA standards are grouped more 
pronouncedly when using rpoB primers than the katG and oxyS as indicated in Figure 5.1a i).   
 
 
1×101 
1×103
1×104
1×107 
1×106
1×102
1×105
i)  
ii) 
iii) 
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Figure 5.1b Corresponding melt curves, to the graphs in Figure 5.1a, produced by the iQ5 
Optical System Software, for PCR products, which had been amplified using DNA standards 
ranging from 1×101 to 1×107 genomes/μl in 10-fold increments as templates and each of the 
three primer sets for the genes, i) rpoB, ii) katG and iii) oxyS. 
PCR product melting point = approximately 92°C 
i) 
PCR product melting point =  approximately 88°C 
PCR product melting point =  approximately 89°C 
ii) 
iii) 
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Figure 5.2 The standard curves generated using Ct values after analysing DNA 
standards, containing known genome numbers, with real-time PCR assay using each 
primer pair for (a) rpoB, (b) katG and (c) oxyS. The standard curves also display the 
calculated regression line for each set of data points and the coefficient of correlation 
(R2) for each standard curve. 
 
 
 
a) 
b) 
c) 
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The number of genomes/ml culture was calculated by multiplying the number of 
genomes/μl by the volume Buffer AE used for DNA elution. As the DNA had been 
extracted from 1ml culture initially, the calculation provided the number of 
genomes/ml culture. The calculated values were plotted on a graph of time (days) 
versus number (No) of genomes/ml (Figure 5.3b).   
 
5.3.3 Quantification of MTBC cultures using c.f.u. 
In addition to the OD600 and number of genomes data, c.f.u. data were also collected 
at each time point. Whilst taking aliquots of culture for reading OD600 and for DNA 
extraction, two separate 30µl aliquots, from each culture were diluted 1 in 10 in 
separate 1.5ml microcentrifuge tubes each containing 270µl Middlebrook 7H9 with 
0.05% Tween-80 medium (without OADC). The contents of the tubes were mixed 
carefully by pipetting, before making five further 10-fold serial dilutions. As two 30µl 
aliquots were taken from each culture initially, there were two sets of dilutions and 
ultimately duplicate c.f.u. counts at every dilution for each culture. A volume of 50µl 
of each diluted culture was transferred onto half of a Middlebrook 7H11 agar plate 
and then carefully spread in that half of the plate. The agar plates had been prepared 
as described in Section 2.1.3. After inoculating the plates and letting them dry, all 
plates were sealed with parafilm, placed in a sealed bag and incubated at 37°C for 3 to 
4 weeks depending on when colonies could be seen. 
 
The colonies were counted on the plates and recorded. For each culture and each time 
point, the average number of c.f.u. was calculated using the data from a dilution factor 
at which there was the most reliable c.f.u. count (10-200 colonies). The number of 
colonies/ml culture was calculated by multiplying the average c.f.u. count by 20 (as 
50µl of diluted culture was plated) and this value was multiplied by the dilution 
factor. The resulting values were plotted on a graph of time (days) versus No of 
colonies/ml (Figure 5.3c).   
      
5.3.4 Results of comparing MTBC quantification methods  
The three growth curves produced when plotting OD600/ml culture, number of 
genomes/ml culture, and number of colonies/ml culture at each sampling day has been 
shown in Figure 5.3, for one of the Panel B strains, M. tuberculosis CAS, isolated 
from a patient born in India, as an example as the curves were similar for the other 
four strains in Panel B. 
 - 144 -
Figure 5.3 The growth curves produced for M. tuberculosis CAS strain, isolated from a patient 
born in India, using the three different quantification methods including (a) OD600, (b) number of 
genomes and (c) number of colonies. The blue and red curves represent each of the replicates, as 
there were two cultures per strain from which samples were taken. 
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As expected, the growth curve for OD600 for all of the strains followed the typical 
pattern with the lag phase at the beginning and then the exponential phase, followed 
by the plateaux indicating the mycobacteria had reached stationary phase. The same 
lag phase and exponential phase was seen when plotting the number of genomes/ml 
culture, but after plateaux, the typical horizontal line was not seen. Instead, just as the 
curve started to plateaux, the line became more haphazard with the points being up 
and down. This was observed with the genomes/ml culture growth curves for all of 
the M. tuberculosis strains. 
 
The c.f.u. data from this experiment did not produce the complete standard bacterial 
growth curves as was observed with the OD600 and real-time PCR data. For some 
sampling points the data did not fit into the typical growth curve pattern. This was the 
case for each set of duplicate cultures for each M. tuberculosis strain. According to 
the OD600 and real-time PCR data the mycobacterial cells reached exponential phase 
by day 8 or 9 for each set of duplicate cultures for each of the strains; but the c.f.u. 
data for all of the cultures did not reflect this. For M. tuberculosis Beijing strain, cells 
entered the exponential phase at day 16, and were still actively dividing at day 19, but 
after this time point there was a sudden decrease in c.f.u. count, which was not 
observed with the curves produced using OD600 and real-time PCR data. This seemed 
to be a general trend with the c.f.u. data for all of the strains as the M. tuberculosis 
LAM10 mycobacterial cells entered the exponential phase at day 18 and while at day 
23 the c.f.u. count increased, there was a sudden decrease at day 28 followed by 
another increase from day 36 to 49. 
 
The M. tuberculosis CAS mycobacterial cells (isolated from the patient born in 
Somalia and India) entered the exponential phase at a much later stage (day 28 and 
29, respectively) than the other strains. The cells were still actively dividing up until 
day 37 and 44, respectively, after which there was a decrease in the c.f.u. count. The 
growth curves produced using the c.f.u. data for M. tuberculosis EAI5 was similar to 
that of the M. tuberculosis CAS strain, isolated from a patient born in India, shown in 
Figure 5.3c, except mycobacterial cells entered the exponential phase slightly earlier 
at day 19 and continued to actively divide until day 29. After this time point there was 
a decrease in c.f.u. count instead of the typical plateaux seen with the growth curves 
produced using the OD600 and real-time PCR data.   
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For further validation of real-time PCR for mycobacterial quantification, any 
correlation between the genomes/ml culture data and the data from the other two 
quantification methods was investigated by plotting scatter graphs. The scatter graphs 
corresponding to the data for M. tuberculosis CAS, from the patient born in India, can 
be seen in Figure 5.4. There was good correlation between OD600/ml culture and 
genomes/ml culture, as there was a linear relationship between the two measurements 
that could be defined by an equation (Figure 5.4a). Although there were linear 
relationships between OD600 and genomes/ml for the other strains, the equations were 
slightly different. As expected, after the lack of the typical growth curve pattern with 
c.f.u. data, there was no correlation between number of colonies/ml culture and 
genomes/ml culture for any of the strains (Figure 5.4b). 
 
5.4 DISCUSSION 
 
As the present study was focused on comparing the effects of the Panel B 
mycobacterial cells in in vitro and in vivo models, it was important to ensure that the 
same numbers of mycobacterial cells of each strain was used for infections to obtain 
comparable data and to exclude mycobacterial cell numbers used for experiments as a 
variable. Usually, c.f.u. count is used to quantify the numbers of mycobacterial cells, 
but cells tend to clump together meaning individual bacilli are not necessarily 
quantified. In addition, as mycobacteria are slow growing bacteria, it would take at 
least 3 weeks for colonies to grow on plates therefore delaying the set-up of 
experiments. For the purposes of the present study, it was necessary for cells to be 
actively growing in the exponential phase of the bacterial growth curve. 
 
It was, therefore decided to investigate a more accurate and quicker method of real-
time PCR to quantify the number of individual mycobacteria and to be able to set up 
phenotypic assays on the same day as quantification. Cultures of the Panel B M. 
tuberculosis strains were prepared and at regular intervals aliquots of the culture were 
quantified using real-time PCR to quantify number of genomes, c.f.u. count by plating 
cultures onto Middlebrook 7H11 plates and finally by measuring OD600. The data 
from the latter two methods were used to validate the real-time PCR data against as 
these two methods have previously been used for quantifying bacteria. 
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 Figure 5.4 Graphs showing the correlation between (a) number of genomes/ml 
culture and OD600/ml culture and (b) number of genomes/ml culture and number of 
colonies/ml culture for M. tuberculosis CAS strain, isolated from a patient born in 
India. 
 
a)  
 
 
 
 
 
 
 
 
 
 
b) 
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The similarity between curves produced using the real-time PCR and OD600 data 
demonstrated that the lag phase and exponential phase of the bacterial growth curve 
could be followed using quantitative data from real-time PCR (Figure 5.3a and b). 
However, once mycobacteria reached the stationary phase, the growth curves 
produced using real-time PCR data, for all of the M. tuberculosis strains, did not 
follow the plateaux seen in typical growth curves. A possible explanation for this was 
that the cultures were getting old and there was mycobacterial cell death and 
degradation of mycobacterial DNA. For the purposes of carrying out phenotypic 
experiments in the present study, this was not significant, as actively growing and 
dividing mycobacteria, which would be in the exponential phase, would be required. 
 
For this particular experiment, it was not as easy to validate the real-time PCR data 
against the c.f.u. data, as it had been with the OD600 data, because there was a sudden 
decrease in the c.f.u. count for all of the M. tuberculosis strains at some time points 
during the experimental time course. A possible explanation for this could be loss of 
viable mycobacterial cells in the cultures, but this is not corroborated by the real-time 
PCR data, which quantified the number of genomes. There was an increase in the 
number of genomes during the exponential phase of the growth curve, which was 
reflected by the growth curves produced using the OD600 data. However, as mentioned 
in Section 2.6.6, it is important to note that as with OD600, quantifying the number of 
genomes does not discriminate between viable and dead mycobacteria therefore 
measuring DNA levels is not a measure of viability. 
 
In addition, whilst there was a decrease in c.f.u. count with the M. tuberculosis 
LAM10 strain, there was an increase in the number of c.f.u. at the next sampling time 
points, demonstrating that there was no loss of viability in this culture. Another 
explanation could be an insufficient concentration of growth supplement (OADC) in 
the Middlebrook 7H11 plates as fresh plates were prepared at each sampling point or 
a need to improve the techniques for c.f.u. counting of mycobacteria.     
 
There was good correlation between the OD600 and real-time PCR data for all of the 
M. tuberculosis strains and the growth curves produced using the real-time PCR 
quantification data followed the typical trend of a bacterial growth curve. When using 
OD600 and real-time PCR all viable and non-viable mycobacteria would have been 
included for quantification so both of these methods would be more ideal for bacterial 
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cells in the exponential phase of the bacterial growth curve. Converse to this, c.f.u. 
counting of bacterial cells only quantifies the viable cells in the culture. 
 
For the purposes of the present study, whilst an OD600 of 0.2 was used as a marker of 
mycobacterial cells entering the exponential phase of the growth curve, as can be seen 
in the OD600 growth curve in Figure 5.3a, real-time PCR was used as a concurrently 
more rapid method for quantifying MTBC cultures for further in vitro and in vivo 
experiments. In order to avoid introducing variables into the experiments it was 
ensured that exactly the same DNA extraction and real-time PCR protocols were used 
for every independent experiment.  
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CHAPTER 6 
 
IN VITRO PHENOTYPICAL ANALYSIS OF M. TUBERCULOSIS COMPLEX 
STRAINS 
 
6.1 INTRODUCTION 
 
Whilst the aim of the present study was to create a panel of M. tuberculosis strains for 
general TB research and vaccine evaluation studies, the preliminary panel A 
(containing 42 strains including a broad spectrum of M. tuberculosis strains and 
representatives from global population of strain families; refer to Sections 2.3.2 and 
3.2.4), would have been too large for vaccine evaluation studies, therefore a smaller 
number of strains were selected for final analysis. As the final panel should ideally 
contain strains of different ranges of phenotypes and virulence, it was important to 
initially establish if there were any phenotypic differences between various circulating 
strains and also if there were any differences between circulating strains and 
laboratory strains, which are currently used for vaccine evaluation studies (Williams 
et al., 2005; Vipond et al., 2006). 
 
A series of in vitro experiments were performed using six circulating strains (Panel B) 
selected from the five major lineages defined by Baker et al., 2004 and the M. 
africanum lineage identified by Gagneux et al., 2006, and four control strains 
including laboratory M. tuberculosis H37Rv from HPA, MRU and Porton Down, M. 
tuberculosis H37Ra from NCTC and vaccine M. bovis BCG (Baker et al., 2004; 
Gagneux et al., 2006). 
 
The in vitro phenotypic experiments aimed to investigate variation in growth of 
strains in cell-free and in vitro tissue culture systems and other parameters such as 
cytokine production. Depending on the data from the experiments, virulence factors 
might be identified that would eventually play a very influential role during selection 
of strains for vaccine evaluation studies. Growth rates of all ten strains were obtained 
using a higher throughput MGIT 960 system (which gives better reproducibility of 
viable growth) and this data was compared with growth in an in vitro tissue culture 
system. 
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Currently, in the HPA, MRU the protocol for the MGIT 960 system provided by the 
manufacturer involves inoculating MGIT tubes with a drop of culture calibrated 
visually using a McFarland turbidity standard and using Pasteur pipettes; however, 
this means that the exact number of bacilli being used for inoculation is unknown. So 
as well as using the growth rate data to identify any phenotypic differences between 
strains for the purposes of the present study, the data provided additional insight into 
the effects of inoculum sizes on the general growth rates of mycobacterial cells in a 
cell-free culture system. 
 
6.2 THE GROWTH RATES OF M. TUBERCULOSIS COMPLEX STRAINS 
IN MGIT 960 CULTURE SYSTEM 
 
6.2.1 The effect of inoculum sizes on growth rates 
In order to reliably relate growth rate data obtained when using the MGIT 960 culture 
system with results obtained from tissue culture experiments, the same cultures were 
used to set up both experiments on the same day. This meant there was growth rate 
data available from three independent experiments. For each strain, duplicate MGIT 
7ml tubes were inoculated with each of the inoculum sizes, ranging from 6 genomes 
(real-time PCR had been used to quantify mycobacteria hence denotation of inoculum 
size as genomes) to 600,000 genomes in 10-fold increments. The tubes were 
incubated in the MGIT 960 system, which automatically produced growth curves real-
time so it was easy to monitor when curves reached plateaux indicating that 
mycobacteria had reached the stationary phase. Figure 6.1a shows the growth curves 
produced by the MGIT 960 system automatically and Figure 6.1b shows the growth 
curves, produced using the raw numerical data from the MGIT 960 system, which 
were then used to calculate the growth rate at mid-logarithmic phase. 
 
The average growth rate of duplicates at each inoculum size was calculated for the 
laboratory control strain, M. tuberculosis H37Rv (HPA, MRU) to identify which 
inoculum size produced the most reliable growth curves according to the 
manufacturer’s recommendations. A graph showing the average growth rates at each 
of the inoculum sizes for M. tuberculosis H37Rv (HPA, MRU) is shown in Figure 
6.2. 
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As the inoculum size increased the growth rate increased, reaching a peak of 310 
growth units/hour at an inoculum size of 6,000 genomes, after which as the inoculum 
size increased further the growth rate decreased. The growth rates at the two extreme 
inoculum sizes of 600,000 and 6 genomes, was approximately three times slower than 
the peak growth rate. Ideally, the exponential phase of the growth curves generated by 
the MGIT 960 system should not commence too soon or too many days post-
inoculation. According to the manufacturer’s manual after inoculating MGIT tubes 
with M. tuberculosis culture, positivity should be achieved 6 to 10 days (144 to 240 
hrs) post-inoculation. Referring to the growth curves in Figure 6.1b, the recommended 
positivity was achieved at inoculum sizes of 6,000 and 600 genomes. For this reason, 
the growth rates for all of the Panel B, laboratory control and vaccine strains was 
calculated at inoculum sizes of  6,000 and 600 genomes. 
 
6.2.2 Growth rates of strains after inoculating MGIT tubes 
At both of the inoculum sizes, 6,000 and 600 genomes, the fastest growth rate was 
observed with the M. tuberculosis Beijing strain (approximately 450 and 350 growth 
units/hour, respectively) (Figure 6.3). The M. tuberculosis CAS strain, isolated from 
the patient born in Somalia, had the slowest growth rate at an inoculum size of 6,000 
genomes (the CAS strain grew approximately twice as slowly as the Beijing strain at 
6,000 genome inoculum size). At an inoculum size of 600 genomes, M. africanum 
had the slowest growth rate (2.3 times slower than the Beijing strain at 600 genome 
inoculum size). At each of the inoculum sizes, there was an approximate 50 growth 
units/hour difference in growth rate between both of the CAS strains (isolated from 
the patients born in India and Somalia) and between the laboratory control strain M. 
tuberculosis H37Rv (from HPA, MRU and Porton Down), with the faster growth 
rates being observed with the CAS strain from India and the H37Rv strain from 
Porton Down. 
 
 
 
 
Figure 6.1 Graphs showing (a) an example of the growth curves produced by the MGIT detection system after inoculating MGIT tubes with 60 000, 6 000, 600, 60 and 6 genomes of 
M. tuberculosis H37Rv culture as indicated on the graph and (b) growth curves that were produced using raw numerical data from the MGIT detection system, to illustrate the effect 
of different inoculum sizes (600 000, 60 000, 6 000, 600, 60 and 6 genomes) of M. tuberculosis H37Rv culture on the bacterial growth curves and the time taken for mycobacterial 
cells to reach the exponential and stationary phases of the growth curves after inoculating 2 MGIT tubes (represented by 2 separate curves) with each of the inoculum sizes. 
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Figure 6.1 continued 
b) 
 
Figure 6.2 The average growth rates (growth units/hour), of the three independent experiments, at the mid-logarithmic phase of growth curves produced by the MGIT 
960 after inoculating MGIT 7ml tubes with different inoculation sizes of 600,000, 60,000, 6,000, 600, 60 and 6 genomes for M. tuberculosis H37Rv (from HPA, 
MRU). 
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 Figure 6.3 The average growth rates (growth units/hour) for each of the Panel B, laboratory control and vaccine strains at inoculation sizes of 6,000 and 600 
genomes. 
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6.3 INFECTION OF THP-1 CELLS WITH M. TUBERCULOSIS 
COMPLEX STRAINS 
 
6.3.1 Growth of TB strains in THP-1 cells after infection  
For all strains, cultures from the same passage (passage 2) were used for tissue culture 
experiments that involved infecting PMA-activated, non-differentiating, macrophage-
like THP-1 cells with mycobacteria, which had been grown to an OD600 0.2 to ensure 
that they were actively growing at the time of infection, at an MOI of 1. Therefore 
300,000 THP-1 cells were infected with 300,000 mycobacteria (quantified by real-
time PCR). A passage number close to the original archive cultures (passage 2) was 
used to avoid any loss of virulence during culturing. Controls were also set up in 
which THP-1 cells were non-infected (Middlebrook 7H9 media was added instead of 
mycobacteria) and controls in which THP-1 cells were stimulated with LPS and IFN-
γ. 
 
For each strain and control, enough infections were set up so duplicate samples could 
be collected at day 1, 4 and 7 post-infection. Before day 1 sampling, any 
unincorporated mycobacteria were washed away so the effects of only intracellular 
mycobacteria were measured. Sampling involved collecting pellets of infected THP-1 
cells (to measure the fold enhancement or multiplication of mycobacteria post-
infection) and supernatant (to measure levels of cytokine production using ELISA 
assays. Three independent tissue culture infection experiments were set up. 
 
DNA was extracted from all cells in the pellets and real-time PCR was performed 
using primers for actin to measure numbers of THP-1 cells and primers for rpoB gene 
to measure numbers of mycobacterial cells. These calculated levels, given by the Ct 
values during real-time PCR, were used to calculate the ratio of numbers of 
mycobacteria:THP-1 cells as apoptosis of PMA-activated THP-1 and human alveolar 
macrophages has been shown to differ between virulent and non-virulent strains 
(Keane et al., 1997; Balcewicz-Sablinska et al., 1998; Keane et al., 2000; Riendeau et 
al., 2003). Ratios of day 4:day 1 and day 7:day 1 were used as a statistic to 
demonstrate the fold enhancement or multiplication of mycobacteria after infecting 
THP-1 cells. Fold enhancement data was available from three independent 
experiments and is shown in Figure 6.4. 
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The lowest multiplication rate at both day 4 and 7 post-infection, relative to day 1 
post-infection, was observed in THP-1 cells infected with the avirulent laboratory 
control strain, M. tuberculosis H37Ra. The fold enhancement values of both of the M. 
tuberculosis H37Rv strains was similar at day 4 and 7 but in comparison with H37Ra, 
whilst the fold enhancement at day 4 was the same, at day 7 the value was 
approximately 2 times higher. The multiplication rate of the vaccine strain, M. bovis 
BCG, was slightly higher than H37Ra at day 4 and 7 post-infection (2 and 1.4 times 
higher, respectively) (Figure 6.4).   
 
There was clearly a higher multiplication rate of the Beijing strain in THP-1 cells than 
the other Panel B and laboratory control strains (Figure 6.4). Using the avirulent 
laboratory control strain as the baseline, at day 4 post-infection, the multiplication 
rate, relative to day 1 post-infection, was approximately 7 times higher, whilst at day 
7 the rate was approximately 16 times higher. The markedly higher multiplication rate 
of the Beijing strain was observed in all of the repeated independent experiments. The 
increased multiplication rate of the Beijing strain in comparison to the other Panel B 
M. tuberculosis strains was also observed in primary macrophages isolated from 
peripheral blood mononuclear cells (PBMC) (data not shown). 
 
The multiplication rates of the other Panel B M. tuberculosis strains were similar at 
both day 4 and 7 post-infection at an average fold enhancement of 2 and 13, 
respectively. Whilst the multiplication rate for M. africanum was the same as M. 
tuberculosis EAI5, LAM10 and both CAS strains at day 4 post-infection, the rate was 
two times higher than these four M. tuberculosis strains at day 7 post-infection 
(Figure 6.4). 
 
6.3.2 Cytokine production after infecting THP-1 cells 
 The supernatant, which was collected at each of the time points, day 1, 4 and 7, was 
used to measure levels of cytokine produced during infection and activation of THP-1 
cells. ELISA assays, to measure the amounts of human TNF-α, IL-10, IL-1β and IL-
6, were performed using commercial kits from eBioscience (refer to Section 2.6.5). 
The average cytokine levels, in pg/ml, from the three independent infection 
experiments, calculated from the OD450 values obtained after reading ELISA plates, 
were plotted onto graphs (refer to Figure 6.5). The graphs contain data from the Panel 
B strains, M. tuberculosis H37Rv (HPA, MRU), and non-infected THP-1 cells. 
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Results of cytokine production after infecting THP-1 cells with M. tuberculosis 
H37Rv (HPA, Porton Down), M. tuberculosis H37Ra (NCTC), M. bovis BCG and 
stimulating THP-1 cells with LPS and IFN-γ will be discussed in this section. 
 
In general, higher concentrations of human TNF-α production were observed with the 
largest amount being produced by THP-1 cells that had been activated by IFN-γ at 
day 1 (approximately 4500pg/ml). Generally, the lowest concentrations were 
observed with human IL-10 production, with the largest amount being produced by 
THP-1 cells infected with the laboratory strain, M. tuberculosis H37Rv from HPA, 
MRU at day 4 (approximately 14pg/ml). 
 
At day 1 there was twice as much production of TNF-α after infecting THP-1 cells 
with the clinical TB strains than the non-infected THP-1 cells, whilst at day 4 and 7 
TNF-α production was 1.3 times higher than the non-infected cells. In general, the 
lowest levels of TNF-α production was detected in non-infected THP-1 cells and cells 
activated by LPS; there was only a very slight decrease in TNF-α production from 
day 1 to 4 after which levels remained the same (Figure 6.5a). The Beijing strain 
produced the highest levels of TNF-α at day 1 post-infection, whilst THP-1 cells 
infected with M. africanum produced the lowest amount of TNF-α. At day 4 and 7 
post-infection the production of TNF-α by Beijing infected THP-1 cells was lower 
than the other Panel B strains. 
 
At day 1, the production of human IL-10 from non-infected THP-1 cells and THP-1 
cells infected and activated with the different mycobacterial strains and IFN-γ and 
LPS ranged from 5 to 6pg/ml (Figure 6.5b). During the whole time course of 7 days 
IL-10 production by non-infected THP-1 cells and IFN-γ and LPS activated THP-1 
cells was lower than the IL-10 production by THP-1 cells infected with the Panel B 
and laboratory control strains. 
 
At day 1 and 7 the highest and lowest production of IL-10 was observed when THP-1 
cells were infected with EAI5 and M. africanum strains, respectively (Figure 6.5b). At 
day 4, the highest IL-10 production was observed with both of the CAS strains. 
Between day 1 and 4 there was a general increase in IL-10 production, but the 
increase was more prominent (approximately 2.4 fold) in THP-1 cells infected with 
H37Rv (HPA, MRU) (Figure 6.5b). For the remaining strains the increase between 
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day 1 and 4 was 1.8 fold or less. Production of IL-10 between day 4 and 7 remained 
level for the majority of mycobacterial strains, except for H37Rv (MRU). For this 
strain, a slight decrease in IL-10 production was observed (0.8 fold). 
 
Whilst at day 1 similar amounts of IL-10 was produced by the non-infected THP-1 
cells and cells infected with the clinical TB strains, at day 4 and 7 1.6 times more IL-
10 was produced by THP-1 cells infected with the TB strains than the non-infected 
cells. It was important to note that the levels of IL-10 produced by THP-1 cells 
infected with both of the CAS strains (isolated from patients born in India and 
Somalia) was the same at each of the time points during the 7 day experimental period 
(Figure 6.5b).   
 
Production of human IL-1β by non-infected THP-1 cells and cells activated by LPS 
was notably lower than IL-1β production by THP-1 cells infected with each of the 
Panel B and laboratory control strains (Figure 6.5c). At day 1, 4 and 7 there was 7, 5 
and 2.3 times more IL-1β produced by the clinical TB strains than the non-infected 
THP-1 cells, respectively. Production of IL-1β by THP-1 cells activated by IFN-γ 
remained constant at day 1, 4 and 7 at approximately 350pg/ml. For some strains, 
there was an increase in IL-1β production between day 1 and 4 followed by a 
decrease between day 4 and 7. One such example was IL-1β produced by THP-1 cells 
infected with M. bovis BCG as production increased from 227 to 361pg/ml between 
day 1 and 4 but then decreased to 340pg/ml at day 7. As was observed with THP-1 
cells activated by IFN-γ, there was constant IL-1β production by THP-1 cells infected 
with H37Rv (HPA, MRU), but at approximately 400pg/ml. For some strains, like 
CAS (isolated from the patient born in India), production of IL-1β remained constant 
at approximately 420pg/ml between day 1 and 4 and then slightly decreased to 
370pg/ml by day 7. 
 
Comparing the production of IL-1β from THP-1 cells infected with the different Panel 
B strains showed that the CAS, isolated from the patient born in India, and M. 
africanum strains produced the highest and lowest levels of IL-1β, respectively, at day 
1 and 4 post-infection. At day 7 THP-1 cells infected with the CAS strain, from India, 
produced the lowest levels of IL-1β, whilst the highest levels were produced by the 
LAM10 strain. 
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At day 1 post-infection, human IL-6 production ranged from 25pg/ml (non-infected 
THP-1 cells) to 220pg/ml (THP-1 cells activated with IFN-γ). Non-infected THP-1 
cells produced the lowest levels of IL-6 at approximately 25pg/ml and remained at 
this level during the 7 day experiment period (Figure 6.5d). At day 1, 4 and 7 there 
was 2.5, 11.9 and 14.8 times more IL-6 produced by the clinical TB strains than the 
non-infected THP-1 cells, respectively. The highest levels of IL-6 production were 
observed at day 4 and 7 with THP-1 cells infected with the Beijing strain (839 and 
895pg/ml, respectively). With the exception of non-infected THP-1 cells, for the other 
infected and activated THP-1 cells, there was a general increase in IL-6 production 
between day 1 and 4. The most notable increase was observed when THP-1 cells were 
infected with the five Panel B M. tuberculosis strains, H37Rv (HPA, Porton Down) 
and M. bovis BCG with an approximate 6 to 7 fold increase. From day 4 to 7, IL-6 
production either remained constant or decreased. The levels remained constant for 
THP-1 cells infected with the Beijing, H37Rv (HPA, MRU) and EAI5 to name a few 
(Figure 6.5d). A decrease was observed in THP-1 cells infected with strains like M. 
bovis BCG, in which a 0.7 fold decrease was observed. At day 1, 4 and 7 post-
infection, the highest levels of IL-6 were produced by THP-1 cells infected with the 
Beijing strain and the lowest levels produced by M. africanum 
 
 
Figure 6.4 Graph showing the average fold enhancement (growth of mycobacteria relative to THP-1 cells present) from the three independent experiments when the mycobacterial 
cell:THP-1 cell ratio of day 4 and day 7 post infection was compared with the ratio at day 1. This statistic was calculated for THP-1 cells infected with M. tuberculosis strains, CAS 
(from patients born in India and Somalia), Beijing, EAI5, and LAM10, M. africanum, H37Rv (from HPA, MRU and HPA, Porton Down), H37Ra, and M. bovis BCG. 
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Figure 6.5 Graphs showing the average concentrations (from the three independent experiments) of human (a) TNF-α, (b) IL-10, (c) IL-1β and (d) IL-6 at day 1, 4 and 7 after 
infecting macrophage-like THP-1 cells with M. tuberculosis strains, CAS (from patients born in India and Somalia), Beijing, EAI5, LAM10, M. africanum, and H37Rv (from HPA, 
MRU). Also shown is data from the negative control, non-infected THP-1 cells.  
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6.4 DISCUSSION  
 
As MTBC primarily infects alveolar macrophages before undergoing multiplication, a 
human macrophage-like model in vitro system (THP-1) was chosen to investigate 
variation in the phenotype of the different MTBC strains. Initially, THP-1 cells were 
proliferative and non-adherent but after activation with PMA, the cells changed from 
monocytes to macrophage-like cells, which were non-proliferative and adherent. 
Studies have demonstrated that activated THP-1 cells provided a reliable alternative 
to peripheral blood monocyte and bone-marrow derived macrophages to identify 
differences in the virulence of different M. tuberculosis strains (Theus et al., 2004; 
Sow et al., 2007). PMA-activated THP-1 cells have been used successfully for 
previous research into the effects of M. tuberculosis on macrophages and the various 
mechanisms involved in the survival of these bacilli once taken up by macrophages 
(Theus et al., 2005; Lee et al., 2007; Theus et al., 2007). 
 
Since mycobacterial cells are usually actively dividing during infection, THP-1 cells 
were infected with actively dividing mycobacterial cells. In addition, once activated, 
THP-1 cells survive for a week, reinforcing the importance of infecting THP-1 cells 
with actively dividing mycobacterial cells. From previous experiments and results, it 
was observed that mycobacteria were in the exponential phase of the bacterial growth 
curve, during which bacteria are actively dividing, at OD600 0.2 (refer to Section 5.3). 
Therefore, cultures were prepared at the appropriate OD600 two days prior to infecting 
THP-1 cells. Macrophage-like THP-1 cells were infected at an MOI of 1 so 300 000 
THP-1 cells were infected with an equal number of mycobacterial cells, which had 
been quantified using real-time PCR. The negative control was an equivalent volume 
of Middlebrook 7H9 medium. 
 
After infecting THP-1 cells with the ten strains and activating THP-1 cells with LPS 
and IFN-γ, supernatant and cells were collected at days 1, 4 and 7 to monitor the 
effect of the strains, but cells could be collected at day 3 instead of day 4 (data not 
published). The infected THP-1 cells were pelletted and after DNA extraction, real-
time PCR was performed to work out the fold enhancement of mycobacteria relative 
to the THP-1 cells present at day 4 and 7 post-infection when compared with day 1 
post-infection. In essence the fold enhancement data showed the multiplication and 
growth of the different strains in an in vitro model. 
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 Primers that targeted the rpoB region of the M. tuberculosis genome were used to 
quantify the amount of mycobacteria present and primers for actin were used to 
quantify the amount of THP-1 cells. It was decided to calculate fold enhancement of 
mycobacteria in this way as apoptosis of PMA-activated THP-1 cells is dependent on 
the virulence of the strains (Keane et al., 1997; Balcewicz-Sablinska et al., 1998; 
Keane et al., 2000; Riendeau et al., 2003). The data from these previous studies 
demonstrated that virulent strains like M. tuberculosis H37Rv, Erdmann and wild-
type M. bovis induced decreased apoptosis of THP-1 and human alveolar macrophage 
cells in vitro than the low virulence strains like M. tuberculosis H37Ra, avirulent M. 
bovis BCG and M. kansasii. 
 
Levels of human TNF-α, IL-10, IL-1β and IL-6 in the supernatants were measured 
using ELISA assays. It was decided to measure levels of these particular cytokines 
because of the role that they play in the immune response to M. tuberculosis infection 
(Bogdan et al., 1991; Marques et al., 1999; Stenger et al., 2001; Fremond et al., 2004; 
Theus et al., 2005). 
 
The production of human TNF-α, IL-10, IL-1β and IL-6 was notably less with the 
negative controls than levels produced upon infection with the strains in all of the 
independent experiments. Theus et al., 2005 also observed that there was an 
undetectable level of TNF-α and IL-10 production from non-infected PMA-activated 
THP-1 cells (Theus et al., 2005). The data from the present study indicated that the 
medium used for culturing all of the strains did not affect the assay and that any 
differences seen in the production of cytokines was due to infection of THP-1 cells 
with the mycobacterial strain.  
 
The other controls included the addition of LPS and IFN-γ to THP-1 cells. These were 
potentially positive controls, but LPS and IFN-γ have been used for different purposes 
in previous studies and their effect on cytokine production varied according to which 
cytokine was being measured. Once alveolar macrophages are infected with 
mycobacterial cells, macrophages are activated to increase cell-mediated Th1-type 
response, which leads to an increase in production of IFN-γ, IL-2 and IL-12. In some 
studies IFN-γ has been used to stimulate macrophage-like cells before infection with 
M. tuberculosis strain instead of stimulating cells with IFN-γ on its own (Park et al., 
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2006; Sow et al., 2007). However, the object of this study was to test the hypothesis 
that there were no phenotypic differences between the strains so IFN-γ was not added 
along with the strains to avoid introducing a variable. 
 
LPS, a component of bacterial cell walls, has previously been used to compare levels 
of TNF-α and IL-6 after stimulating macrophages with medium, LPS and control 
strains, including M. tuberculosis H37Ra and H37Rv and vaccine M. bovis BCG 
strain (Fremond et al., 2004). In this study the levels of TNF-α were similar when 
macrophages were stimulated with LPS and M. tuberculosis H37Rv, whilst there were 
notably higher levels of IL-6 when comparing LPS stimulated macrophages with 
those infected with the vaccine strain and M. tuberculosis H37Rv.  However, whilst 
LPS was used as a potential positive control, the levels of all cytokines in the present 
study upon activating THP-1 cells with LPS were only slightly higher than the 
cytokine levels for non-infected THP-1 cells but markedly lower than cytokine levels 
when adding the different strains to the THP-1 cells. In another study by Marques et 
al., 1999 LPS proved to be a particularly strong inducer for TNF-α production 
(Marques et al., 1999). 
 
The data from the present study demonstrated that there was a markedly higher 
growth and multiplication of M. tuberculosis Beijing strain than the other Panel B, 
laboratory control and vaccine strains at day 4 and 7 indicating that there was 
continuously increased growth of the Beijing strain throughout the infection. The 
growth rate of a Beijing strain in vitro has been investigated previously by Theus et 
al., 2007. This study investigated any associations between intracellular growth of the 
M. tuberculosis Beijing strain and production of TNF-α and IL-10. It was concluded 
that there was an inverse relationship between TNF-α production and intracellular 
growth rate; hence the slower growing Beijing strains induced secretion of higher 
levels of TNF-α (Theus et al., 2007). Following this principle it would be expected 
that there would be lower levels of TNF-α after infecting THP-1 cells with the 
Beijing in comparison with TNF-α levels produced after infecting THP-1 cells with 
the other strains that had been evaluated in the present study. However, whilst the 
highest multiplication rates were observed after infection with the Beijing strain, 
higher levels of TNF-α were produced by the THP-1 cells infected with the Beijing 
strain than THP-1 cells infected with the other four Panel B MTBC strains (two M. 
tuberculosis CAS strains, M. tuberculosis EAI5, M. tuberculosis LAM10 and M. 
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africanum). In the study by Theus et al., 2007 there was an inverse relationship 
between production of TNF-α and IL-10, which was the same as what had been 
observed in the other studies previously discussed and also in the present study. 
 
Infection of alveolar macrophages with M. tuberculosis H37Rv and H37Ra induced 
IFN-γ production via the Th1 immune response pathway, enhancing the killing of 
intracellular mycobacteria by activating macrophages to become microbicidal and 
stimulating the recruitment of more macrophages which will eventually form 
granulomas (Bogdan et al., 1991; Fenton et al., 1997; Fremond et al., 2004; Bhatt et 
al., 2007). 
 
Autoregulation within macrophages occurs as IFN-γ production can be blocked by 
production of immunosuppressive and anti-inflammatory IL-10, which is induced by 
the Th2 pathway (Fenton et al., 1997; Bhatt et al., 2007). The findings from these 
studies correlate with the present study as THP-1 cells activated with IFN-γ produced 
very little IL-10 as levels were very similar to those produced by non-infected THP-1 
cells. Conversely, THP-1 cells activated with IFN-γ produced higher levels of TNF-α, 
IL-1β and IL-6. This inverse relationship in the production of these cytokines has 
been observed in previous studies and is discussed later.    
 
Whilst IL-10 inhibits the production of IFN-γ, IL-10 also down-regulates production 
of TNF-α, which is a crucial cytokine for eliciting a pro-inflammatory response, and 
both IFN-γ and TNF-α, in conjunction, are important for controlling TB infection 
(Bogdan et al., 1991; Marques et al., 1999; Stenger et al., 2001). Infection with M. 
tuberculosis generally leads to increased production of TNF-α by macrophages, 
which induces production of reactive nitrogen intermediates that work in synergy with 
IFN-γ to kill mycobacterial cells (Bhatt et al., 2007). On its own, TNF-α helps to 
control secretion of other cytokines and stimulate apoptosis of infected macrophages 
to reduce bacterial burden. 
 
In the present study, we focused on the analysis of the production of pro-
inflammatory cytokines, TNF-α, IL-1β and IL-6 which had been shown to vary 
during virulent infection of macrophages (Ragno et al., 2001; Volpe et al., 2006). 
This study demonstrated that these pro-inflammatory cytokines played a particularly 
important role in the immune response against M. tuberculosis infection and it had 
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already been demonstrated that IL-1β was involved in granulomatous inflammation. 
A pronounced reduced level of IL-10 production in comparison with the significantly 
higher detected levels of TNF-α, IL-1β and IL-6 was observed in the present study, 
which correlated to the previous literature. 
 
In the present study, the cytokine production data provided some insight into the 
possible immune response induced after infection of THP-1 cells with the Panel B 
wild-type strains. During the early stages in infection of THP-1 cells, at day 1, cells 
infected with the Beijing strain produced the highest levels of TNF-α and IL-6 
indicating that there is an early pro-inflammatory response to this strain. Based on the 
principles described by Ragno et al., 2001 and Volpe et al., 2006 virulent strains 
induce higher production of pro-inflammatory cytokines showing that the Beijing 
strain is more virulent than the other Panel B strains. 
 
Contrary to the production of TNF-α and IL-6 production observed with the Beijing 
strain, THP-1 cells infected with M. africanum produced the lowest levels of TNF-α 
and IL-6 indicating that this MTBC strain is not as virulent as the Beijing strain but 
this is not conclusive as more experiments need to be performed for confirmation. The 
lowest production of IL-1β was also observed with M. africanum further supporting 
the evidence that this strain is not as virulent as the other Panel B M. tuberculosis 
strains. 
 
In addition to growth in an in vitro cellular model, growth in a MGIT cell-free model 
was compared using an ideal inoculum of 600 and 6,000 TB genomes. At both of 
these inoculum sizes the fastest growth rate was observed with the M. tuberculosis 
Beijing strain. The M. tuberculosis CAS strain, isolated from the patient born in 
Somalia, and M. africanum had the slowest growth rate at inoculum size of 6,000 and 
600 genomes, respectively. Higher growth rates were observed with the Beijing strain 
in the tissue culture and cell-free culture system when compared to the Panel B 
strains.  
 
A study by Park et al., 2006 used M. tuberculosis H37Rv and clinical isolates of 
known virulence to demonstrate that the fast growth rate of strains in an intracellular 
environment was a virulence factor during the early stages of M. tuberculosis 
infection and relating the growth rate to TNF-α production profiles showed that the 
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more virulent strains induced increased levels of TNF-α production (Park et al., 
2006). Our study confirms that the Estonian Beijing isolate which over a decade has 
come to dominate the TB population in patients in Estonia grows more quickly than 
other clinical and laboratory strains tested and initially produced higher levels of 
TNF-α. 
 
Referring back to Section 3.2.4, one of the factors that had been used to select strains 
for Panel A had been partially based on the sizes of clusters. In the study by Theus et 
al., 2005, the element of cluster size was brought together with growth rate of strains 
and levels of cytokines produced after infecting activated THP-1 cells with clustered 
and unique clinical isolates (Theus et al., 2005). Whilst MIRU and ETR profiles were 
used for cluster analysis in the present study, the study by Theus et al., 2005 used 
IS6110 RFLP patterns. There was a more rapid intracellular growth of unique isolates 
with greater levels of TNF-α production and lower levels of IL-10 production in 
comparison with clustered isolates, therefore during early infection there was a 
positive correlation between clustered isolates and IL-10 production but a negative 
correlation with TNF-α production (Theus et al., 2005). Ultimately, the study 
determined that growth rate and production of IL-10 and TNF-α were good 
phenotypic markers for investigating epidemiologically relevant strains, whilst 
providing insight into virulence of M. tuberculosis strains as IL-10 antagonises the 
production of pro-inflammatory cytokines, IFN-γ, TNF-α and IL-12, disrupting the 
host immune defence against TB infection. 
 
The collective data from all of the in vitro experiments disproved the initial null 
hypothesis that there were no differences between the different M. tuberculosis strains 
as it was obvious that the M. tuberculosis Beijing strain behaved differently to the 
other strains in its intracellular growth rate and the growth rate in a cell-free culture 
system, showing that this is a potentially virulent strain based on previous literature 
(Theus et al., 2005; Park et al., 2006; Theus et al., 2007). The increased production of 
the pro-inflammatory cytokines, TNF-α and IL-6, compared to the other Panel B 
strains and the low levels of the anti-inflammatory cytokine, IL-10, produced after 
infecting THP-1 cells with the Beijing strain further demonstrated the potential 
virulent nature of the Beijing strain in comparison to the other Panel B strains.  
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CHAPTER 7 
 
THE STABILITY OF AEROSOLS DERIVED FROM THE M. 
TUBERCULOSIS COMPLEX STRAINS 
 
7.1 INTRODUCTION 
 
Data from in vitro tissue culture experiments indicated that there were differences in 
the phenotypes of the circulating clinical strains included for analysis. The M. 
tuberculosis Beijing strain was included because it differed from the other circulating 
clinical, laboratory control and vaccine strains due to its higher growth in the 
activated THP-1 model. The remaining strains were selected based on the four main 
M. tuberculosis lineages defined by Baker et al., 2004. The final panel of strains, 
included M. tuberculosis Beijing (lineage I), LAM10 (lineage II), both CAS strains 
isolated from patients born in India and Somalia (lineage III) and EAI5 (lineage IV). 
 
After performing in vitro experiments the next step would normally be to narrow 
down the panel of strains by selecting those of interest for analysis using low 
throughput in vivo experiments. For the purposes of this particular study, we tested 
the hypothesis that there were no differences in the phenotype or behaviour of the 
strains in in vivo experiments involving aerosol challenge of guinea pigs. During the 
preparation of the aerosols from cultures of each strain for guinea pig challenge 
studies, it was decided to perform All Glass Impinger-30 (AGI-30) sampling 
primarily to ensure that any differences seen between the M. tuberculosis strains, after 
infecting guinea pigs, were due to differences in virulence alone rather than 
differences in concentrations of delivered doses of mycobacteria and to validate that 
the Henderson apparatus, through which the aerosolised culture flowed, was working 
within the required parameters. However, these studies would also offer some insight 
into the stability of strains as aerosols because TB is transmitted via the respiratory 
route as aerosols produced whilst coughing and sneezing. As mentioned in Section 
2.8.2 the AGI-30 sampler jar drew up air through an inlet from the Henderson 
apparatus and dissolved the aerosols containing TB bacilli in the 5ml sterile distilled 
water in the AGI-30 sampling jar. 
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As part of our overall aim we sought to investigate whether the stability of aerosols 
produced by these strains contributed to overall differences in phenotype. In previous 
studies, guinea pigs have been challenged with standard laboratory strains of M. 
tuberculosis H37Rv and M. bovis; these data provide a foundation from which to 
investigate the in vivo effects of wild-type strains that were circulating within London 
and which have more relevance for public health (Williams et al., 2000; Williams et 
al., 2005). 
 
7.2 INVESTIGATION OF THE STABILITY OF AEROSOLS OF 
CIRCULATING M. TUBERCULOSIS COMPLEX STRAINS  
 
The stability of each strain as an aerosol was tested using an AGI-30 sampling device. 
Cultures containing 1×107 c.f.u. had been used for previous guinea pig challenge 
procedures performed at Porton Down. However, as mycobacteria had been 
quantified using real-time PCR for the tissue culture experiments, this quantification 
method was also used to obtain 1.5ml of culture containing 1×107 mycobacterial 
genomes for each of the five strains (refer to Section 5.3 for the comparisons between 
using real-time PCR and c.f.u. for MTBC quantification). After dilution, the final 
working concentration of cells was 1×106 mycobacterial genomes. Cultures contained 
actively growing mycobacterial cells. 
 
Cultures were aerosolised using a 3-jet collison nebulizer, after which aerosols were 
passed through the Henderson apparatus to be delivered to four AGI-30 samplers 
containing 5ml sterile distilled water into which the aerosols would be captured. 
Mycobacterial samples from the collison and AGI-30 samplers were serially diluted 
and plated onto Middlebrook 7H11 agar plates, incubated for 4 weeks and then 
colonies were counted. After taking into account the volume of culture plated and the 
dilution factor, the c.f.u./ml of mycobacteria in the collison were compared with 
c.f.u./ml from the AGI-30 samplers to identify if there were any differences in the 
survival of the strain in an aerosolised state. 
 
Figure 7.1 shows the number of viable mycobacterial cells at each of the stages of the 
experiment, i.e. colony forming units were monitored in the collison nebulizer prior to 
aerosolisation for AGI-30 sampling and before each of the guinea pig challenges. A 
sample of the stock culture was also plated onto agar plates to obtain c.f.u./ml data 
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primarily to verify the mycobacterial concentration of the stock cultures and to ensure 
that the 1 in 10 dilution of the 5 strains, to prepare cultures at a working concentration 
for the collison nebuliser, was performed as accurately as possible. 
 
From the plots for each of the five strains, the number of bacilli quantified using real-
time PCR was approximately one log10 higher than the viable c.f.u. count. The lowest 
and highest viable c.f.u./ml was observed for M. tuberculosis EAI5 and LAM10, 
respectively, and the difference between the stock culture counts for these strains was 
one log10 c.f.u./ml between approximately 1×106.5 c.f.u./ml and 1×105.5 c.f.u./ml. The 
c.f.u./ml for all of the other strains was either just above or below 1×106 c.f.u./ml. 
 
The viable c.f.u. count at 0 mins represented the number of c.f.u. after diluting stock 
cultures 1 in 10. Theoretically, the final number of c.f.u. should be 1×106 in 15ml with 
one log10 decrease between stock and diluted cultures. However, as the c.f.u. count of 
the stock culture was lower than 1×107 c.f.u. in 1.5ml, the c.f.u. counts at 0 mins were 
lower than expected. Whilst the expected decrease was observed for M. tuberculosis 
LAM10 strain, there was a two log10 drop in c.f.u./ml for M. tuberculosis CAS 
isolated from the patient born in Somalia and the decrease for all other strains was 
slightly more than one log10. 
 
The diluted cultures were firstly used for AGI-30 sampling in which cultures were 
aerosolised for 5 mins, during which time aerosols had been passed through the 
Henderson apparatus ready for collection in the AGI-30 samplers. After the AGI-30 
sampling was complete, an aliquot of culture in the collison was plated for c.f.u. count 
before carrying on to challenge two sets of eight guinea pigs by the aerosol route. The 
c.f.u./ml counts for all of the strains were similar to the counts in the diluted cultures 
pre-challenge. 
 
The final two points of each plot in Figure 7.1 represented the c.f.u./ml in the collison 
after each of the guinea pig challenges. For M. tuberculosis Beijing strain, the 
c.f.u./ml after each challenge was similar to that of the diluted culture and after AGI-
30 sampling. For all of the other strains the c.f.u./ml was either similar or slightly 
higher than the counts of diluted cultures and after AGI-30 sampling. These trends 
indicated that the starting concentrations of mycobacteria were similar between the 
AGI-30 sampling, first challenge and then the second challenge. 
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Figure 7.2 shows the c.f.u. counts of the five M. tuberculosis strains that had been 
collected in the AGI-30 sampler after aerosolised diluted culture had been passed 
through the Henderson nebulizer. For all strains, except M. tuberculosis LAM10 
strain, the c.f.u. counts in the four samplers were similar and on average there were 
approximately 1×102 c.f.u. in each of the samplers. For the LAM10 strain the number 
of c.f.u. varied between samplers, the largest difference being one log10 c.f.u./ml 
between approximately 1×103 c.f.u./ml, observed in replicate 3, and 1×102 c.f.u./ml, 
observed in replicates 2 and 4. The approximate average c.f.u. count from the LAM10 
replicates was 1×102.5 c.f.u./ml, which is marginally higher than counts for the other 
strains. This increase may be due to a higher mycobacterial concentration in the stock 
culture for LAM10 than the other strains. The higher concentration in the collison 
may mean more mycobacterial bacilli passed through the apparatus and delivered to 
the AGI-30 samplers. 
 
From these data, there is no indication that there is a difference in the ability of the 
five strains to survive in the aerosolised state, as a similar number of c.f.u. were 
recovered after being passed through the Henderson apparatus. Statistical analysis 
using the two sample t-test (p<0.05) confirmed that there was indeed no significant 
difference, between the M. tuberculosis strains, in the aerosols captured in the AGI-30 
samplers. Importantly, all 5 strains retained their viability during the period of 
aerosolisation, which would mean that all guinea pigs would be challenged with an 
equivalent dose enabling a direct comparison to be made of their virulence in this 
model. 
 
 
 
 
 
Figure 7.1 Log10 c.f.u./ml of mycobacteria in cultures for each of the strains including M. tuberculosis Beijing (Estonia), CAS (India), CAS (Somalia), EAI5 (India) 
and LAM10 (UK). The log10 c.f.u./ml was taken for stock culture, in diluted culture at 0 mins, and then in the collison, after aerosolisation for AGI-30 sampling after 
5 mins, and after aerosol challenge of each set of 8 guinea pigs at 10 and 15 mins. (b) Log10 c.f.u./ml of mycobacteria collected in the four AGI-30 samplers after the 
cultures for strains were aerosolised and passed through the Henderson apparatus. 
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Figure 7.2 Log10 c.f.u./ml of mycobacteria collected in the four AGI-30 samplers after the cultures for 
M. tuberculosis (a) Beijing (Estonia), (b) CAS (India), (c) CAS (Somalia), (d) EAI5 (India) and (e) 
LAM10 (UK) strains were aerosolised, passed through the Henderson apparatus and the aerosols were 
dissolved in 5ml distilled water. 
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Figure 7.2 continued 
d) 
e) 
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7.3 DISCUSSION 
 
TB bacilli are transmitted via aerosols and the prolonged stability of aerosols might 
aid in the successful transmission of certain strains, and be a potential property of 
more virulent strains. Whilst there are previous studies investigating the virulence of 
clinical strains in vivo, there was limited previous data showing correlations between 
aerosol stability and virulence of M. tuberculosis strains to prove or disprove this 
hypothesis (Williams et al., 2005; Palanisamy et al., 2009). 
 
For the purposes of this study, M. tuberculosis cultures had been used, but in reality 
aerosols are produced from saliva or sputum as an infected individual coughs or 
sneezes. In a study by Lever et al., 2000, the survival of aerosols generated from 
saline containing mycobacterial bacilli was compared with survival of aerosols from 
artificial saliva and revealed that there were no differences in the rate of aerosol 
survival whether saliva or broth cultures were used for experiments (Lever et al., 
2000). 
 
As AGI-30 sampling is a low throughput technique, and previous studies performed 
by staff at HPA, CEPR have produced historical aerosol survival data using M. 
tuberculosis H37Rv, strains were selected from those that had been included 
previously for tissue culture experiments. It was decided to compare the aerosol 
stability of cultures of circulating clinical strains from Panel B. After performing 
AGI-30 sampling using cultures for these five strains and analysing the data, there 
was no significant difference between strains in the c.f.u./ml collected in the AGI-30 
samplers relative to the initial c.f.u./ml in the cultures. This showed that there was no 
significant difference in the stability of the tested strains in their aerosolised state. 
There have been very few studies that have focused on the stability of aerosols alone, 
as most studies have used aerosol production for infecting mice and guinea pigs to 
investigate the effects of vaccines in vivo (Williams et al., 2000; Williams et al., 
2005; Williams et al., 2005; Vipond et al., 2006; Ordway et al., 2007). 
 
However, Lever et al., 2000, investigated the aerosol stability of different 
Mycobacterium species, as opposed to different M. tuberculosis strains, and 
demonstrated that despite the variation seen in human disease caused by these species, 
the survival of M. tuberculosis, M. avium and M. intracellulare in their aerosol state 
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was similar. These data partially support the results produced in the present study 
because despite the increased virulence of M. tuberculosis Beijing observed in the in 
vitro model, there were no differences in the stability of aerosols produced by the 
culture. 
 
A crucial point is that the procedures used in the present study were performed in a 
controlled environment and whilst the data may provide some insight, the controlled 
conditions are artificial. In reality there are a plethora of other factors and variables 
that might influence the stability of aerosols, for example, ultraviolet light, wind 
speed, and temperature. The effects of these factors would be hard to investigate in an 
artificial model, which may explain the limited data available surrounding this topic. 
Nevertheless any research into aerosol stability may explain the observed 
epidemiological trends in global TB, for instance the dominance of the M. 
tuberculosis CAS strain in the Indian subcontinent. Is it possible that the climate in 
this region supports the prolonged stability of this strain? As it stands at the moment, 
data show that successful transmission of Mycobacterium species or strains is due to 
the prolonged contact of TB patients with other individuals that are in close proximity 
(Lever et al., 2000). The similarities in the aerosol survival patterns for strains meant 
that any differences in virulence observed between strains during in vivo experiments 
was due to the strain and not due to the delivery of variable numbers of bacilli. 
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CHAPTER 8 
 
IN VIVO PHENOTYPICAL ANALYSIS OF M. TUBERCULOSIS COMPLEX 
STRAINS 
 
8.1 INTRODUCTION  
 
In Section 6.3, the clinical strains in Panel B (M. tuberculosis Beijing, CAS India, 
CAS Somalia, EAI5, LAM10 and M. africanum) and laboratory control strains (M. 
tuberculosis H37Rv from HPA, MRU and Porton Down, M. tuberculosis H37Ra, M. 
bovis BCG) were used for in vitro experiments, infecting activated macrophage-like 
THP-1 cells, to test the null hypothesis that all strains had the same phenotype and 
behaved in a similar manner during infection. This hypothesis had been disproved 
after in vitro analysis showed there was a marked increase in the growth of M. 
tuberculosis Beijing strain compared to the other circulating and control strains. 
 
The behaviour of strains in an in vitro assay may not necessarily resemble what would 
happen in vivo, therefore it was decided to test the same null hypothesis in an in vivo 
model. Mice have been used in previous TB studies, especially when investigating the 
in vivo immune response, as genetically engineered breeds can be more easily 
produced and there is a wider availability of immunological reagents for these animals 
(Lopez et al., 2003; Flynn 2006). However, there is a lack of similarity between 
mouse and human pathology, both pulmonary and extrapulmonary, after TB infection. 
There are also important differences between murine and human immunology. In 
contrast, there are strong histological correlations between primary pulmonary lesions 
observed in guinea pigs and humans and there is good similarity in the 
extrapulmonary dissemination of TB bacilli in the two models (Bhatia et al., 1961; 
Prabhakar et al., 1987). 
 
The extrapulmonary dissemination and pulmonary lesions are both crucial stages in 
human TB infection making guinea pigs a more attractive model for the purposes of 
the present study. Guinea pigs have successfully been used in previous in vivo studies 
for vaccine evaluation and investigating the infectivity and virulence of clinical and 
laboratory M. tuberculosis strains (Bhatia et al., 1961; Prabhakar et al., 1987; 
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Williams et al., 2000; Williams et al., 2005; Williams et al., 2005; Vipond et al., 
2006). 
 
Whilst all Panel B strains had been included in in vitro tissue culture experiments, 
they could not all be included in in vivo guinea pig experiments with a reasonable 
number of replicates as it would have been too costly with the limited numbers of 
guinea pigs available, it was decided to select M. tuberculosis LAM10, Beijing, EAI5 
and two CAS strains to represent the four M. tuberculosis lineages out of the six 
major phylogenetic lineages to prove or disprove the initial null hypothesis (Baker et 
al., 2004; Gagneux et al., 2006). The same strains had been included for the AGI-30 
sampling investigated in Chapter 7. 
 
8.2 BODY WEIGHT OF GUINEA PIGS INFECTED WITH M. 
TUBERCULOSIS COMPLEX STRAINS  
 
8.2.1 The effect on total body weight 
In order to have a suitable number of replicates for each of the two time points at 
which guinea pigs would be culled, five groups of sixteen guinea pigs were aerosol 
challenged with each of the five clinical M. tuberculosis strains. Cultures for each of 
the M. tuberculosis strains were aerosolised using nebulizers and passed through a 
Henderson apparatus, but whereas for AGI-30 sampling aerosols were captured in 
sampling jars containing water, on this occasion aerosols were delivered straight to 
the snout of the guinea pigs so approximately 10 mycobacterial bacilli would be 
retained in the lungs of guinea pigs. 
 
Post-challenge, guinea pigs were kept under controlled conditions and the body 
weight for all guinea pigs was assessed at regular intervals, which was possible as 
there was 100% survival of guinea pigs prior to culling. The average percentage 
weight change, for guinea pigs infected with the different strains, was plotted over 
time post-challenge and results of this analysis can be seen in Figure 8.1a. Variation 
in weight gain is linked to variation in pathogenicity of infecting strains. The area 
under the plotted curves for each of the strains was calculated using SigmaPlot 
(version 10.0) to represent the data more clearly and to visualise the effect of infecting 
guinea pigs with the different strains; results of this analysis can be seen in Figure 
8.1b. 
 184
 In general, there was an increase in the body weights of guinea pigs irrespective of 
which strain was used to infect animals, which was expected. However, a closer 
analysis of the curves in Figure 8.1a showed that throughout the whole time course, 
the increase in weight of guinea pigs infected with the Beijing strain was lower than 
the other four circulating strains, with the highest percentage weight gain being for 
guinea pigs infected with the CAS strain isolated from the patient born in India. The 
largest difference in body weight change between guinea pigs infected with Beijing 
and Indian CAS strains was approximately 8% between day 29 and 43, whilst the 
smallest difference was approximately 5% at day 23. The percentage weight change 
curve for guinea pigs infected with the CAS strain isolated from the patient born in 
Somalia was very similar to, but just below, the curve for the Indian CAS-infected 
guinea pigs. 
 
Statistical analysis using the Mann-Whitney test (p<0.05) proved that there were 
significant differences in the percentage body weight change between guinea pigs 
infected with the Beijing and Indian CAS strains, at days 23, 29, 37, 43 and 57 post-
challenge (p=0.024, 0.014, 0.018, 0.007, 0.041, respectively). At day 37 post-
challenge there was a significant difference between animals infected with Beijing 
and Somalia CAS strains (p=0.024) and at day 43 there was a significant difference 
between guinea pigs infected with Indian CAS and LAM10 strains (p=0.031). 
 
The differences in percentage weight change of guinea pigs infected with the different 
M. tuberculosis strains was further emphasised when looking at the overall change in 
body weight by calculating the area under the curves (Figure 8.1b). There was a 200 
unit2 difference between the area under the curves for percentage body weight change 
in guinea pigs infected with the Beijing and Indian CAS strain, with the smallest area 
occurring in animals infected with the Beijing strain. This difference was statistically 
significant (p=0.007) using the Mann-Whitney test. The values for area under the 
curves for the other strains were around 500 units2 and although these values were 
intermediate to those for guinea pigs infected with the Beijing and Indian CAS strains, 
there was a significant difference between the area under the curves for the Indian 
CAS and LAM10 (p=0.031). 
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Due to the limited number of guinea pigs available for the present project, a group of 
guinea pigs infected with the virulent laboratory control strain M. tuberculosis H37Rv 
was not included in the present study. However, there was data for the laboratory 
control strain available from previous studies performed at HPA, CEPR 
(Movahedzadeh et al., 2008; Vipond et al., 2008).  There was also data for a negative 
control group of guinea pigs infected with an M. tuberculosis double mutant strain, 
which had deletions in the inositol-1-phosphate synthase gene, ino1, and trpD, a gene 
encoding the tryptophan biosynthetic enzyme, anthranilate phosphoribosyltransferase 
(Movahedzadeh et al., 2008). The data from the study by Movahedzadeh et al., 2008 
demonstrated that this nutritional mutant strain was severely attenuated after infecting 
guinea pigs therefore the data produced after using this strain to infect guinea pigs 
served as a guide to represent what an unvaccinated-unchallenged weight data set 
would look like.  
 
The weight of guinea pigs infected with the M. tuberculosis double mutant increased 
steadily over a 60 day period post-challenge and by day 60 there was a 113.6% 
change in body weight (data not shown). However, the same was not observed in 
guinea pigs infected with the positive laboratory control strain, M. tuberculosis 
H37Rv (data not shown). There was an increase in body weight of the guinea pigs 
infected with M. tuberculosis H37Rv until day 36 post-challenge, but there was only 
an 8.0% body weight change between day 0 and 36. After day 36 the body weight 
started to decrease so the final percentage body weight change at day 63 post-
challenge was 0.85%.  
 
Although this data was from a previous study it provided an insight into any 
differences in the percentage body weight change between guinea pigs infected with 
the laboratory M. tuberculosis H37Rv strain and the five clinical M. tuberculosis 
strains included in the present guinea pig study. The overall percentage body weight 
change 56 days post-challenge for each of the clinical M. tuberculosis strains, M. 
tuberculosis Beijing, CAS (India), CAS (Somalia), EAI5 and LAM10 was 19.4%, 
24.6%, 23.6%, 20.8% and 20.6%, respectively.    
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8.2.2 The effect on lung weight to body weight ratio 
Each of the five clinical M. tuberculosis strains was used to infect sixteen guinea pigs 
and at two time points, day 16 and 56, eight guinea pigs from each group were culled. 
At necropsy at day 56 in addition to recording the total body weight, the weight of the 
lungs was recorded. The lung weight to body weight ratio was calculated and values 
for each guinea pig plotted along with the mean ratio for each group (Figure 8.2). 
 
When looking for differences between the circulating strains, the mean lung to body 
weight ratio for guinea pigs infected with the Beijing strain was higher than the means 
for the other four circulating strains. The lowest mean ratio was observed with the 
groups of guinea pigs infected with both of the CAS strains, with the mean ratio for 
animals infected with Somalia CAS being slightly lower than the Indian CAS. After 
performing the Mann-Whitney statistical analysis test (p < 0.05), it was concluded 
that the lung to body weight ratio of guinea pigs infected with the Beijing strain was 
significantly higher than the ratios obtained when guinea pigs had been infected with 
Indian and Somalia CAS strains (p=0.041 and 0.024, respectively). In addition, the 
ratios of guinea pigs infected with EAI5 were significantly higher than the ratios of 
animals infected with the Somalia CAS (p=0.018). 
 
There was lung to body weight ratio data from the historical controls in previous 
studies described in Section 8.2.1 where guinea pigs were challenged with M. 
tuberculosis H37Rv and the M. tuberculosis double mutant strain (Movahedzadeh et 
al., 2008; Vipond et al., 2008). There were some differences when comparing the 
lung to body weight ratios of guinea pigs infected with the circulating strains in the 
present study with the data from previous experiments. The lung to body weight ratios 
of guinea pigs challenged with the double mutant strain (negative control; mean lung 
to body weight ratio=4.16; data not shown) was approximately three times lower than 
the ratios of the guinea pigs that had been infected with the circulating and laboratory 
strains. In contrast, the mean lung to body weight ratio of the group of guinea pigs 
infected with M. tuberculosis H37Rv (mean lung to body weight ratio=15.5; data not 
shown) was approximately 0.7 times higher than the ratios of the circulating strains. 
 
 187
Figure 8.1 Graphs showing (a) the mean percentage change in body weight of guinea pigs 
post-challenge with each of the five M. tuberculosis strains (Beijing; Indian CAS; Somalia 
CAS; EAI5; LAM10) and (b) the area under each of the percentage growth change in body 
weight curves, in Figure 8.1a, for the five circulating strains. 
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Figure 8.2 A graph showing the lung to body weight ratio at the time of necropsy 56 days post-challenge of guinea pigs with each of the five M. tuberculosis strains 
(Beijing, Indian CAS, Somalia CAS, EAI5, LAM10), M. tuberculosis H37Rv challenged control guinea pigs and control guinea pigs [both sets of control data were 
provided by Vipond et al., 2008 and Movahedzadeh et al., 2008]. Each point represents lung to body weight ratio for an individual guinea pig and horizontal lines 
represent the mean lung to body weight ratio in each group. 
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8.3 THE DISSEMINATION OF MYCOBACTERIA FROM THE LUNGS 
TO THE SPLEEN OF GUINEA PIGS 
 
8.3.1 Mycobacterial load at day 16 post-challenge 
Eight guinea pigs from each group that had been aerosol challenged with each of the 
five M. tuberculosis strains were culled at 16 days post-challenge. The lung and 
spleen from each animal was dissected and after homogenisation, samples were plated 
onto Middlebrook 7H11 agar plates. After plates had been incubated for 4 weeks, the 
number of colonies in all plates was counted and for each animal the c.f.u./ml in the 
lungs and spleen was calculated and plotted onto graphs along with the mean c.f.u./ml 
for each group of eight guinea pigs (Figure 8.3). Calculating c.f.u./ml in lungs and 
spleen at the early time point of 16 days post-challenge provided an insight into the 
infectivity of the M. tuberculosis strains in vivo. 
 
In general, the c.f.u./ml in the lungs for each group of guinea pigs was higher than the 
c.f.u./ml in the spleen. When looking at the c.f.u./ml in the lungs, it was observed that 
there were similar numbers of c.f.u./ml in guinea pigs that had been infected with the 
Beijing, Somalia CAS and EAI5 strains with approximately 1×103.5 c.f.u./ml, whilst 
lower counts were observed in the guinea pig groups infected with the Indian CAS 
and LAM10 strains with approximately 1×103.2 c.f.u./ml. 
 
From those groups of guinea pigs with higher numbers of c.f.u. in lungs, animals 
infected with the EAI5 strain had the highest c.f.u./ml in the spleen demonstrating a 
higher rate of dissemination. The spleen counts in the groups infected with the Beijing 
and Somalia CAS strains were low at approximately 1×101 c.f.u./ml, showing a 
slower rate of dissemination. The lowest c.f.u./ml in the spleen was observed for the 
guinea pigs infected with the LAM10 strain. 
 
In general, at the early time point, it could be concluded that guinea pigs had been 
successfully infected with TB. There was a slow rate of dissemination of 
mycobacteria from the lungs to the spleen in guinea pigs infected with M. tuberculosis 
Beijing, Indian and Somalia CAS, and LAM10 strains. The faster rate of 
dissemination 16 days after infecting guinea pigs with the EAI5 strain could mean 
that this strain was more infective than the other strains, demonstrating that there are 
differences in the behaviour of the strains in an in vivo model at an early time point.   
 190
 8.3.2 Mycobacterial load at day 56 post-challenge 
The remaining guinea pigs in each group were culled at a later time point of 56 days 
post-challenge to assess the development of infection. The dissected lung and spleen 
tissue was treated in exactly the same way as tissues dissected at day 16 post-
challenge (Figure 8.4). There were clear differences in the way the strains behaved as 
infection had clearly progressed further.  
 
There was an increase of mycobacterial load in lungs for guinea pigs that had been 
infected with the Beijing and LAM10, indicating that these strains had more potential 
to persist during infection. The increase in mycobacterial load in the lungs was greater 
in those guinea pigs infected with LAM10. For the other groups of guinea pigs 
infected with the CAS and EAI5 strains, there was a decrease in mycobacterial load in 
the lungs (compared to day 16; Figure 8.3) as infection progressed, which suggested 
that the guinea pigs were able to control infection with these strains more effectively 
than infection caused by the Beijing and LAM10 strains. The decrease in 
mycobacterial load was more prominent in guinea pigs infected with the EAI5 strain 
and after performing the Mann-Whitney statistical analysis test (p < 0.05) there was a 
significant difference between the groups of guinea pigs infected with EAI5 and 
LAM10 (p=0.018). 
 
There was a general increase in mycobacterial load in the spleen for all groups of 
guinea pigs as infection had progressed to day 56 post-infection. The largest increase 
in mycobacterial load, of approximately 1×103.2 c.f.u./ml, in the spleen was observed 
in guinea pigs infected with the Beijing strain, indicating that this strain was more 
virulent than the others as there was increased dissemination of mycobacteria from the 
lung to the spleen during the progression of infection. A marked increase in bacterial 
load of approximately 1×102.5 c.f.u./ml was observed in spleens isolated from guinea 
pigs infected with the LAM10 strain. The increased load in animals infected with 
these two strains is reflected by the increased mycobacterial load in the lungs from 
these guinea pigs, which reinforced the initial suggestion that these strains were more 
persistent and potentially more virulent. The mycobacterial load in the spleen was 
significantly higher in guinea pigs infected with the Beijing strain than in guinea pigs 
infected with the Indian and Somalia CAS and EAI5 strains (p=0.003, 0.041, 0.031, 
respectively). Also there was a significantly higher mycobacterial load in the spleens 
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of guinea pigs infected with LAM10 strain than those infected with the India CAS 
strain (p=0.024). 
 
The smallest increase in the mycobacterial load in the spleen was seen in guinea pigs 
infected with EAI5 strain, which is interesting as the spleen mycobacterial load 16 
days post-challenge was higher than the spleen mycobacterial load of guinea pigs 
infected with the other four strains. This suggested that whilst dissemination of the 
EAI5 strain was quicker than the other strains in the early stages of infection, as 
infection progressed, the immune system of the guinea pigs was able to control 
infection as there was no significant increase in the dissemination of mycobacteria 
from the lung to spleen 56 days post-challenge. 
 
8.4 HISTOPATHOLOGY OF TISSUE 56 DAYS POST-CHALLENGE 
 
8.4.1 Histopathology of spleen tissue 
At 56 days post-challenge, as well as determining the mycobacterial load in spleen 
and lung tissue and weight of lungs, sections of lung and spleen were taken and 
stained with haematoxylin and eosin for routine examination, with van Giesen 
staining method for detecting encapsulated lesions and with Alizarin Red stain for 
identifying calcified lesions. Slides were examined by a veterinary pathologist and all 
lung and spleen sections were scored according to the size of lesions present and the 
degree of consolidation, which was displayed by a specific morphological change of 
the lesion. The scores were assigned according to the criteria shown in Table 2.2; 
Section 2.9.3. The number of foci of caseation and calcified lesions were also 
recorded for lung tissue. The histopathology scores for the spleen and lung tissue and 
the numbers of caseated foci and calcified lesions in lung tissue from guinea pigs 
infected with the five different M. tuberculosis strains is shown in Figure 8.5. 
 
In the spleen sections, the least pathology (average score=1) was observed in guinea 
pigs infected with the Indian CAS strain (refer to Figure 8.5a; refer to Figure 8.6bi for 
a histopathology image from one of the spleen sections taken from a guinea pig 
challenged with the Indian CAS strain). This degree of pathology when compared 
with the other strains correlated with the mycobacterial load in the spleen 56 days 
post-challenge. The highest observed pathology (average score=4) was in animals 
infected with the Beijing strain (refer to Figure 8.6ai for a histopathology image from 
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one of the spleen sections taken from a guinea pig challenged with the Beijing strain), 
with significant pathology also being observed for the Somalia CAS and EAI5 strains 
(refer to Figure 8.6ci, and di for a histopathology image from one of the spleen 
sections taken from a guinea pig challenged with the Somalia CAS and EAI5 strains, 
respectively). Again, this correlated with the mycobacterial load in the spleen of these 
animals. Surprisingly, despite the fact that there was a higher mycobacterial load in 
the spleens taken from guinea pigs infected with the LAM10 strain than the Somalia 
CAS and EAI5 strains, the pathology score was lower (average score=3) (refer to 
Figure 8.6ei for a histopathology image from one of the sections taken from a guinea 
pig challenged with the LAM10 strain). 
 
8.4.2 Histopathology of lung tissue 
The overall score for the degree of consolidation in the lung tissue was higher than in 
the spleen tissue. As with the spleen tissue, the lowest score was given to lung 
sections taken from guinea pigs infected with the Indian CAS strain (refer to Figure 
8.6bii for a histopathology image of one of the lung sections taken from a guinea pig 
challenged with the Indian CAS strain). The score for Indian CAS strain was in 
accordance with the mycobacterial load observed in the lung tissue. A similar score 
was assigned to lung sections taken from guinea pigs infected with LAM10 strains, 
which as with the spleen sections, did not correlate with the mycobacterial load 
observed in lungs at day 56 post-challenge. Refer to Figure 8.6eii for a histopathology 
image of one of the lung sections taken from a guinea pig challenged with the LAM10 
strain. 
 
As with the spleen sections, the higher scores were assigned to lung sections taken 
from guinea pigs infected with the Beijing, Somalia CAS and EAI5 strains (refer to 
Figure 8.6aii, cii, and dii for a histopathology image of one of the lung sections taken 
from a guinea pig challenged with the Beijing, Somalia CAS and EAI5 strains, 
respectively). These higher scores correlated with the mycobacterial load in lungs 
isolated from guinea pigs infected with Beijing and Somalia CAS. 
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Figure 8.3 Graphs showing the number of c.f.u./ml in (a) the lungs and (b) the spleen, which 
were dissected 16 days post-challenge from five groups of 8 guinea pigs infected with M. 
tuberculosis strains (Beijing, Indian CAS, Somalia CAS, EAI5, LAM10). Each point 
represents the c.f.u. count for individual guinea pigs and horizontal lines represent the mean 
c.f.u. counts in each group. 
(No significant difference between strains when performing Mann-Whitney statistical test p<0.05) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lung c.f.u. 16 days post-challenge
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
Beijing (Estonia) CAS (India) CAS (Somalia) EAI5 (India) LAM10 (UK)
M. tuberculosis  strain (Country of birth)
N
o.
 o
f v
ia
bl
e 
M
. t
ub
er
cu
lo
si
s
 (L
og
10
 c
.f.
u.
/m
L)
Plot
Mean
a) 
 
 
 
 
 
Spleen c.f.u. 16 days post challenge
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
Beijing (Estonia) CAS (India) CAS (Somalia) EAI5 (India) LAM10 (UK)
M. tuberculosis  strain (Country of birth)
N
o.
 o
f v
ia
bl
e 
M
.
10
 Plot
 
 
 
 
 
 
 
 
 
 tu
be
rc
ul
os
is
 (L
og
 c
.f.
u.
/m
L)
Mean
b) 
 194
Figure 8.4 Graphs showing the number of c.f.u./ml in (a) the lungs and (b) the spleen, which 
were dissected 56 days post-challenge from five groups of 8 guinea pigs infected with M. 
tuberculosis strains (Beijing, Indian CAS, Somalia CAS, EAI5, LAM10). Each point 
represents the c.f.u. count for individual guinea pigs and horizontal lines represent the mean 
c.f.u. counts in each group. 
 * Mann-Whitney statistical test (p<0.05) 
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Figure 8.5 Graphs showing (a) the average histopathology scores, with standard deviation 
bars, for each group of 8 guinea pigs whose spleens were dissected 56 days post-challenge 
with the five M. tuberculosis strains and (b) the average histopathology score for the same 
groups of guinea pigs whose lungs were dissected 56 days post-challenge with the five 
strains, but also shown is a breakdown of the scores for consolidation, caseation/necrosis, 
and calcification seen during examination. 
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Figure 8.6 Histopathology images of guinea pig i) spleen and ii) lung sections following dissection 56 
days post-challenge with (a) M. tuberculosis Beijing (Estonia); (b) M. tuberculosis CAS (India); (c) M. 
tuberculosis CAS (Somalia); (d) M. tuberculosis EAI5 (India); and (e) M. tuberculosis LAM10 (UK) 
strains and staining with haematoxylin and eosin. (Refer to the scale bar on individual images for 
measurements and refer to Table 2.2 for the criteria used for histopathology scoring of sections). 
NOTE: Histopathology scores in Figure 8.5 are averages of all sections taken from guinea pigs in each of the 
five groups challenged with each of the five M. tuberculosis strains and the scores assigned in Figure 8.6 are 
for the images shown; therefore there may be differences in the scores.  
 
 
 i) Image of a spleen section illustrating a histopathology score of 4 with 11 moderate to large sized 
lesions. 
a) M. tuberculosis Beijing (Estonia) 
ii) Image of a lung section illustrating epithelioid macrophages and evenly distribute
ded by peripheral blood vessels (with lymphocyte cuffs), all of which toget
sed granuloma. 
d lymphocytes 
surroun her formed an 
unorgani
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i) Image of a spleen section illustrating a histopathology score of 0 with no detected lesions or 
abnormalities. 
b) M. tuberculosis CAS (India) 
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ii) Image of a lung section illustrating a histopathology score of 0 as no lesions or abnormalities were 
detected. 
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i) Image of a spleen section illustrating a histopathology score of 9 with more than 30 large sized 
lesions some of which are caseated. 
c) M. tuberculosis CAS (Somalia) 
ii) Image of a lung section illustrating a histopathology score of 3 with medium sized lesions and 20-
33% consolidation. 
i) Image of a spleen section illustrating a histopathology score of 5 with 22 lesions. 
d) M. tuberculosis EAI5 (India) 
ii) Image of a lung section illustrating a histopathology score of 1 with a small unorganised granuloma. 
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i) Image of a spleen section illustrating a histopathology score of 2 with 6 small non-caseated lesions. 
e) M. tuberculosis LAM10 (UK) 
 
ii) Image of a lung section illustrating two small unorganised granuloma with a histopathology score of 
1. 
There were no significant differences between the M. tuberculosis strains in the extent 
of caseation/necrosis and calcification seen in the lung sections (refer to Figure 8.5b). 
There was less caseation/necrosis and calcification in lung sections taken from guinea 
pigs infected with the Indian CAS and LAM10 strains than the other strains. This 
means that mycobacterial load would not necessarily correlate with the degree of 
caseation/necrosis and calcification as there was a lower load in lungs isolated from 
the guinea pigs infected with the Indian CAS than in lungs from animals infected with 
the LAM10 strain. Similarly, the mycobacterial load in lungs dissected from guinea 
pigs infected with EAI5 strain was as low as Indian CAS, but there was more 
caseation/necrosis and calcification seen in the EAI5 infected lung sections than any 
of the other strains. So while there are fewer M. tuberculosis EAI5 bacilli present, 
they may cause more pathological damage to the infected tissue. There was a similar 
level of caseation/necrosis and calcification seen in lung sections taken from guinea 
pigs infected with the Beijing and Somalia CAS strains. 
 
8.5 DISCUSSION 
 
The protocol that was used in the present study for the aerosol challenge of guinea 
pigs had previously been evaluated for the purpose of comparing infectivity of M. 
tuberculosis strains and whilst testing the null hypothesis, the data offered additional 
information about the degree to which strains were pathogenic (Williams et al., 2005). 
In the study by Williams et al., 2005, a higher dose of mycobacterial bacilli had been 
administered to the guinea pigs via aerosols delivered to the snouts of the guinea pigs, 
but the study had shown that the validity of the assay remained with the lower dose 
used in the present study and that such a dose would more closely resemble natural 
doses. However, for the purposes of comparing data from the present study with data 
from previous studies the administered dose is an important factor to take into 
consideration. 
 
The weight of guinea pigs was assessed post-challenge and this can be used as a 
sensitive read-out of the extent of infection. The lower increase in weight gain of 
guinea pigs infected with the Beijing strain when compared with the data for guinea 
pigs infected with the other four strains suggested that this strain was causing more 
severe disease than the other strains. 
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Supplementing the weight change data with the lung to body weight ratio data further 
demonstrated that there was a difference in the effect of the Beijing strain on disease 
progression in guinea pigs. Comparing the data for the five strains with the data from 
the non-infected guinea pigs proved that the weight gain patterns of guinea pigs 
infected with the five strains was caused by infection with the strains. Comparison 
with the previous data from guinea pigs infected with M. tuberculosis H37Rv showed 
that there were some differences in the weight gain patterns between circulating and 
laboratory strains (Movahedzadeh et al., 2008; Vipond et al., 2008). However, as 
mentioned earlier it is important to remember that the dose of H37Rv administered to 
the guinea pigs was higher than the dose administered for the five circulating strains 
making direct comparison difficult. 
 
Mycobacterial load was evaluated in lungs and spleens from half of the guinea pigs 
from each group infected with the different strains at the early time point of day 16 
post-challenge. Day 16 post-challenge is a very early time-point in guinea pigs and 
although it is expected that little to no dissemination from the lungs to the spleen 
would take place, the presence of any mycobacteria in the spleen 16 days post-
challenge has been used as a marker of infectivity and pathogenicity of M. 
tuberculosis strains (Williams et al., 2005). Other studies have also demonstrated that 
virulence of clinical isolates of M. tuberculosis strains can be assessed by calculating 
the number of viable mycobacterial cells in the spleen (Prabhakar et al., 1987; 
Balasubramanian et al., 1992).  
 
Using this principle and the c.f.u. data from lungs and spleen at day 16 obtained from 
the present study, we would conclude that the Beijing, Somalia CAS and EAI5 strains 
all shared some of the markers of higher pathogenicity compared to the Indian CAS 
and LAM10 strains (reflected in the very low dissemination of bacilli from the lung to 
the spleen in the latter two strains).  
 
Data for mycobacterial burden in the lungs and spleen was also obtained at a later 
time point of 56 days post-challenge to further assess virulence in terms of persistence 
relative to day 16 post-challenge. The pathogenicity of the strains was also evaluated. 
The pathology of lung and spleen tissue involved looking at the degree of 
consolidation, caseation/necrosis and calcification. Consolidation scores are an 
important marker for loss of lung tissue functionality, and general pathology of tissue 
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post-challenge offered valuable information when considering the virulence of M. 
tuberculosis strains (Dunn et al., 1995; Williams et al., 2005). 
 
Compared to 16 days post-challenge, at the later time point, there was a significant 
increase in extrapulmonary dissemination of mycobacterial bacilli from the lungs to 
the spleen of guinea pigs infected with the Beijing strain, whilst there was still strong 
replication of mycobacteria in the lungs. The histopathology scores for spleen and 
lungs reflected the mycobacterial loads observed in the organs taken from animals 
infected with the Beijing strain showing that there was reduced functionality of tissues 
in these organs 56 days post-challenge. There was also increased necrosis and 
calcification observed in the lungs of guinea pigs infected with the Beijing strain. 
Collectively, these data suggested that the Beijing strain was more pathogenic and 
virulent when compared with the other strains. 
 
The Beijing strain was selected not only to represent M. tuberculosis lineage I, but 
because this Estonian strain was of particular interest for clinical purposes as an MDR 
strain of the same molecular genotype (12 MIRU and 3 ETR profile) had changed 
from first appearing in the Estonian population to now dominating the TB population, 
over a period of 10 years. If the fully sensitive Beijing strain could illicit a 
significantly more pathogenic effect in vivo, this might partly explain the success of 
this strain in Estonia and reflect on how the MDR strain might have gained 
dominance. 
 
In a study by Palanisamy et al., 2009, the virulence of different clinical M. 
tuberculosis strains was demonstrated using a guinea pig model. The panel of strains 
included MDR and drug sensitive Beijing and non-Beijing strains (Palanisamy et al., 
2009). The study showed that the MDR strains drug sensitive Beijing and non-Beijing 
strains did not grow as well as the laboratory control strain, M. tuberculosis H37Rv, 
in the lungs, whilst there was higher growth of bacilli observed with the drug sensitive 
Beijing and non-Beijing strains when compared to M. tuberculosis H37Rv. In 
addition there was a higher lung histopathology score for the drug sensitive strains 
than M. tuberculosis H37Rv and the MDR strains. Palanisamy et al., 2009 concluded 
that clinical M. tuberculosis strains caused different degrees of pathology and that the 
disease seen with the clinical strains differed to the disease caused by M. tuberculosis 
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H37Rv. The same observations were noted in the present study after performing both 
in vitro and in vivo analysis of the clinical M. tuberculosis strains in Panel B. 
 
A lower mycobacterial burden was seen in the lungs when the Somali CAS strain was 
used to infect guinea pigs compared to the Beijing strain. There was also significantly 
less dissemination, but the histopathology scores were very similar, possibly 
suggesting that not many Somalia CAS bacilli are required to cause pathology. A 
similar scenario in mycobacterial load in the lungs and spleen was observed for the 
isoniazid resistant LAM10 strain, which is responsible for the North London, UK, TB 
outbreak. However, the degree of consolidation, caseation/necrosis, and calcification 
was lower than that of the Somalia CAS strain, indicating that whilst virulence of the 
LAM10 strain may be expressed by extrapulmonary dissemination, there was reduced 
pathology post-challenge. 
 
When comparing the data obtained from guinea pigs infected with the Indian CAS 
strain with data from the other strains, there were very low levels of replication in the 
lungs and very low levels of dissemination at day 16, but at day 56, whilst there was 
still a similar mycobacterial load in the lungs, there was very little dissemination in 
comparison to the other strains. The histopathology scores and levels of necrosis and 
calcification in tissue taken from guinea pigs infected with the Indian CAS strain was 
lowest out of all of the strains, supporting the conclusion that this may be the least 
virulent of the five strains that were evaluated. It is important to note that the two 
CAS strains seem to behave differently, indicating that even strains within the same 
M. tuberculosis family vary. 
 
Besides the study by Palanisamy et al., 2009, there have been very few studies 
investigating the effects of clinical M. tuberculosis strains in an in vivo model. Lopez 
et al., 2003 investigated the pathogenesis of M. tuberculosis strains from four 
different genotype families (Beijing, Somali, Haarlam and Canetti) from different 
geographical locations using a mouse model (Lopez et al., 2003). The laboratory 
control strain, M. tuberculosis H37Rv, had been included for comparison. There was a 
higher rate of mortality in mice that had been infected with the Beijing strain and a 
higher mycobacterial burden was observed in the lungs with the Beijing strain than 
the other strains that were evaluated. The higher bacillary load in the lungs was also 
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observed in the present study. This study concluded that after infecting mice with the 
Beijing strain, a non-protective immune response was propagated.  
 
As was concluded after performing the in vitro experiments in the present study, 
results from the in vivo analysis of the M. tuberculosis strains belonging to the 
different phylogenetic lineages disproved the null hypothesis and clearly showed that 
there were differences in the way in which strains behaved during infection. Lopez et 
al., 2003, arrived at a similar conclusion, which stated that “genetically different M. 
tuberculosis strains evoked markedly different immunopathological event” (Lopez et 
al., 2003).    
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CHAPTER 9 
 
GENERAL DISCUSSION 
 
9.1 SUMMARY OF PRESENT STUDY 
 
The main aim of the present study was to construct a panel of MTBC strains that 
would be as representative of the global population of TB strains as possible and 
include a broad spectrum of M. tuberculosis strains against which any vaccine should 
be effective. This panel of strains would be useful for future vaccine evaluation 
studies and general TB research. 
 
The first step towards creating this representative panel involved the identification of 
common and unique clinical, wild-type M. tuberculosis strains circulating within the 
city of London, UK, which consists of an ethnically diverse population and could be 
used as a model of global TB diversity. Molecular typing using a discriminative panel 
of MIRU, ETR and VNTR loci was performed on MTBC isolates from TB cases 
reported within London during a one year time period. Cluster analysis of all MIRU-
VNTR profiles was carried out to identify common and unique strains. After 
excluding serial isolates (multiple isolates from the same patient) to avoid bias, cluster 
analysis of 2261 profiles yielded 235 clusters, with the largest cluster consisting of 53 
isolates and the smallest cluster consisting of 2 isolates, and 1036 unique isolates. 
 
In order to ensure there was sufficient global representation of the M. tuberculosis 
strains included in the present study epidemiological analysis was performed. All 
isolates that had been typed using MIRU-VNTR analysis were also subjected to 
spoligotyping, which helped to identify which MTBC family isolates belonged to. 
The spoligotyping data along with country of birth data for the patients was used for 
epidemiological analysis. The majority of patients were born in East Africa and the 
Indian Subcontinent, but there were patients that had also been born in other high 
burden regions including Western Africa, Eastern and South East Asia, South-Central 
Asia, Middle Africa and Southern Africa. Geographical associations were identified 
between some M. tuberculosis families and particular global regions, for example, 
patients born in the Indian subcontinent were infected mainly with M. tuberculosis 
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CAS and EAI families, whilst the majority of patients born in South-East Asia were 
infected with M. tuberculosis Beijing and EAI families. 
 
The data from the present study was corroborated by similar associations identified in 
previous studies between the EAI and CAS families and the Middle Eastern and 
Central Asian region, and between the Beijing strain and the Far Eastern regions 
(Filliol et al., 2002; Vitol et al., 2006). Studies have also identified associations 
between M. africanum and countries such as Ghana and Nigeria within the Western 
Africa region as was identified in the present study (Vitol et al., 2006; Gagneux et al., 
2007).  In the present study M. tuberculosis Beijing strains were also isolated from 
patients born in Eastern Europe. Previous studies have identified the prevalence of the 
Beijing family in Eastern European countries like Russia and Estonia (Kruuner et al., 
2001; Toungoussova et al., 2002; Drobniewski et al., 2005; Gagneux et al., 2007). 
The epidemiological analysis in the present study revealed that there were 
representatives from all MTBC families and almost all global regions. 
 
As it would be impossible to perform phenotypic analyses on all isolates circulating 
within London, a preliminary panel of MTBC strains had to be selected, to include a 
broad spectrum of M. tuberculosis strains, which was as representative of the global 
TB strain population as possible, and against which any vaccine should prove 
effective. Cluster analysis helped to identify the most dominant strains circulating in 
London, and based on the hypothesis that infectious strains are more successful (e.g. 
higher clustering rates), an algorithm was designed to identify associations between 
clusters, MTBC family identification and the country of birth of patients, to select 
MTBC strains of interest for the preliminary panel (Panel A). This panel also included 
strains that did not fit in with the general patterns identified in the clusters reflecting 
more transient contact and therefore potentially higher strain infectivity. Panel A 
contained 42 strains, which were made up of 10 different MTBC families from 
patients born in 17 different countries. 
 
It was predicted that investigating the phenotype of strains would allow the 
identification of differences between strains if the initial hypothesis was correct that 
strains were more common or dominant in a population because of some underlying 
advantage in comparison with other TB strains. An experimental approach was taken 
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to prove or disprove the null hypothesis that all TB strains are phenotypically the 
same.     
 
A smaller panel of MTBC strains (Panel B) was selected from the preliminary panel 
of strains in Panel A by performing phylogenetic analysis on all MTBC isolates that 
had been included for molecular typing. Isolates were successfully assigned to one of 
six lineages (four M. tuberculosis and M. bovis lineages defined by Baker et al., 2004 
and the M. africanum lineage defined by Gagneux et al., 2006) using MIRU-VNTR 
profiles and supplementary SNP analysis data. Strains for Panel B were selected from 
each of the six lineages.  In summary, Panel B included a M. tuberculosis Beijing 
strain (from a patient born in Estonia), a LAM10 strain (from a patient born in the 
UK), two CAS strains (from patients born in Somalia and India), an EAI5 strain (from 
a patient born in India) and an M. africanum strain. For phenotypic experiments, also 
included were the laboratory control strains: M. tuberculosis H37Rv (supplied by 
HPA, MRU), M. tuberculosis H37Rv and M. bovis BCG (supplied by HPA, Porton 
Down), and M. tuberculosis H37Ra (HPA, NCTC). 
 
The Panel B and laboratory control strains were included for in vitro phenotypic 
analyses in tissue culture models and cell-free mycobacterial culture systems. Firstly, 
PMA-activated macrophage-like THP-1 cells were infected with each of the strains 
after which the growth of intracellular mycobacteria and cytokine production profiles 
were investigated. The growth rates of the strains were investigated in mycobacterial 
cell-free culture systems (7ml MGIT Middlebrook 7H9 tubes). 
 
The data from these in vitro experiments disproved the initial null hypothesis as the 
M. tuberculosis Beijing strain behaved differently to the other strains. The 
intracellular growth rate and the growth rate in the cell-free culture system of the 
Beijing strain was higher than the other strains, which meant this strain was 
potentially more virulent using the principles described previously (Theus et al., 
2005; Park et al., 2006; Theus et al., 2007). The increased production of the pro-
inflammatory cytokines, TNF-α, compared to the other Panel B strains and the low 
levels of the anti-inflammatory cytokine, IL-10, produced after infecting THP-1 cells 
with the Beijing strain further demonstrated the virulent nature of the Beijing strain in 
comparison to the other strains as had been established in previous studies (Park et al., 
2006; Theus et al., 2007). 
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 The association between the intracellular growth of the M. tuberculosis Beijing strain 
and production of the cytokines, TNF-α and IL-10, has been investigated previously 
(Theus et al., 2007). There was an inverse relationship between intracellular growth 
rate of the Beijing strain and production of TNF-α; therefore strains with an increased 
intracellular growth rate produced less TNF-α. Whereas an inverse relationship was 
identified between intracellular growth rate and TNF-α production by Theus et al., 
2007, a study by Park et al., 2006, demonstrated that the more virulent strains both 
grew better and produced more TNF-α (Park et al., 2006; Theus et al., 2007). 
 
In the present study, the highest multiplication rates were observed after infecting 
THP-1 cells with the Beijing strain and higher levels of TNF-α were produced by the 
THP-1 cells infected with the Beijing strain than THP-1 cells infected with the other 
four Panel B MTBC strains (two M. tuberculosis CAS strains, M. tuberculosis EAI5, 
M. tuberculosis LAM10 and M. africanum). 
 
The panel of strains was subsequently narrowed down by further selecting strains of 
interest for in vivo analyses in order to test the original null hypothesis. Strains 
representing the four M. tuberculosis lineages out of the six major phylogenetic 
lineages were selected (M. tuberculosis LAM10, Beijing, EAI5 and the two CAS 
strains). 
 
The in vivo experiments involved aerosol challenge of guinea pigs. During the 
aerosolisation of mycobacterial cultures it was decided to perform AGI-30 sampling, 
primarily to ensure that any observations after infecting guinea pigs with each of the 
strains were due to differences in virulence of the M. tuberculosis strain alone, rather 
than physical differences of the bacteria, but it was recognised that these data may 
offer insights into the stability of strains as aerosols. There were no significant 
differences between strains in the c.f.u./ml collected in the AGI-30 samplers relative 
to the initial c.f.u./ml in the cultures indicating that there was no significant difference 
in the stability of the tested strains in their aerosolised state. 
 
In vivo analyses of the M. tuberculosis strains in the guinea pig model demonstrated 
that there were differences between the wild-type clinical M. tuberculosis strains as 
well as differences between the wild-type clinical strains and laboratory control strain, 
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M. tuberculosis H37Rv (e.g. weight data). The percentage weight change in guinea 
pigs infected with the Beijing strain was significantly lower than the other clinical 
strains after using the Mann-Whitney statistical test. The lung to body weight ratio at 
the time of necropsy was significantly higher for the Beijing strain than both of the 
CAS strains and the ratios observed after guinea pigs were infected with laboratory 
control strain was higher than all of the clinical strains.  
 
The largest increase in lung and spleen mycobacterial load was observed in guinea 
pigs infected with the Beijing strain indicating that this strain had more potential to 
persist during infection and was more virulent than the other strains due to the 
increased dissemination of mycobacteria from the lung to the spleen during TB 
infection. 
 
In conclusion, the data from the in vitro and in vivo analyses in the present study, 
disproved the null hypothesis and showed that there were phenotypic differences 
between the wild-type M. tuberculosis strains that were of clinical relevance and also 
differences between the wild-type and laboratory control strains. These conclusions 
indicated that there is a need to perform future vaccine evaluation studies not only 
using standardised laboratory challenge strains (such as H37Rv and Erdmann) but 
also with wild-type circulating strains from relevant global regions. This will be 
particularly relevant when a lead vaccine candidate is identified, and which will 
require more extensive evaluation before being introduced for mass vaccination and 
possibly before primate studies are instituted. Also, if evaluation studies showed that a 
particular vaccine was more effective against a M. tuberculosis strain isolated from a 
patient born in a high TB burden region it could lead to a successful niche vaccine. 
 
9.2 FUTURE WORK 
 
All of the strains in the preliminary panel (Panel A) need to undergo in vitro 
evaluation by calculating the growth rates of strains using the MGIT 960 culture 
system and inoculum sizes of 600 and 6,000 genomes, calculating the fold 
enhancement of strain growth after infecting PMA-activated THP-1 cells and 
measuring the production of human TNF-α, IL-10, IL-1β and IL-6 by infected THP-1 
cells. In order to better monitor the production of each cytokine earlier, more 
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extensive time points need to be investigated, because the highest levels of the 
cytokine, TNF-α, were produced by day 1 post-infection. 
 
The data from THP-1 cells for in vitro experiments needs to be corroborated using 
primary cell lines such as bone-marrow derived macrophages or primary macrophages 
from PBMCs. Other variables also need to be investigated. In the present study an 
MOI of 1 was used to infect the THP-1 cells with the mycobacterial strains. Different 
MOIs need to be evaluated. During further experiments the effect of infecting 
macrophage cell-lines could be monitored by observing the cells using inverted 
microscopy during the time course of infection. 
 
The data from the in vitro experiments performed on the entire Panel A strains would 
help to narrow down this panel to include the most virulent MTBC strains. This 
would provide insight into potential correlations between the virulence of a particular 
strain and the dominance of the strain in the population. The dominance of a strain 
would be determined using the size of clusters to which the strains were initially 
assigned. 
 
In the present study Panel B included a strain from each of the lineages defined by 
Baker et al., 2004 and Gagneux et al., 2006. However, there was only one strain per 
lineage, so to establish if there are true differences between the lineages, more strains 
need to be selected to represent each of the lineages and in vitro experiments need to 
be repeated to confirm the results and conclusions in the present study. 
 
As well as testing the null hypothesis that there are no differences between the strains 
from the different lineages, the hypothesis needs to be tested on strains within the 
same lineage to confirm if strains within lineages are phenotypically the same. In 
addition, the phenotypic differences between the fully drug sensitive and MDR M. 
tuberculosis Beijing strains needs to be evaluated as the Estonian Beijing strain that 
has dominated the population in Estonia is an MDR strain, whilst the strain included 
in the present study was a fully drug sensitive equivalent strain with the same MIRU 
and ETR profiles. 
 
In addition to evaluating laboratory control strains, M. tuberculosis H37Rv and 
H37Ra, and the vaccine strain, other laboratory control strains like the virulent 
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Erdmann strain needs to be included alongside the clinical wild-type strains to 
conclusively establish that the clinical strains are different to laboratory control and 
vaccine strains. 
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APPENDIX 1 
 
 
The expected molecular weights, in base pairs, of amplified fragments with various copy numbers in MIRU loci. 
 
Molecular weight of fragment (base pairs) Copy 
number 2 4 10 16 20 23 24 26 27 31 39 40 
0 189 103 219 367 215 78 325 244 272 106 194 229 
1 238 189 272 420 292 131 375 295 325 159 243 280 
2 287 264 325 473 369 183 425 344 378 212 292 331 
3 336 339 378 526 446 235 475 393 431 265 341 382 
4 385 414 431 579 523 287 525 442 484 318 390 433 
5 434 489 484 632 600 339 575 491 537 371 439 484 
6 483 564 537 685 677 391 625 540 590 424 488 535 
7 532 638 590 738  443  589 643 477 537 586 
8 581 713 643   495  638  530 586 637 
9 630 788 696   547  687  583 635 688 
10  863 749   599  736  636  739 
11   802   651  785    790 
12        834     
13        883     
14        932     
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APPENDIX 2 
 
 
The expected molecular weights, in base pairs, of amplified fragments with various 
copy numbers in ETR and VNTR loci. 
 
Molecular weight of fragment (base pairs) Copy 
number A B C 2163B 2347 3232 2163A 1982 3336 4052 
0 195 121        117 178 270   
1 270 174 133 133 385 242 186 256 325 266 
2 346 227 187 202 441 286 255 334 380 376 
3 422 280 242 273 501 330 324 412 435 488 
4 499 333 297 343 556 372 393 490 490 596 
5 570 386 350 412 611 415 462 568 545 710 
6 645 439 405 480 667 458 531 646 600 820 
7 720 492 460 548 724 501 600 727 655 935 
8 795 545 515 617 781 546 669 802 710 1050 
9 870 598 570 686 838 587 738 880 765 1165 
10 945 651 625 755   630 807 958 820 1280 
11 1020   824   673 876 1038 875   
12    892   716 945 1126 930   
13    963   759 1014 1272 985   
14    1034   802 1083 1350 1040   
15    1105   839 1152 1428 1095   
16    1176   888 1221   1150   
17        931 1290   1205   
18        974 1359   1260   
19        1017 1428    
20        1060 1497    
21        1103 1566    
22        1150 1635    
23        1200 1704    
24        1247 1773    
25          1842    
26          1911    
27          1980    
28          2049    
29          2118    
30          2187    
31          2256    
32          2325    
33          2394    
34          2463    
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APPENDIX 3 
 
The calculation used to perform a cell count of THP-1 cells using a Kova slide II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kova slide II 
 
 
 
The number of bright, clear round cells (x) were counted in the smaller grids shaded 
in grey, making sure not to include cells that were in the spaces between the smaller 
grids. 
 
The following calculation was done to establish the number of THP-1 cells per ml, 
which had been pooled in the falcon tube:- 
 
x × 3 =  the number of cells in the whole large grid 
 = the number of cells/μl as 1μl covers the large grid 
 
To account for the 1 in 2 dilution with Trypan blue solution:-  
Number of cells/μl × 2 = actual number of cells/μl 
 
Therefore:- 
Number of cells/ml  =  actual number of cells/μl × 1000 
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APPENDIX 4 
 
The calculation used to determine the number of genome molecules/µl. 
 
Total M. tuberculosis genome 4,411,529 base pairs (b.p.) 
Total guanidine + cytosine      2,894,585 b.p. (single strand) 
     5,789,170 b.p. (double strand) 
Total adenosine + tyrosine       1,516,944 b.p. (single strand) 
     3,033,888 b.p. (double strand) 
Compound molecular weight for base pairs:-  
adenosine base 331.2 g/mol  cytosine base  307.2 g/mol 
guanidine base 347.2 g/mol  tyrosine base  322.2 g/mol 
 
guanidine + cytosine (307.2+347.2) ÷ 2 = 327.2 g/mol 
adenosine + tyrosine (331.2+322.2) ÷ 2 = 326.7 g/mol 
Compound molecular weight for M. tuberculosis genome:-  
 guanidine + cytosine 5,789,170 b.p. × 327.2 g/mol = 1,894,216,424 g/mol 
 adenosine + tyrosine 3,033,888 b.p. × 326.7 g/mol = 991,171,209.6 g/mol 
 Total = 2,885,387,633.6 g/mol 
However when 2 bases bind a water (H2O) molecule is lost. 
The compound molecular weight for H2O is 18 g/mol. 
There are 4,411,529 b.p., but when calculating the g/mol H2O lost the calculation is:- 
4,411,528 b.p. × 18 g/mol = 79,407,504 g/mol 
Therefore the actual g/mol of genome = 2,885,387,633.6 - 79,407,504 
      = 2,805,980,129.6 g/mol 
 
Avogadro’s constant = 6.02 × 1023 molecules/mol 
The DNA concentration in the extract measured by nanodrop 
 = 124.1 ng/μl (1.241 × 10-7 g/μl) 
2,805,980,129.6 g  = 1 mol 
1.241 × 10-7 g/μl =  (1.241 × 10-7 g/μl ÷ 2,805,980,129.6 g) mol 
   =  4.422697035 × 10-17 mol in 1μl 
 
1 mol    =  6.02 × 1023 molecules 
4.422697035 × 10-17 mol =   (4.422697035 × 10-17 mol × 6.02 × 1023 molecules) 
    =   26,624,636.15 molecules in 1μl 
 
Therefore the DNA standard contains 2.7 × 107 genome molecules/μl. 
 
 
To address conflicting results about the stability of vari-
able number tandem repeat (VNTR) loci and their value in 
prospective molecular epidemiology of Mycobacterium tuber-
culosis, we conducted a large prospective population-based 
analysis of all M. tuberculosis strains in a metropolitan set-
ting. Optimal and reproducible conditions for reliable PCR 
and fragment analysis, comprising enzymes, denaturing con-
ditions, and capillary temperature, were identified for a panel 
of hypervariable loci, including 3232, 2163a, 1982, and 4052. 
A total of 2,261 individual M. tuberculosis isolates and 265 
sets of serial isolates were analyzed by using a standardized 
15-loci VNTR panel, then an optimized hypervariable loci 
panel. The discriminative ability of loci varied substantially; 
locus VNTR 3232 varied the most, with 19 allelic variants 
and Hunter-Gaston index value of 0.909 . Hypervariable loci 
should be included in standardized panels because they can 
provide consistent comparable results at multiple settings, 
provided the proposed conditions are adhered to.
Globally, tuberculosis (TB) accounts for almost 2 mil-lion deaths each year (1). Although TB notification 
rates in the United Kingdom (13.8/100,000 in 2007) re-
main low, rates differ substantially by region: London 
(43.2/100,000) accounts for ≈40% of all TB cases regis-
tered in the United Kingdom, and ≈75% of TB patients in 
London were born abroad (2). Rates of drug resistance also 
are higher in London than in the rest of the United King-
dom: 8.6% of isolates are isoniazid resistant, and 1.2% are 
multidrug resistant (UK Health Protection Agency; www.
hpa.org.uk).
In settings where incidence of TB is low or moderate, 
molecular genotyping is used to investigate suspected TB 
outbreaks, laboratory cross-contamination, and reactivation 
and (at a population level) to identify clustered cases that 
are not apparently linked; for the latter purpose, the highest 
possible level of discrimination is required (3). For these 
purposes, insertion sequence (IS) 6110 restriction fragment 
length polymorphism (RFLP) analysis—often supplement-
ed with spoligotyping and, more recently, with variable 
number tandem repeat (VNTR) typing—is used routinely.
The highest levels of epidemiologic discrimination 
of strains of the Mycobacterium tuberculosis complex 
(MTBC) can be achieved by using multilocus VNTR typ-
ing, but these results depend on the number and loci used, 
particularly for homogenous strain groups such as the 
Beijing family (3–5). This approach overcomes technical 
difficulties associated with IS6110-RFLP and is amenable 
to automation that results in a high throughput (6–10). 
A standardized panel of 15 + 9 VNTR loci (24 loci) has 
been proposed (7,11), but it is unclear whether sufficient 
discrimination would be seen when the panel is used in 
populations with a substantial prevalence of homogenous 
MTBC families (4,5,12). In addition, the discriminative 
power of VNTR loci may vary markedly among genetic 
families (7,13). Recent studies evaluating the discriminative 
power of VNTR typing have produced conflicting results 
that were generated by using convenience samples (small 
populations with low diversity or populations confined to a 
single geographic setting). These studies highlighted a need 
for larger population-based studies to identify discrimina-
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tive VNTR loci and ascertain their applicability for various 
genetic groups.
Concerns about the stability and reproducibility of 
particularly useful hypervariable loci, such as 3232, 2163a, 
3336, and 1982 (3–5,14), have been raised (7,15). As a 
result, they have been excluded from the proposed inter-
national panels for VNTR typing. For these reasons, we 
conducted a study to examine the stability of hypervariable 
loci and the parameters associated with reproducibility, to 
select loci suitable for prospective molecular epidemiologic 
studies, and to evaluate the discriminatory power of these 
loci at a population level in a metropolitan setting.
Materials and Methods
Bacterial Isolates
A total of 2,261 individual MTBC isolates (1 per pa-
tient) were included in this prospectively designed popula-
tion study. These isolates represented 95.7% of the bacteri-
ologically confirmed TB cases reported from the 30 London 
hospitals in the 12 months from April 2005 through March 
2006. These isolates had been characterized by using spoli-
gotyping, and all but 4 were assigned to 1 of 36 spoligotype 
families (16,17). Multiple isolates were available from 265 
patients (11.7%), resulting in serial isolate sets of 2–6 iso-
lates, which had been sampled at intervals of 3 days to 11 
months (N = 632).
Multilocus VNTR Analysis
All extracts were typed by using 15 mycobacterial in-
terspersed repetitive unit (MIRU)-VNTR loci as previously 
described (3). Isolates clustered when the 15 MIRU- Hunter-
Gaston index value VNTR profiles we used were reanalyzed 
with an additional panel of VNTR loci 2163b, 2347, 3232, 
2163a, 1982, 3336, and 4052 as previously described (3,5) 
after optimization of factors affecting reproducibility (see 
Hypervariable Loci Optimization). Variability or discrimi-
nation at a locus was assessed by using the Hunter-Gaston 
Discriminative Index (HGDI) (18). Loci with HGDI values 
<0.3, 0.3–0.6, and >0.6 were considered poorly, moderate-
ly, and highly discriminative, respectively (19).
Hypervariable Loci Optimization
We selected 16 previously characterized MTBC iso-
lates to cover the complete range of repeat sizes at control 
loci MIRU 26 and exact tandem repeat (ETR)–B and experi-
mental hypervariable loci VNTRs 1982 and 3232 (except 0 
repeats for the locus 3232). For each of the 16 extracts, four 
10-µL PCRs were conducted for each of the primer mixes 
in duplicate. Of these 4 reactions, the first was performed 
as described previously with BIOTAQ polymerase (Bio-
line, London, UK) (any enzyme in the given context means 
enzyme in conjunction with the buffer recommended and 
supplied by a manufacturer). Three other sets of PCRs were 
conducted under different amplification conditions (1).
Method 1
Diamond DNA polymerase (Bioline) was used (9). 
The PCR amplification cycle was 3 min at 95°C, followed 
by 35 cycles of 30 s at 95°C, 30 s at 60°C, and 2 min at 
72°C, and 1 final cycle of 5 min at 72°C (2).
Method 2
HotStartTaq DNA polymerase (QIAGEN, Hilden Ger-
many) was used. Each 10-µL reaction contained 1× PCR 
buffer (QIAGEN), 0.25 U/µL of the relevant polymerase, 
0.2 µmol/L dNTPs, 0.125 µmol/L of relevant primer, and 
5% dimethylsulfoxide. The DNA amplification cycle was 
15 min at 95°C, followed by 35 cycles of 30 s at 94°C, 30 
s at 60°C, and 1 min at 72°C, and a final cycle of 10 min 
at 72°C (3). 
Method 3
HotStartTaq Plus DNA polymerase (QIAGEN) was 
used. The PCR mixture was the same as in method 2, and 
the amplification cycle was the same, except that the initial 
95°C activation time was reduced to 5 min.
We manually calculated the number of repeats within 
each PCR product by resolving 4 µLof each product on a 
1.2% (wt/vol) agarose gel (Agarose LE Analytical grade; 
Promega, Southampton, UK) against a 2,000-bp Hyper-
Ladder II standard (Bioline). The number of repeats at each 
locus also was calculated by sizing in a denaturing capil-
lary electrophoresis system using a CEQ 8000 instrument 
with a DNA Size Standard 600 (Beckman Coulter, High 
Wycombe, UK) and MapMarker D1 labeled 640–1000 
(BioVentures, Inc., Murfreesboro, TN, USA) because frag-
ments were expected to be >600 bp. Three parameter sets 
(Table 1) were used to analyze all fragments. The different 
parameters examined were capillary temperature (60°C for 
methods 1 and 2 and 50°C for method 3, respectively), de-
naturation time (120 s for method 1 and 180 s for methods 2 
and 3, respectively) and separation time (60 min for meth-
ods 1 and 2 and 70 min for method 3, respectively). Frag-
ment data traces were automatically analyzed by using the 
scheme shown in Table 1. For locus 3232, we accounted 
for offset values (i.e., difference among actual sizes of PCR 
fragments and apparent sizes indicated by electrophoresis) 
when calculating number of repeats in Table 1.
Assessing Stability and Reproducibility of VNTR Loci
All isolates were grouped into 265 sets of serial isolates 
(2–6 isolates each) and typed at all 22 loci. Primer sequenc-
es for all loci were as described previously (3,9,20,21). PCR 
was set up by using BIOTAQ polymerase for amplifying 
12 MIRU and 3 ETR loci and Diamond polymerase for the 
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additional 7 VNTR loci. Capillary electrophoresis was per-
formed by using the parameters described in method 1.
Results
Optimization of Hypervariable Loci
We evaluated factors that potentially affect the repro-
ducibility of hypervariable VNTR loci by using various 
PCR and capillary and manual electrophoresis separation 
conditions as described in the Materials and Methods. The 
ability to correctly amplify different VNTR loci depended 
on the enzyme used (Table 2); all polymerases efficiently 
amplified MIRU 26 and ETR-B, as indicated by the pres-
ence of PCR fragments on agarose gels and capillary elec-
trophoresis peaks. However, locus VNTR 3232 was ampli-
fied effectively only with Bioline Diamond (15/16 strains, 
93.8%). Although all polymerases except Bioline BIOTAQ 
were able to amplify DNA at locus VNTR 1982, longer 
fragments were amplified more efficiently by QIAGEN 
and Bioline Diamond polymerases. Therefore, Diamond 
polymerase was selected for the amplification of additional 
VNTR loci.
We assessed 3 methods for capillary electrophoresis. 
For each locus, apparent fragment sizes were plotted against 
expected fragment sizes for each method (Figure 1).
MIRU 26 fragments sizes were as expected for all al-
lelic variants (except for the variant with 2 repeats) when 
BIOTAQ and Diamond polymerases were used, but sizes 
were larger than expected with QIAGEN polymerases. The 
smaller ETR-B fragments with 1 and 2 repeats all gave ex-
pected sizes with methods 1 and 2 but were less than ex-
pected with method 3 (where the capillary temperature was 
decreased). These results did not affect overall interpreta-
tion. For the higher number of repeats (4–6 repeats), all 
polymerases generated fragments that, when analyzed by 
using method 3, gave apparent sizes lower than expected. 
In some cases, this result affected the interpretation. The 
apparent sizes of VNTR 1982 fragments were all similar 
to the expected values independent of the polymerase used 
and the method used for capillary electrophoresis.
Serial Isolates
Amplification was performed by using BIOTAQ 
polymerase for 12 MIRU and 3 ETR loci and Diamond 
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Table 1. Expected molecular weights of Mycobacterium 
tuberculosis of fragments at each locus, with different numbers  
of copies, London, UK, 2005–2006* 
Length of expected fragments for each locus, bp 
No. repeats MIRU 26 ETR-B VNTR 1982 VNTR 3232†
0 244 121 178
1 295 174 256 242
2 344 227 334 286
3 393 280 412 330
4 442 333 490 372
5 491 386 568 415
6 540 439 646 458
7 589 492 727 501
8 638 545 802 546
9 687 598 880 587
10 736 651 958 630
11 785 1,038 673
12 834 1,116 716
13 883 1,194 759
14 932 802
15 845
16 888
17 931
18 974
19 1,017
20 1,060
*MIRU, mycobacterial interspersed repetitive unit; ETR, exact tandem 
repeat; VNTR, variable number tandem repeats. 
†No isolates had 0 repeats in locus 3232 in our population. 
Table 2. Number of DNA extracts (from n = 16) for which peaks were detected by different conditions for capillary electrophoresis of
Mycobaterium tuberculosis after amplifying the loci with different polymerases, London, UK, 2005–2006* 
Bioline polymerases‡ QIAGEN polymerases‡ 
Locus Method† BIOTAQ Diamond HotStartTaq HotStartTaq Plus 
MIRU 26 1 16 16 16 (1) 16 (1) 
2 15 16 16 (1) 16 (1) 
3 16 16 16 16
ETR-B 1 16 16 16 (1) 16 (1) 
2 15 16 16 (1) 16 (1) 
3 16 16 16 (2) 16 (2) 
VNTR 1982 1 8 13 14 14
2 9 13 12 14
3 6 11 12 14
VNTR 3232 1 11 15 13 14
2 10 15 14 14
3 11 (3) 15 (7) 13 (6) 13 (4) 
*MIRU, mycobacterial interspersed repetitive unit; ETR, exact tandem repeat; VNTR, variable number tandem repeats. 
†Refer to Table 1. 
‡Numbers in parentheses represent number of extracts whose calculated number of repeats were higher and lower than the expected value on the basis 
of that produced by the standard procedure (method 1). 
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polymerase for 7 VNTR loci with the optimized param-
eters in method 1. Analysis was blinded. No disagreements 
occurred in the interpretation of VNTR repeat numbers 
among isolates in a set. In a proportion of isolates (N = 
124), genotyping results were validated by using both cap-
illary electrophoresis and manual electrophoresis for PCR 
fragment separation, and again, no discrepancies were 
found between VNTR loci copy numbers in strains isolated 
from the same patient at different time points (Figure 2).
Population Genotyping in Metropolitan Setting  
with 2 Panels of VNTR Loci
A total of 2,261 MTBC isolates circulating in London 
with known spoligotypes were genotyped by using a defined 
set of 15 loci (12 MIRU and 3 ETR); all known spoligotyp-
ing families were represented in the test population (online 
Technical Appendix, available from www.cdc.gov/EID/
content/15/10/1609-Techapp.pdf). Complete 15-loci profiles 
were obtained for 2,046 strains (90.5% of all strains). Data 
for the remaining profiles were incomplete for >1 locus. 
Overall PCR failure rate was 1.6%, with the highest number 
of failures (n = 72) at locus ETR-A and the lowest number 
of failures (n = 4) at locus ETR-C. When PCR failed, DNA 
was reextracted from original cultures, and genotyping was 
attempted again. If the second attempt was unsuccessful, the 
results for the locus were marked as missing.
Genotyping of MTBC isolates by using 15 MIRU-ETR 
loci yielded 1,036 unique profiles and 235 clusters contain-
ing 2–53 isolates (Table 3). Clustered profiles were shared 
by 1,225 isolates, giving a clustering rate of 54.2%.
Subsequently, 1,196 (97.6%) of 1,225 isolates (15 
MIRU-ETR clustered isolates) were subjected to second-
ary typing by using VNTR loci 2163b, 2347, 3232, 2163a, 
1982, 3336, and 4052. Resolution improved because strains 
that had been clustered initially were subdivided into new 
groups: 1,730 isolates now had unique genotyping patterns, 
and the remaining 502 isolates were grouped into 158 clus-
ters, giving a new, substantially lower, clustering rate of 
22.2% (Table 3).
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Figure 1. Effect of various enzymes and separation conditions on amplification and detectable molecular weights of PCR fragments for 
4 variable number tandem repeat (VNTR) loci. A) Mycobacterial interspersed repetitive unit locus 26; B) locus exact tandem repeat; C) 
locus 1982; D) locus 3232.
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Variability and Discriminative Power of VNTR Loci
The discriminative ability of VNTR loci varied mark-
edly among the 22 VNTR loci and among spoligotyping 
families (online Technical Appendix) with locus VNTR 
3232 showing the greatest variation (HGDI = 0.909 and 19 
allelic variants) and loci MIRU 2 and 20, the least (HGDI = 
0.134 and 0.196; number of allelic variants 4 and 3, respec-
tively). Twelve loci each had >10 allelic variants. MIRU 
4 showed moderate discriminative power, and MIRU 
10, MIRU 16, MIRU 23, MIRU 26, MIRU 40, ETR-A, 
ETR-C, and VNTR 2163B, 2163A, 1982, 3232, 3336, and 
4052 showed high discriminative power with HGDI val-
ues varying from 0.524 to 0.909. None of the 22 loci were 
monomorphic in the current study. With the exception of 
VNTR 2347, all loci included in the additional VNTR pan-
el displayed higher variability than the primary panel of 15 
MIRU-ETR loci used for UK national typing, which indi-
cates their potential for increasing the power of prospective 
molecular genotyping.
The discriminative power of VNTR loci also varied 
among spoligotype families. The mean 15 MIRU-ETR 
HGDI value for the Beijing family was low (0.163), which 
indicates that this family is relatively homogeneous, even 
within the diverse London population settings. Notably, 
mean 15 MIRU-ETR HGDI values for genetic families 
within the Euro-American lineage (T, Haarlem, S, X, 
Latin American–Mediterranean) were generally higher 
(0.307–0.378) than those for Beijing and Central Asian 
(CAS) (0.235). Within spoligotype families, the additional 
7 VNTR increased variability in all cases, except for M. 
bovis. The highest HGDI were seen in the Latin Ameri-
can–Mediterranean family with locus 2163B; in Beijing, 
Haarlem, and M. africanum with VNTR 3232; in East Af-
rican–Indian with VNTR 2163A; in X with VNTR 1982; 
in T with VNTR 3336; and in CAS with VNTR 4052. 
Within the East African–Indian family, the hypervariable 
loci VNTR 3232 varied little, with 93.7% isolates having 
a single copy. A small proportion of strains (Table 4) ana-
lyzed by using more discriminative loci, including VNTR 
3232, 1982, 2163A, and 3336, generated PCR products that 
were too large for automated analysis but were resolved 
manually.
Discussion
Polymorphisms in rapidly evolving repetitive se-
quences, such as minisatellite VNTR, are a valuable tool 
for prospective epidemiologic analyses and provide a high 
degree of discrimination in situations in which few a priori 
epidemiologic data are available. In this population-based 
study, we genotyped 2,261 individual MTBC isolates ob-
tained from patients residing in London by using 22 VN-
TR-MIRU loci.
Conflicting views on the use of hypervariable loci for 
typing have been reported, even when loci such as VNTR 
3232 have been shown to have high discriminatory pow-
er (3,5,14). Some studies have demonstrated difficulty in 
amplification of multiple alleles, absence of PCR ampli-
fication products, varying data interpretation, and lack of 
reproducibility among laboratories (7). Similar problems 
were found with another potentially valuable hypervariable 
locus, VNTR 1982 (5,7). Therefore, we believed that by 
identifying the conditions that provided good, reproducible 
discrimination, we would be able to define the optimal con-
ditions that would enable molecular epidemiologists to use 
VNTR 1982 and 3232. We addressed variability and repro-
ducibility for these 2 loci using MIRU 26 and ETR-B as 
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Figure 2. Agarose gel showing the stability of amplified fragments of 
variable number tandem repeat (VNTR) 3336 from 2 serial isolates 
isolated from 4 patients. Lane 1, patient A, isolate 1, isolated 2005 
Jun 20, 8 copies; lane 2, patient A, isolate 2, isolated 2005 Jul 11, 
8 copies; lane 3, patient B, isolate 1, isolated 2005 Jul 8, 9 copies; 
lane 4, patient B, isolate 2, isolated 2005 Aug 8, 9 copies; lane 5, 
patient C, isolate 1, isolated 2005 Nov 11, 7 copies; lane 6, patient 
C, isolate 2, isolated 2005 Nov 15, 7 copies; lane 7, patient D, 
isolate 1, isolated 2005 May 16, 6 copies; lane 8, patient D, isolate 
2, isolated 2005 May 25, 6 copies. 
Table 3. Discriminatory power of VNTR typing used in the study in establishing true minimum cluster size as marker of real 
transmission rate* 
Genotyping method 
No. distinct profiles 
(variety of types) 
No.
clusters 
Size of clusters, 
no. isolates 
Clustering
rate, % (n/N) 
Recent transmission 
rate, % ([n – c]/N)
No. unique 
isolates
MIRU15 (n = 2261) 1,271 235 2–53 54.2 44.0 1,036
MIRU15 + Spoligotyping 1,619 196 2–48 37.1 29.0 1,423
MIRU15 + VNTR7 1,888 158 2–35 22.2 17.0 1,730
*MIRU, mycobacterial interspersed repetitive unit; VNTR, variable number tandem repeats; n, no. clustered cases; N, total no. of strains; c, no. of clusters.
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controls that give stable comparable results in both agarose 
gel and capillary electrophoresis and have been used previ-
ously in a multilaboratory comparative study (7).
In all cases, identical data were produced for MIRU 26 
and ETR-B irrespective of the DNA polymerase used. Am-
plification of VNTR 1982 and 3232 varied with different 
DNA polymerases, particularly when expected fragments 
were long.
The differing performances of polymerases for am-
plifying different loci can be explained by their varying 
properties. BIOTAQ polymerase is a basic Taq that can 
be used for a wide range of templates, whereas Diamond 
polymerase has been modified by a point mutation at the 
active site of the enzyme, enabling it to read through re-
gions of secondary structure, microsatellites, and guanine 
cytosine–rich templates, such as those found in the M. tu-
berculosis genome. The QIAGEN polymerases are chemi-
cally modified polymerases with a high specificity similar 
to that of Diamond polymerase; thus they showed similar 
capabilities in amplifying VNTR 1982 and 3232. In addi-
tion, the buffer used with the QIAGEN polymerases is de-
signed to increase the specificity of primer binding, mak-
ing these polymerases suitable for dealing with complex 
genomic DNA.
Conditions that affect the denaturation of PCR prod-
ucts, and therefore their linearity before fragment sizing by 
electrophoresis, would be expected to influence apparent 
sizes of PCR fragments and copy number enumeration. We 
investigated the influence of DNA denaturation time and 
capillary separation temperature. As expected, we found 
that lowering the separation rate increased the discrimina-
tion of fragments >1,000 bp.
A marked difference was observed when the capillary 
temperature was decreased (method 3), which was indepen-
dent of the polymerase used and locus investigated and dem-
onstrated that separation conditions are critical for the cor-
rect interpretation of the VNTR typing results. In method 3, 
apparent fragment sizes were smaller and offset values were 
markedly larger, to the point that in some cases the calcu-
lated copy number was different from that expected.
Taking all the data together, we used BIOTAQ for 
amplifying MIRU and ETR loci, and Diamond polymerase 
for amplifying the extra 7 hypervariable VNTR loci, us-
ing the separation conditions detailed in method 1. We also 
demonstrated the reproducibility and stability of the extra 
7 VNTR loci by comparing 22 MIRU-VNTR profiles from 
serial isolates. The resulting profiles of serial isolates from 
the same patients were identical, indicating that the condi-
tions used for fragment amplification, detection, and analy-
sis were ideal for typing of these loci and that these loci 
could be used for routine genotyping.
Clustering rates seen by using 15 MIRU-ETR loci far 
exceeded those previously reported when IS6110 RFLP was 
used in a London population study (22,23). We concluded 
that 15-MIRU-ETR genotyping was insufficiently discrimi-
native and was producing so-called false clustering. This 
view was supported by the spoligotyping results in which 38 
(16%) of 235 isolates of 15 MIRU-ETR clusters contained 
isolates that belonged to >2 spoligo families (Table 3).
Applying all 22 loci gave the lowest clustering rate 
(22.2%) in MTBC strains obtained over 1 year from a sin-
gle metropolitan setting (London), a rate almost identical 
to the proportion established in previous studies conducted 
in London in 1993 and 1995–1997 (22,23) and similar to 
previously reported rates in population-based studies in 
low- to-middle TB incidence settings where RFLP and 
PCR-based genotyping methods were used (11,24–26). 
These findings suggest, from the public health viewpoint, 
that TB transmission in London has remained stable over 
the past decade. Our study provides strong evidence that 
PCR-based methods, especially VNTR-MIRU, can replace 
IS6110 RFLP typing for prospective analysis and that 12 
MIRU (27), and 15 MIRU-ETR loci panels alone are insuf-
ficiently discriminating for evaluation of TB transmission.
The recently proposed VNTR panel (3,5,7,11) pro-
vides similar degrees of discrimination (comparable to that 
achieved by IS6110 RFLP), although discrimination of in-
dividual VNTR loci is not equal for different MTBC genetic 
families (13). Inclusion of highly polymorphic VNTR loci 
effectively differentiates strains within highly conserved 
groups and is vital for prospective genotyping. Our study 
demonstrated that even in settings of low TB incidence and 
relatively low TB transmission rates, TB families, such as 
Beijing and CAS, remain more conserved than others, and 
hypervariable loci (e.g., VNTR 3232, 2163A, 4052) pro-
vide much higher discrimination than MIRU and ETR loci 
either alone or in combination.
Our current results agree with the preliminary results 
of our earlier studies about the applicability of hypervari-
able VNTR loci (VNTR 3232, VNTR 3336; VNTR 2163a, 
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Table 4. Allelic variants of additional hypervariable VNTR loci that cannot be resolved with the CEQ automated sequencer*† 
Locus
Maximum no. repeats suitable for 
automated analysis Fragment size, bp 
Proportion of strains with allelic variants beyond 
the automated system resolution, % 
3232 15 830 4.1
1982 9 880 11.9
2163A 11 876 10.8
3336 11 875 21.1
*Beckman Coulter, Fullerton, CA, USA. 
†VNTR, variable number tandem repeats. 
Analysis of M. tuberculosis Strains, UK
and VNTR1982, in particular) and recent reports (28–30) 
demonstrating their effectiveness for discrimination among 
Beijing strains. This agreement suggests that these loci are 
discriminating and reproducible, especially where Beijing 
strains are dominant (e.g., China, Russia, Baltic countries) 
(28) and should be included in standardized VNTR panels. 
They can be used successfully at multiple laboratories with 
consistent results, provided the conditions for proposed 
reaction and PCR fragment separation are adhered to and 
specific DNA polymerases are used.
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